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Abstract  4 
Abstract 
Vitamin K reduction is essential and catalyzed by two enzymes in vitro. Vitamin K 2,3-
epoxide reductase complex subunit 1 (VKORC1) reduces vitamin K to sustain γ-
carboxylation of vitamin K dependent (VKD) proteins. This modification is important to 
physiologically activate all VKD proteins, which are involved in blood coagulation, bone 
and glucose metabolism. Inhibition of VKORC1 by oral anticoagulants (OACs) is clinical-
ly used in therapy and prevention of thrombosis. However, OACs also inhibit the iso-
zyme VKORC1-like1 (VKORC1L1), which may have antioxidative properties and is sus-
pected to reduce vitamin K to scavenge reactive oxygen species. 
Specific inhibition data for various OACs were examined by means genetically engi-
neered VKOR deficient HEK 293T cells. Inhibition profile differed in terms of therapeutic 
OACs with 4-hydroxycoumarin and 1,3-indandione backbone. In contrast, rodenticides 
investigated showed similar susceptibility for both enzymes. To explain the distinct inhi-
bition pattern in silico and in vitro analysis was performed which identified a warfarin 
binding site in VKORC1L1 other than VKORC1 binding site.  
The function of VKORC1L1 in vivo is still unclear. In order to check the effect of the ab-
sence of the enzyme, we generated Vkorc1l1-/- mouse by CRISPR/Cas9 gene editing. 
Those mice were viable in homozygous state, in contrast to Vkorc1-/- mice, and showed 
normal fertility. However, they were slender and smaller in size and showed reduced 
cholesterol and glucose levels in plasma compared to their wild type littermates. Further 
phenotyping is needed to describe those mice in more detail. 
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Zusammenfassung 
Die Reduktion von Vitamin K ist essentiell und wird durch zwei Enzyme katalysiert. Die 
Vitamin K 2,3-Epoxid Reduktase Complex Untereinheit 1 (VKORC1) reduziert Vitamin K 
welches für die γ-Carboxylierung von Vitamin K abhängigen Proteinen benötigt wird. 
Durch die post-translationale Modifikation werden alle Vitamin K abhängigen Proteine 
physiologisch aktiviert, welche in der Blutgerinnung als auch u.a. im Knochen- und Glu-
kosestoffwechsel eine Rolle spielen. Orale Antikoagulantien (OAKs) hemmen spezifisch 
die VKORC1 und werden in der Therapie und Prävention von Thrombosen eingesetzt. 
Neben der VKORC1 existiert ein Isoenzym, die VKORC1-like 1 (VKORC1L1), welches 
ebenfalls durch OAKs gehemmt werden kann. Diesem Enzym werden anti-oxidative 
Eigenschaften zugeschrieben, denn durch die Reduktion von Vitamin K können reaktive 
Sauerstoffspezies unschädlich gemacht werden. 
Um das Inhibitionsprofil verschiedener OAKs zu untersuchen wurden HEK 293T Zellen 
genetisch manipuliert, so dass eines oder beide Enzyme ausgeschaltet waren. Dabei 
zeigte sich, dass die VKORC1 (im Vergleich zu VKORC1L1) wesentlich sensitiver ge-
genüber den therapeutischen OAKs der Gruppen der 4-Hydroxycoumarine und 1,3-
Indandione ist. Im Gegenteil dazu zeigten die untersuchten Rattengifte eine gleich hohe 
Wirksamkeit für beide Enzyme. Um der Ursache der unterschiedlichen Wirksamkeiten 
nachzugehen wurden in silico und in vitro Analysen durchgeführt. Es konnte gezeigt 
werden, dass VKORC1 und VKORC1L1 unterschiedliche Warfarin-Bindungsstellen ha-
ben.  
Die Funktion der VKORC1L1 in vivo ist noch nicht bekannt. Um den Einfluss des En-
zyms im Mausmodell zu untersuchen wurde eine Vkorc1l1-/- Maus mittels der 
CRISPR/Cas9 Technologie generiert. Im Gegensatz zu Vkorc1-/- Mäusen zeigten die 
Vkorc1l1-/- Mäuse keine Auffälligkeiten, was ihre Lebensfähigkeit und Fruchtbarkeit an-
geht. Allerdings sind sie kleiner und schmaler und weisen reduzierte Cholesterol- und 
Glucosespiegel im Plasma auf. Um genauere Aussagen treffen zu können ist es nötig 
den Phänotyp der Vkorc1l1-/- Mäuse genauer zu charakterisieren. 
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List of abbreviations 
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4HC 4-hydroxycoumarin 
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ALP/AP Alkaline phosphatase 
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AST Aspartate aminotransferase 
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crRNA CRISPR RNA 
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ddNTP Dideoxyribonucleotide triphosphate 
dest.  destillatus 
DEXA Dual-energy X-Ray absorptiometry 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DSB Double strand break 
dsDNA Double stranded DNA 
DTT Dithiothreitol 
E. coli Escherichia coli 
e.g.  exempli gratia, for example 
ECG Electrocardiogram 
ER Endoplasmatic reticulum 
ERGIC ER-Golgi intermediate compartment 53 kDa protein 
ES cells Embryonic stem cells 
et al. et altera 
F Factor (e.g. FII ,FVII) 
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g Gram 
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Gla γ-carboxy glutamate 
Glu Glutamate (glutamic acid) 
GRP Gla-rich protein 
GTH Gesellschaft für Thrombose und Hämostase 
HCT Hematocrit 
HEK Human embryonic kidney cells 
hFIX Human FIX 
HGB Hemoglobin 
HR Homologous recombination 
HRP Horseradish peroxidase 
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1 Introduction 
1.1 Blood coagulation 
Hemostasis is defined as a physiological response to blood vessel injury and bleeding. It 
involves the concerted action of vasculature, platelets, and plasma factors and is divided 
into primary and secondary hemostasis. The primary hemostasis rapidly initiates after 
endothelial damage and is characterized by vascular contraction, platelet adhesion, and 
formation of a soft aggregate plug. The secondary hemostasis is initiated following the 
release of tissue factor (TF) and involves a complex sequence of events known as the 
blood coagulation cascade (see Figure 1). This process encompasses serial steps 
where each coagulation factor (F) activates another in a chain reaction that finally re-
sults in the conversion of fibrinogen to fibrin. The main goal of secondary hemostasis is 
to stabilize the soft plug of primary hemostasis and therefore to facilitate the arrest of the 
hemorrhage. 
 
Figure 1: Blood coagulation cascade of secondary hemostasis.  
The intrinsic and extrinsic pathways merge in the common pathway, which is characterized by 
the activation of FX and subsequent cross-linking of fibrin monomers. Feedback mechanisms are 
shown in red (negative) and green (positive). Vitamin K dependent proteins are boxed in blue 
(Figure taken and modified from https://en.wikipedia.org/wiki/Coagulation visited on 13-Jan-2018)  
1.2 Vitamin K 
The discovery of vitamin K resulted from experiments by Henrik Dam and coworkers 
who investigated dietary deficiency diseases [1]. When chick was fed in a fat and cho-
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lesterol-free diet, they developed large subcutaneous and intramuscular hemorrhages. 
The disease phenotype was not prevented by administration of ascorbic acid as well as 
vitamin A, C and D. In the 1930’s Dam proposed that the antihemorrhagic factor causing 
the bleeding phenotype was a fat soluble vitamin, which he called vitamin K (K stands 
for German/Scandinavian Koagulation) [2]. Vitamin K is important for the function of nu-
merous proteins within the body [3]. Three different forms of vitamin K (named K1 to K3) 
are existing, whereby K1 (phylloquinone) and K2 (menaquinone, MK-4 through MK-13, 
dependent on the length of the isoprene side chain) are naturally occurring and K3 is of 
synthetic origin. The parent structure of all K vitamins is 2-methyl-1,4 naphthoquinone, 
the K vitamins differ in the side chain in C3 position (Figure 2). Vitamin K1 is mainly 
found in green leafy vegetables as well as olive and soybean oil, whereas vitamin K2 is 
present in meat (beef), butter, egg yolks, cheese and fermented soybeans (reviewed in 
[4]). For healthy adults, adequate intakes of vitamin K range from 55 to 90 µg/d for adult 
women and 65–120 µg/d for adult men [5].  
 
Figure 2: Forms of vitamin K.  
A: phylloquinone (vitamin K1), which is the primary dietary source; B: menaquinones (vitamin K2), 
which can vary in length from MK-4 to MK-13; C: menadione (vitamin K3), which is supplemented 
to animal food [4]. 
 
Vitamin K deficiency can occur in persons of any age due to different reasons (malnutri-
tion, disease-associated). However, infants are at higher risk for hemorrhagic dis-
ease [6]. The vitamin K content of human milk is low and only little vitamin K crosses the 
placenta. Furthermore, the newborn’s reservoir of vitamin K is small and expression of 
coagulation factors is low but increases during first months of life. Thus, vitamin K defi-
ciency can result in hemorrhage, which is counteracted by vitamin K prophylaxis at the 
time of birth [6].  
Vitamin K1 is the primary dietary source for human beings and is poorly absorbed but 
has a high hepatic concentration. In contrast, menaquinones are mainly found in extra-
hepatic tissues, which are converted from vitamin K1. Nakagawa and colleagues identi-
fied UBIAD1 (UbiA prenyltransferase domain-containing protein 1) being responsible for 
conversion of K1 to MK-4 [7]. 
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1.3 Vitamin K cycle 
The dietary source of vitamin K is vitamin K quinone (K), which needs to be reduced to 
vitamin K hydroquinone (KH2) for post-translational modification of vitamin K dependent 
(VKD) proteins. KH2 serves as cofactor for γ-glutamyl carboxylase (GGCX), the enzyme 
responsible for γ-carboxylation and thus biological activation of VKD proteins. GGCX 
oxidizes KH2 to vitamin K 2,3-epoxide (K>O), while simultaneously adding CO2 to glu-
tamic acid (Glu) of vitamin K dependent proteins to form γ-carboxyglutamic acid (Gla). 
K>O in turn is recycled by VKORC1 (vitamin K 2,3-epoxide reductase complex subunit 
1) to KH2 to serve for another γ-carboxylation as cofactor. The cyclic process of vitamin 
K reduction by VKORC1 and KH2 oxidation by GGCX is known as vitamin K cycle 
(Figure 3) [8].  
 
Figure 3: Overview of the vitamin K cycle.  
VKORC1 catalyzes the reduction of vitamin K quinone to hydroquinone, which serves as sub-
strate for γ-carboxylation of vitamin K dependent proteins. By carboxylation of glutamic acid resi-
dues those proteins get biologically activated. During γ-carboxylation, vitamin K hydroquinone is 
oxidized to K epoxide, which is reduced to hydroquinone via K quinone by VKORC1. The recy-
cled vitamin K hydroquinone is again available as a co-factor of GGCX. Modified from [8]. 
 
Generally, VKORC1 and GGCX are the key enzymes participating in cyclic conversion 
of vitamin K. However, at least two other proteins are known to be able to reduce KH2. 
VKORC1L1 (vitamin K 2,3-epoxide reductase complex subunit 1 like 1), a paralog of 
VKORC1, was shown to utilize K1 as well as K1>O to drive γ-carboxylation of a reporter 
protein in vitro [9, 10].  
In addition, it has been speculated that NAD(P)H:quinone oxidoreductase 1 (NQO1) 
might function as a bypass enzyme in the vitamin K cycle. Although NQO1 has been 
shown to catalyze the reduction of menadione in vitro [11], it is expected that NQO1 is 
not responsible for γ-carboxylation of VKD proteins in the classical vitamin K cycle [12].  
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1.4 Proteins of the vitamin K cycle 
1.4.1 GGCX 
Recycling of vitamin K provides KH2, which is an important co-factor of GGCX. During γ-
carboxylation the γ-hydrogen of the glutamate is abstracted, followed by the addition of 
CO2 [13]. Simultaneously, GGCX oxidizes KH2 to K>O to provide the energy required for 
γ-carboxylation [14]. GGCX is an integral ER membrane glycoprotein comprised of five 
(or seven) transmembrane domains, whereby the N-terminus resides in the cytoplasm 
and C-terminus in the ER lumen [15]. Mutations in the GGCX gene (NG_011811.29) can 
cause vitamin K-dependent clotting factors deficiency type 1 (VKCFD1, OMIM 
#277450). Besides affecting hemostasis, clinical manifestations have been linked to 
mutations in GGCX causing Pseudoxanthoma elasticum (PXE)-like phenotype. Zhu et 
al. found that Ggcx+/- mice developed normally, exhibited normal survival and fertility, 
and showed normal plasma levels of VKD coagulation factors [16]. However, only 50% 
of Ggcx-/- offspring survived to term and those that were born succumbed to massive 
intraabdominal hemorrhage shortly after birth [16]. 
1.4.2 VKORC1 
The VKORC1 gene (NG_011564.1) encodes vitamin K 2,3-epoxide reductase complex 
subunit-1, a small transmembrane protein of the ER, which was identified 2004 inde-
pendently by two groups [17, 18]. The gene contains 3 exons, spans approximately 5 kb 
and is mapped to chromosome 16p11.2. The mRNA has a size of about one kb and 
encodes a protein of 163 amino acids with a calculated relative molecular mass of 18 
kDa. The crystallographic structure of human VKORC1 (hVKORC1) is not solved until 
now. In silico analysis based on bacterial homologue Synechococcus sp. (synVKOR) 
[19] revealed, depend on the algorithm used, a three or four transmembrane (4TM) 
model (Figure 4) [20, 21]. Recently, the membrane topology of VKORC1 was investigat-
ed by Cao and coworkers and confirmed the 4TM model [22]. In the 4TM model, N- and 
C-terminus face the cytosol. The loop is located between TM1 and TM2 and resides in 
the ER lumen. 
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Figure 4: Four transmembrane model of hVKORC1.  
The protein passes the membrane four times, whereby N- and C-terminus are located in the cy-
toplasm. The loop between the first two TMs contains the conserved cysteines Cys43 and Cys51 
and resides in the ER lumen. The active center (CXXC motif) is situated in the fourth TM. In addi-
tion, red labeled circles represent human mutations leading to coumarin resistance, yellow circle 
show the mutation associated with VKCFD 2 (modified from [23]). 
 
The ability of vitamin K recycling is highly conserved among species and VKORC1 
homologues are found in bacteria, archaea, plants and mammals but not in yeast and 
fungi [24]. Characteristic for all VKOR (vitamin K 2,3-epoxide reductase) homologs is the 
CXXC motif in the active site which is essential for reduction of quinone substrates [25]. 
The cysteines 132 and 135 of the CXXC motif form a disulfide bridge that becomes re-
duced for catalytic activity. Additionally, there are two other cysteines located in the loop 
(Cys43 and Cys51) and a conserved serine at amino acid position 57 (or threonine in 
some VKORC1 homologues) in the large loop of VKORC1 [26]. The loop cysteines are 
thought to participate in an electron relay in which a redox partner first reduces the 
Cys43–Cys51 disulfide bond to generate free thiols that then reduce the Cys132–
Cys135 disulfide bond, thus leading to activation of VKORC1 [26]. These four cysteines 
and the serine/threonine are absolutely conserved and define proteins of the VKOR fam-
ily.  
In close proximity to the CXXC motif the hydrophobic Thr138-Tyr139-Ala140 (TYA) motif 
is located. Mutations in these particular amino acids show resistance to coumarins in 
vitro and in vivo suggesting being involved in drug binding [27].  
Up to now, only one mutation in VKORC1 has been described to cause a bleeding phe-
notype. VKCFD2 (vitamin K-dependent clotting factors deficiency type 2, OMIM 
#607473) is triggered by a point mutation in the VKORC1 gene, whereby arginine at 
position 98 is substituted by tryptophan. The phenotype is characterized by reduced 
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VKD blood coagulation factor levels and can be reversed by oral administration of K1 
leading to increased serum K1>O level [28], but the mechanism by which vitamin K sup-
plementation rescues VKD coagulation factor levels is not understood.  
Beside the VKCFD2 phenotype, 26 mutations in VKORC1 have been assigned with dif-
ferent requirements of oral anticoagulants (OACs) for stable anticoagulation 
(OMIM #12270) [21, 29]. The inhibitory profile of these mutations were assessed in a 
recently described cell-based FIX assay [30] and revealed increased half-maximal in-
hibitory concentration (IC50) over a range of 2.5-fold and 8.5-fold compared to wild-type 
VKORC1, reflecting clinical OAC resistance phenotypes that range from moderate to 
severe resistance [21]. 
Spohn and colleagues generated VKORC1-deficient mice in order to investigate the 
deleterious effect of the enzyme on blood coagulation. Vkorc1-/- were born at the ex-
pected Mendelian ratio, appeared normal, but died between postpartal day P1 and P20. 
Heterozygous VKORC1-deficient (VKORC1+/-) mice developed normally, showed normal 
survival rate and fertility and were phenotypically indistinguishable from their wild-type 
littermates [31, 32]. To rescue the lethal phenotype non-physiological high doses of vit-
amin K quinone was devised to bypass the vitamin K cycle (30–50 μg vitamin K per off-
spring per day, orally administered). In this rescue approach the survival rate of Vkorc1-/- 
mice was indistinguishable from their heterozygous and wild-type littermates. However, 
VKD clotting factor activities remained significantly reduced in Vkorc1-/- mice compared 
to their wild-type and heterozygous littermates. Cessation of supplementation led to 
death of Vkorc1-/- mice within one week. Beside the bleeding phenotype, a significant 
reduction in length of the long bones of both Vkorc1-/- and Vkorc1+/- mice compared to 
their wild-type littermates was observed [31]. 
Expression studies in rodents revealed a predominant mRNA occurrence in liver, under-
lining the importance of vitamin K cycle in the context of blood coagulation since the 
coagulation factors are synthesized and activated in the liver. However, VKORC1 is ex-
pressed in other tissues as well [12] and was almost not influenced by age in rats [33]. 
1.4.3 VKORC1L1 
By database search with the sequence of VKORC1 as query, Rost and colleagues iden-
tified VKORC1L1 (VKORC1-like 1) as a paralog of VKORC1 [17]. VKORC1L1 is 
mapped to chromosome 7 and spans about 86 kb. The gene (NC_000007.14) consists 
of three exons yielding a protein of 176 amino acids. The intronic sequences between 
exon 1/2 and exon 2/3 have a size of 75 kb and 5.3 kb, respectively. The human protein 
shares 50% identity with VKORC1 and approximately 97% identity with mouse and rat 
1 Introduction  18 
Vkorc1l1. It is expected that VKORC1L1 is also comprised of four transmembrane do-
mains with a loop segment between the first and the second TM domain (Figure 5). Both 
termini are located in the cytoplasm, whereas the loop resides in the lumen of the ER 
[22, 34].  
 
Figure 5: A topological model for human VKORC1L1. 
The model is based on sequence alignment to a prokaryotic VKOR homolog protein structure. 
Cysteines in loop important for disulfide bridge are shown in blue, the catalytic center (CXXC 
motif) is given in green [10]. 
 
By protein sequence alignment of VKORC1 and VKORC1L1 loop cysteines were identi-
fied at amino acid positions 50 and 58 in VKORC1L1. The enzyme also comprises an 
active center (CXXC motif), located at amino acids 139 to 142. Tie and colleagues have 
examined loop cysteines and concluded from their experiments that the conserved loop 
cysteines Cys50 and Cys58 participate in active site regeneration through an intra-
molecular pathway [34, 35]. 
Up to now, no disease has been associated with mutations in VKORC1L1 gene. Fur-
thermore, polymorphisms in VKORC1L1 are not connected with different OAC dose re-
quirements as known for VKORC1 [36]. The group of Ferron generated Vkorc1l1 knock-
out mice to investigate the impact of the absent enzyme. When Vkorc1l1+/- mice were 
intercrossed, littermates were born at the expected Mendelian ratio. There was no evi-
dence of hemorrhage in Vkorc1l1-/- mice at any age, and they all survived to adulthood 
[32].  
The physiological function of VKORC1L1 is under debate since the isozyme of VKORC1 
is able to provide KH2 for γ-carboxylation of a reporter protein in vitro [9, 33], i.e. 
VKORC1L1 can produce KH2 utilizing K and K>O as substrate. However, VKORC1L1 is 
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not able to rescue the bleeding phenotype in Vkorc1-/- mice [31]. Furthermore, Ferron 
investigated the ability to rescue Vkorc1-/- genotype in osteoblasts of OCN-specific 
Vkorc1-/- mice. Serum measurement of osteocalcin (OCN) revealed decreased Gla-OCN 
and increased Glu-OCN levels, whereas circulating levels of total OCN were unaffected 
compared to controls. In contrast, measurement in OCN-specific Vkorc1l1-/- mice re-
vealed no difference on the circulating levels of Gla-, Glu-, or total OCN. A double 
knockout of both enzymes in an OCN-specific manner revealed the same levels of OCN 
as measured in OCN-specific Vkorc1-/- mice. Here again, the phenotype of low Gla-OCN 
and high Glu-OCN was reversible by K1 but not K1>O supplementation [32].  
Westhofen and colleagues postulated that VKORC1L1 is involved in antioxidation by 
scavenging reactive oxygen species (ROS). By induction of oxidative stress in vitro 
VKORC1L1 expression was dramatically upregulated. Furthermore, total VKOR enzy-
matic activity (reflecting VKORC1 and VKORC1L1 enzyme activity) was strongly en-
hanced. These results suggest that oxidative stress impacts VKORC1L1 expression, 
thus intracellular levels of KH2 may directly or indirectly counteract ROS and ROS-
induced protein damage [10]. 
1.5 Vitamin K dependent proteins 
About 30 years after its discovery the physiological function of vitamin K was resolved in 
1974 when Stenflo and colleagues described the presence of a glutamate residue in 
prothrombin that is modified to Gla (γ-carboxyglutamic acid) [37]. Since then, at least 14 
more proteins have been identified containing Gla residues, which build the so-called 
VKD protein family. VKD proteins can be grouped whether they are synthesized in- or 
outside the liver (i.e. hepatic and extrahepatic VKD proteins). The distinct Gla residues 
are located typically in the amino-terminal domain of the protein, for which there is a 
high degree of amino acid sequence identity in all vitamin K dependent proteins [38]. 
The Gla residues, modified by GGCX, are required for calcium binding and the calcium 
mediated action of the proteins and thus essential for biological activity. 
1.5.1 Vitamin K dependent coagulation factors 
Well characterized vitamin K dependent proteins are proteins belonging to the coagula-
tion cascade. They are synthesized and activated in the liver [39]. The group is com-
prised of seven proteins that contain 9 to 13 glutamic acid residues in the Gla domain, 
which are all modified during γ-carboxylation. The Gla residues enable Ca2+-mediated 
binding of the proteins to negatively charged phospholipid surfaces provided by blood 
platelets and endothelial cells at the site of injury [40]. The pro-coagulant factors pro-
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thrombin (factor II), factors VII, IX, and X participate in the coagulation cascade resulting 
in the formation of a fibrin clot. In contrast, proteins C, S, and Z have an anticoagulant 
effect [40].  
1.5.2 Vitamin K dependent proteins beyond coagulation 
Beyond the VKD coagulation factors, there are other proteins with widespread physio-
logic function which require γ-carboxylation for their biological activity.  
Gas6 (growth arrest-specific gene 6) shows high similarities with protein S [41], however 
they diverge in their steroid-hormone binding domain. Gas6 is a ligand of receptor tyro-
sine kinases leading to phosphorylation of proteins at tyrosine residues. Gas6 has many 
functions, as it is involved in cell proliferation [42], protection against apoptosis [43], and 
bone differentiation and resorption [44]. Furthermore, it was shown that  Gas6-/- mice are 
protected against thrombosis (by preventing the formation of stable platelet plugs) but 
did not suffer from bleeding [45]. All of the eleven glutamic acid residues in the Gla do-
main are γ-carboxylated. 
Osteocalcin (OCN) is produced by osteoblasts and the γ-carboxylated form binds to hy-
droxylapatite in the extracellular matrix of bone [46]. OCN is modified at three glutamic 
acid residues, whereby five residues are located within the Gla domain. Beside the con-
tribution in bone metabolism, undercarboxylated OCN acts as a hormone in glucose 
homeostasis, energy expenditure, male fertility, brain development, and cognition [32].  
Matrix Gla protein (MGP) is synthesized in many soft tissues, with the highest levels of 
expression in heart, lung, kidney and cartilage [47]. Like OCN, MGP is also found in 
extracellular bone matrix. The major role of MGP is the inhibition of soft-tissue calcifica-
tion which was clearly demonstrated by Luo and co-workers. Mgp-/- mice were indistin-
guishable from their littermates during first two weeks of life. At the age of two months 
KO mice died due to hemorrhage caused by the rupture of thoracic or abdominal aorta 
[48]. 
Like MGP, GRP (Gla-rich protein) serves as an important inhibitor of vascular calcifica-
tion, too [49]. GRP is characterized by 15 glutamic acid residues located in the Gla do-
main and is distributed in bone, cartilage, skin and vasculature [50]. 
Another protein suggested to be vitamin K dependent is periostin, a protein whose ex-
pression is developmentally regulated and is associated with bone, heart, and dental 
ligament ontogeny [51]. However controverse results with regard to the γ-carboxylation 
of periostin are existing [52, 53].  
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Some years ago, four VKD proteins harboring a transmembrane domain have been 
identified [54, 55], namely proline-rich Gla protein 1 (PRGP1) and PRGP2 as well as 
transmembrane Gla protein 3 (TMG3) and TMG4 (also named PRGP3 and 4). Those 
proteins are expressed in various tissues including brain and kidney [55]. Current stud-
ies have shown that PRGP4 may be included in autism and mental retardation in the 
context of a rare genetic disorder WAGR (Wilm's tumor, aniridia, genitourinary malfor-
mations and mental retardation) syndrome [56]. Furthermore, PRGP4 was identified as 
one of the top 10 up-regulated genes in response to three common food allergens [57]. 
However, the biochemical function of these proteins remains to be elucidated.  
1.6 Oral anticoagulants 
Conditions being treated with oral anticoagulants (OACs) include atrial fibrillation, me-
chanical heart valves, venous or arterial thromboembolism, and ventricular assist devic-
es [58]. OACs exert their effect by inhibition of VKORC1 activity [59], which reduces the 
availability of KH2, thus leading to impaired γ-carboxylation of VKD proteins in vivo. In 
addition, VKORC1L1 was also shown to be susceptible to warfarin treatment [10, 33]. 
For many decades, substances like warfarin have been the only choice for long-term 
treatment of before mentioned diseases [60]. More recently, new drugs as direct throm-
bin inhibitors (e.g. dabigatran) and direct factor Xa inhibitors (e.g. rivaroxaban) are used 
in antithrombotic therapy. These direct oral anticoagulants (DOACs) act specifically 
against the active site of one clotting factor, thereby inhibiting the turnover of natural 
substrates [61]. The chemical compounds used in this study belong to the first genera-
tion of OACs and have a 4-hydroxycoumarin or 1,3-indanione backbone. 
The matrix of 4-hydroxycoumarins is coumarin (Figure 6), which is a plant-derived natu-
ral product with a variety of pharmacological functions including anti-inflammatory, anti-
coagulant, antibacterial, antioxidative and anticancer properties [62]. Another naturally 
occurring 4-hydroxycoumarin is ferulenol which is much more potent than coumarin. 
Ferulenol is synthesized by Ferula communis L. and can cause hemorrhage in mam-
mals [63].  
In the 1930s Karl Link identified dicoumarol (Figure 6) as the causative agent of the 
sweet clover disease, a hemorrhagic disorder in cattle. Thereby, coumarin is oxidized by 
molds (Asperigillus or Penicillium) in spoiled hay to dicoumarol (3,3’-methylenebis-(4-
hydroxycoumarin)) [64]. Further research of Link and colleagues revealed synthetic 4-
hydroxycoumarin compounds with anticoagulant activity, were warfarin (named in honor 
to Wisconsin Alumni Research Foundation, WARF) was the most potent agent out of 
150 substances. Warfarin was promoted in 1948 as a rodenticide and later shifted to 
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clinical application [65]. The most prominent patient treated with warfarin after myocar-
dial infarction was President Dwight Eisenhower in 1955. Since then, more synthetic 
coumarins have been approved for treatment and prevention of thrombosis. For oral 
anticoagulation therapy, warfarin is the drug of choice in the US, acenocoumarol 
(Southern Europe and Asia) and phenprocoumon (Europe) are used as well (Figure 6).  
 
Figure 6: Chemical structure of coumarin-based oral anticoagulants. 
Coumarin is a naturally occurring agent which can be oxidized to 4-hydroxycoumarin and dicou-
marol by microorganisms. Warfarin, acenocoumarol and phenprocoumon are OACs of synthetic 
origin.  
 
A second compound class of OACs is represented by 1,3-indandiones. Thereof, fluindi-
one represents 70% of oral anticoagulant prescriptions in France (Figure 7) [66]. 
 
Figure 7: Chemical structure of oral anticoagulants with a 1,3-indandione backbone. 
 
Dosing of oral anticoagulants depends on type of coumarin used and the pharmaco-
genetic and pharmacokinetic profile of a patient. The metabolism of coumarins depends 
on hepatic microsomal monooxygenases, mainly CYP2C9 [67–69]. Approximately 40% 
of phenprocoumon is excreted non-metabolized, whereas acenocoumarol and warfarin 
are almost completely metabolized [67]. In contrast, little is known about the metabolism 
of 1,3-indandiones. CYP2C9 haplotypes were shown to have only little impact indicating 
a minor effect on metabolism of those compounds [66].  
The half-lifes of the OACs differ markedly. Of the therapeutically used OACs phenpro-
coumon displays the longest half-life (about 150 h). Half-lifes of warfarin and fluindione 
are intermediate (~40 h and 69 h, respectively) whereas acenocoumarol harbors the 
shortest time (about 6 h) [67, 70]. 
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Originally, coumarins were used for rodent control, because the drug is colorless and 
odorless with a delayed onset of action. Initially, warfarin was introduced as a pesticide 
against rats and mice (and is still in use as rodenticide). In the 1950s and 1960s rodenti-
cides with increased potency and half-live were established [71]. In the early 1960s, it 
was recognized that some rodent strains developed resistance against the “first genera-
tion” rodenticides [72, 73]. Thus, a second generation of rodenticides (also called super-
warfarins) was introduced in the 1970s solving the problem only partially [74]. By substi-
tuting the methyl group of 4-hydroxycoumarin with long, phenyl side-chains these com-
pounds were shown to be more potent with a longer time of action [75]. 
 
Figure 8: Chemical structure of rodenticides with 4-hydroxycoumarin backbone. 
Coumatetralyl and coumachlor belong to the 1
st
 generation of rodenticides, whereas brodifacoum 
and bromadiolone, introduced as super-warfarins, belong to the 2
nd
 generation of rodenticides.  
 
In contrast to the therapeutically used OACs, the half-lives of rodenticides amount a few 
up to several days in rats [76]. Pharmacokinetic data in men are only available as case 
reports of intentional or accidental poisoning. Olmos and Lopez reported a case of brodi-
facoum intoxication, their analysis revealed a half-life of 56 days [77]. Intoxication re-
quires acute treatment with vitamin K1 and fresh frozen plasma followed by long term 
administration of high doses of vitamin K1 until poisoning resolve [71].  
1.7 Aim of the study 
In vitro, vitamin K is recycled by two enzymes, VKORC1 and VKORC1L1, which serves 
as co-factor for γ-carboxylation of vitamin K dependent proteins. In vivo, VKORC1 is the 
key enzyme in liver for vitamin K recycling. Studies highlighting the function of 
VKORC1L1 in vivo and in vitro are sparsely available. Therefore the aim of the study 
was to characterize VKORC1L1 in vitro and in vivo. 
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In vitro, both VKOR enzymes are sensitive to warfarin treatment leading to reduced en-
zyme activity and hence lower KH2 availability. In a first approach, their susceptibility to 
various OACs was analyzed by means of genetically engineered cells which allow indi-
vidual review of VKOR enzyme. Based on the inhibition studies further analysis aimed to 
identify the binding pattern of warfarin to VKORC1L1.  
The second part of this thesis addresses the impact of VKORC1L1 in vivo. Vkorc1l1 
knockout mice were generated by CRISPR/Cas9 technology. In contrast to Vkorc1 
knockout mice, Vkorc1l1 knockout mice are viable. Vkorc1l1-/- mice are slender and 
showed altered glucose and cholesterol plamsa levels. Further characterization of 
Vkorc1l1 knockout mice will give insight to biochemical and pathophysiological function 
of Vkorc1l1 in mice. 
2 Materials  25 
2 Materials  
2.1 Reagents and chemicals 
All the chemicals used were purchased at pro analysis grade.  
4-hydroxycoumarin Dr. Ehrenstorfer GmbH, Wesel 
Acenocoumarol Cayman, Ann Arbor, MI, USA 
Acetic acid Merck, Darmstadt 
Acryl/bisacrylamide solution Sigma-Aldrich, Munich 
Agar Sigma-Aldrich, Munich 
Agarose Biozym Scientific GmbH, Oldendorf 
Ampicillin Sigma-Aldrich, Munich 
APS Sigma-Aldrich, Munich 
BigDye terminator Life Technologies, Darmstadt 
Brodifacoum Sigma-Aldrich, Munich 
Bromadiolon Sigma-Aldrich, Munich 
Cefemandole Sigma-Aldrich, Munich 
Cephalosporin C Sigma-Aldrich, Munich 
Chloroform Fluka, Neu Ulm 
cOmplete mini, EDTA-free Roche Diagnostics, Mannheim 
Coumachlor Sigma-Aldrich, Munich 
Coumarin Sigma-Aldrich, Munich 
Coumatetralyl Sigma-Aldrich, Munich 
Dade Owren’s Veronal Buffer Siemens Healthcare GmbH, Erlangen 
Dicoumarol Merck, Darmstadt 
DMEM, MEM, OptiMEM Life Technologies, Darmstadt 
DMSO Merck, Darmstadt 
DNA ladder (100 bp, 1 kb) Fermentas, St. Leon-Rot 
DNA loading dye Fermentas GmbH, Leon-Rot 
dNTPs Fermentas GmbH, Leon-Rot 
DreamTaq DNA polymerase Fermentas GmbH, Leon-Rot 
EDTA Sigma-Aldrich, Munich 
Ethanol Merck, Darmstadt 
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Ethidium bromide Fluka, Neu Ulm 
FBS – SeraPlus PAN Biotech, Aidenbach 
FIREPol DNA polymerase Solis Biodyne, Tartu, Estonia 
Fluindione BOC Sciences, NY, USA 
Glycerol Merck, Darmstadt 
Glycine  Merck, Darmstadt 
HPLC–grade water Merck, Darmstadt 
iProof High-Fidelity DNA Polymerase Bio-Rad Laboratories, Munich 
Isopropanol Merck, Darmstadt 
Kanamycin Sigma-Aldrich, Munich 
LB broth (Lennox) Sigma-Aldrich, Munich 
LB broth with agar (Lennox) Sigma-Aldrich, Munich 
Methanol Merck, Darmstadt 
Midori green Biozym Scientific GmbH, Oldendorf 
Moxalactam Sigma-Aldrich, Munich 
NEAA Life Technologies, Darmstadt 
NP-40 Sigma-Aldrich, Munich 
Penicillin/streptomycin Life Technologies, Darmstadt 
PfuTurbo DNA polymerase Agilent Technologies, Santa Clara, CA, USA 
Phenindione Sigma-Aldrich, Munich 
Phenprocoumon Roche Diagnostics, Mannheim 
Proteinase K Qiagen, Hilden 
SDS Sigma-Aldrich, Munich 
SOC medium Life Technologies, Darmstadt 
Tris Sigma-Aldrich, Munich 
Triton X-100 Sigma-Aldrich, Munich 
Trizol Life Technologies, Darmstadt 
Trypsin-EDTA (0.05%) Life Technologies, Darmstadt 
Tween-20 Sigma-Aldrich, Munich 
Vitamin K1 Sigma-Aldrich, Munich 
Vitamin K1 epoxide Sigma-Aldrich, Munich 
Warfarin Sigma-Aldrich, Munich 
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2.2 Laboratory equipment 
3130xl capillary sequencer Life Technologies, Applied Biosystems, Karlsruhe 
7500 Fast Real-Time PCR Life Technologies, Applied Biosystems, Karlsruhe 
Centrifuge (5430R-X) Eppendorf, Wesseling-Berzdorf 
Centrifuge (3-16PK) Sigma Laborzentrifugen GmbH, Osterode am Harz 
Chemi doc (Gel Doc XR+) Bio-Rad Laboratories, Munich 
Microscope Carl Zeiss Microscopy GmbH, Göttingen 
Nano-Drop ND 1000 Peqlab Biotechnologie GmbH 
Neubauer chamber Neubauer, DE 
Power supply Biometra, GE healthcare, Munich 
Thermomixer  Eppendorf, Wesseling-Berzdorf 
Thermocycler (MJ Research) Bio-Rad Laboratories, Munich 
Thermocycler (T3000) Biometra, GE healthcare, Munich 
Water bath (Thermostat 2761) Eppendorf, Wesseling-Berzdorf 
96-well plate reader Synergy 2, BioTek Germany, Bad Friedrichshall 
2.3 Consumables  
Labware:  
Centrifuge tubes (15 and 50 ml) Greiner Bio-One GmbH, Solingen 
CryoTube vials VWR International GmbH, Langenfeld 
Filtertips, 10, 200, 1000 µl Sarstedt, Nürbrecht 
Petri dishes Greiner Bio-One GmbH, Solingen 
PCR 8-stripes Thermo Fischer Scientific, Waltham, MA, USA 
Plates for cell culture (6- and 96-well) Greiner Bio-One GmbH, Solingen 
Serological pipettes Sarstedt, Nürbrecht 
Reaction tubes (1,5 and 2 ml) Eppendorf, Wesseling-Berzdorf 
 
Commercially available kits:  
BigDye Terminator v1.1, Life technologies, Darmstadt  
Omniscript Reverse Transcription Kit, Qiagen, Hilden 
Plasmid Mini and Midi Kit, Qiagen, Hilden 
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Qiaquick Gel Extraction Kit, Qiagen, Hilden 
RNeasy Mini Kit, Qiagen, Hilden 
RNase-Free DNase Set, Qiagen, Hilden 
GenElute™ Mammalian Genomic DNA Miniprep Kit, Sigma-Aldrich, Munich 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega Corpora-
tion, Madison, WI, USA 
qScript cDNA Synthesis Kit, Quanta Biosciences/VWR, Langenfeld 
AgPath-ID One-Step RT-PCR Kit, Applied Biosystems/Thermo Fisher Scientific, Wal-
tham, MA, USA 
TaqMan® Gene Expression Master Mix, Applied Biosystems/Thermo Fisher Scientific, 
Waltham, MA, USA 
2.4 Vectors  
pIRES Clontech, Saint-Germain-en-Laye, France 
pCMV6-XL4 Human F9, 
NM_000133.2 (SC126517) 
Origene, Rockville, MD, USA 
pX330-U6-Chimeric_BB-CBh-
hSpCas9 
Addgene, Cambridge, MA, USA 
pCDNA 3.1 myc/His Life Technologies, Karlsruhe 
2.5 Antibodies 
anti-c-myc Sigma-Aldrich, Munich 
ERGIC-53 Santa Cruz Biotechnology, Heidelberg 
goat anti-mouse HRP-conjugated Santa Cruz Biotechnology, Heidelberg 
2.6 Buffers and solutions 
„Stripping“ buffer 1000 ml: 15 g Glycin, 1 g SDS, 10 ml Tween 20, pH 2.2  
10x TBS 0.1 M Tris pH 7.7, 1.5 M NaCl 
10x Transfer buffer 250 mM Tris pH 8.3, 1.92 M glycine, 0.1% w/v SDS 
1x Cathode buffer 0.1 M Tris, 0.1 M tricine, 0.1% w/v SDS 
1x DreamTaq buffer 100 µl 10x DreamTaq buffer, 20 µl 10 mM dTNP mix, 
880 µl water 
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50x TAE buffer 2 M Tris pH 8.5, 50 mM acetic acid, 50 mM EDTA 
5x Anode buffer 0.2 M Tris pH 8.9 
Blocking solution 2.5 g skim milk powder, 50 ml TBS-Tween, 25 µl 
Tween-20 
Lysis buffer for mouse tails 50 mM Tris pH 8.0, 50 mM KCl, 2.5 mM EDTA, 0.45% 
NP-40, 0.45% Tween-20, 0.2 mg/ml Proteinase K 
Lysis buffer for western blot 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40 
MiSeq lysis buffer 10 mM Tris pH 7.5, 1 mM CaCl2, 3 mM MgCl2, 1 mM 
EDTA, 1% Triton X-100, 0.2 mg/ml Proteinase K (added 
prior to use) 
MiSeq lysis buffer 10 mM Tris pH 7.5, 1 mM CaCl2, 3 mM MgCl2, 1 mM 
EDTA, 1% Triton X-100, 0.2 mg/ml Proteinase K (added 
prior to use) 
TBS-Tween 100 ml 10xTBS, 900 ml a.d., 50 µl Tween-20 
TrisCl-SDS buffer 3 M Tris pH 8.45, 0.3% w/v SDS 
2.7 Media for bacterial cultures 
Ten g of Luria-Bertani (LB) Lennox broth or 17.5 g of LB Broth with agar were suspend-
ed in 500 ml water and autoclaved for 15 minutes at 121°C to sterilize. The broth/agar 
was supplemented with 75 mg/l of ampicillin after liquid was cooled down to ~ 50°C. LB 
broth and agar plates were stored at 4°C. 
2.8 Media for cell culture 
Complete DMEM (including 4.5 g/l D-glucose, L-glutamine and pyruvate) or complete 
MEM (including Earle’s salts and L-glutamine) was supplemented with 1% v/v penicil-
lin/streptomycin, 1% v/v NEAA and 10% FBS.  
Expression medium for FIX assay was comprised of OptiMEM supplemented with 0.25 
% w/v BSA (sterile filtrated) and 2.5 mM CaCl2 (sterile filtrated). Before use, vitamin K1 
or vitamin K1 2,3-epoxide was added to a final concentration of 12 µM. Therefore, 6.1 µl 
of 200 mM K1 or K1>O stock (in DMSO or ethanol) solution was added to 100 ml of ex-
pression medium. Stock solutions of 10 mM of 4-hydroxycoumarins and 1,3-indandiones 
were prepared in ethanol and dilution series (10 mM, 5 mM, 2.5 mM, 1.25 mM, 500 µM, 
250 µM, 125 µM, 50µM, 25 µM, 12.5 µM, 5µM, 2.5 µM, 1.25 µM) were prepared. In the 
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assay, each compound was diluted 1:5000 in expression medium including 12 µM K1 or 
K1>O with the respective pre-dilution. 
Freezing medium contained 50% complete medium, 40% FBS and 10% sterile DMSO.  
2.9 Primers 
Primers were designed using online software tools and synthesized by Eurofins MWG 
Operon (Ebersberg) in desalted quality (HPSF). List of primers is given in the appendix. 
2.10 Software  
Dissertation preparation 
 
 Microsoft Office 2008 
 Citavi 5 (version 5.2.0.8; Swiss Academic Soft-
ware GmbH, Wädenswil, Switzerland) 
 SnapGene Viewer 1.3.3 
Primer design 
 
 Oligo Calc (www.basci.northwestern.edu/biotools/ 
oligocalc.html) 
 Primer3web version 4.0.0 (http://primer3.ut.ee/) 
Sequence analysis  
 
 GeneMapper® v.4.1 (Life Technologies, Applied 
Biosystems) 
 SeqScape v2.5 (Applied Biosystems) 
 FinchTV (Geospiza, Inc., Seattle, WA, USA) 
 Gentle (Magnus Manske, Cologne) 
Sequence search   BLAST (Basic Local Alignment Search Tool) 
(www.ncbi.nlm.nih.gov/BLAST/) 
Data analysis 
 
 Kaleidagraph 4.5.2 (Synergy Software, Reading, 
PA, USA) 
 GraphPad Prism 5 (version 5.01, GraphPad Soft-
ware Inc., La Jolla, CA, USA) 
 Image Lab™ Software 5.1 (Bio-Rad Laboratories, 
Munich) 
In silico analysis 
 
 YASARA platform [78] 
 Chimera platform [79] 
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3.1 General methods 
3.1.1 Site-directed mutagenesis  
Site-directed mutagenesis is a method to create specific, targeted changes in double 
stranded plasmid DNA. Therefore primers are designed which contain the desired muta-
tion and are about 30 bp long [80]. For amplification the PFU polymerase was used, an 
enzyme having 5’-3’polymerase activity and 3’-5’ exonuclease activity, which is an im-
portant proof reading feature. By proof reading an incorrect base pair is recognized, ex-
cised and replaced by the correct base. PFU polymerase works more accurate but 
slower (2 min per 1 kb) in comparison to polymerases without this feature (Figure 9). 
 
 
 
 
Figure 9: Chart for site-directed 
mutagenesis.  
After denaturation during PCR 
primers containing desired muta-
tion hybridize to the original plas-
mid and the polymerase amplifies 
the complete vector. Afterwards, 
parent plasmids are digested by 
DpnI, whereby amplified plasmids 
remain intact. 
The reaction was set up as follows: 
 Volume in µl 
1x PFU buffer  23 
Template (10 ng/µl) 1 
Forward primer (20 µM) 0.5 
Reverse primer (20 µM) 0.5 
PFU Polymerase (2.5 U/µl) 0.5 
dH2O 11.5 
Total  25 
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The PCR protocol for the amplification was as follows: 
Step 1 95°C 3 min   
Step 2 95°C 30 s  
Repeat 15x Step 3 60°C 1 min 
Step 4 68°C 2 min/kb 
Step 5 95°C 30 s  
Repeat 15x Step 6 60°C 1 min 
Step 7 68°C 2 min/kb + 2 min 
3.1.2 RF cloning 
Cloning can be performed without use of restriction enzymes. In restriction free (RF) 
cloning the desired DNA fragment is integrated via PCR [81]. The DNA fragment to be 
inserted is called megaprimer and contains overlapping sequences complementary to 
vector sequence (see Figure 10). The megaprimers were amplified using iProof high-
fidelity DNA polymerase and can have a size up to 3 kb. This thermostable polymerase 
possesses a proofreading activity that accurately amplifies long products from a variety 
of DNA templates. Primers used for amplification contained 30 bp of vector sequence 
and 20 bp of target DNA. The resulting PCR products were purified by gel extraction 
(3.1.8) and are then ready to use for RF-PCR. During RF-PCR the megaprimer hybrid-
izes with the single stranded plasmid and the Taq polymerase synthesizes the comple-
mentary strand (Figure 10). The PCR products were subsequently incubated with DpnI 
to destroy the parent plasmid (3.1.3). By means of this technique fragments of interest 
can be inserted, deleted or exchanged.  
 
 
Figure 10: Chart for 
restriction-free cloning. 
In the first PCR the 
megaprimer containing 
complementary se-
quences of the target 
vector is generated. 
The second PCR (RF-
PCR) was used to fuse 
the megaprimer with 
the vector which results 
in an insertion of the 
DNA.  
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The PCR was set up as follows:  
 Volume in µl 
5x HF buffer  4 
dNTP Mix (2.5 mM each) 1.6 
Forward primer (20 µM) 0.5 
Reverse primer (20 µM) 0.5 
Template DNA (10 ng/µl) 1.5 
iProof polymerase (5 U/µl) 0.5 
dH2O 11.5 
Total  20 
 
The PCR protocol for the amplification was as follows: 
Step 1 98°C 30 s   
Step 2 98°C 10 s  
Repeat 35x Step 3 55-65°C 30 s 
Step 4 72°C 1 min/kb 
Step 5 72°C 10 min 
 
PCR products were analyzed by gel electrophoresis and respective bands were cutted 
and extracted (3.1.7). The DNA concentration of the extracted fragment was determined 
(3.1.11). The megaprimer was used in the RF-PCR, the components were set up as 
described below: 
 Volume in µl 
5x Phusion HF buffer  4 
dNTP Mix (2.5 mM each) 1.6 
Megaprimer (50 -100 ng/µl) 1 
Vector (10 ng/µl) 1.5 
Phusion High-Fidelity DNA-Polymerase (2 U/µl) 0.5 
dH2O 11.5 
Total  20 
 
The PCR protocol for the amplification was as follows: 
Step 1 98°C 2.5 min   
Step 2 98°C 30 s  
Repeat 30x Step 3 60°C 1 min 
Step 4 72°C 6 min 
Step 5 72°C 7 min 
 
3 Methods  34 
3.1.3 DpnI digestion 
DpnI is an endonuclease which specifically cuts methylated and hemi-methylated DNA 
at 5´-Gm6ATC-3´. Bacteria methylate their own DNA to discriminate between self and 
foreign DNA. Plasmids amplified in E.coli are methylated, whereby plasmids amplified 
by PCR are not. Therefore, plasmids amplified by PCR (either by site directed mutagen-
esis or RF cloning) are not susceptible to DpnI digestion but the original plasmid, which 
was multiplied in E.coli. To the PCR product (20 or 25 µl) 10 U DpnI were added and 
incubated for 1 h at 37°C. Afterwards, the mixture was transformed into E.coli (see 
3.1.5). 
3.1.4 Manufacturing of competent E.coli Top10 cells 
To enable the cells to take up circular DNA they have to be made competent. Cells can 
be made electroporation-competent, whereby plasmids are introduced by application of 
an electric current. In contrast, chemically competent cells are transformed by heat 
shock. To make bacteria chemically competent, the following protocol was used. A 5 ml 
culture of E.coli Top10 cells was grown in LB media overnight. In the morning, the cul-
ture was transferred to 200 ml LB medium and incubated at 37°C for 2-4 h. When the 
turbidity, measured at 600 nm, reached 0.5 to 0.6, the bacterial culture was transferred 
to four 50 ml falcons and centrifuged at 5000 rpm for 10 min at 4°C. Each pellet was 
resuspended in 9 ml of pre-chilled 100 mM MgCl2 and incubated for 25 min on ice, 
whereby the number of falcons was reduced to two. After centrifugation (4000 rpm, 10 
min, 4°C), each pellet was resuspended in 2 ml 100 mM CaCl2/15% glycerol and united 
to have one suspension. The cells were aliquoted (50 µl) in pre-chilled eppis and stored 
at -80°C until use.  
3.1.5 Transformation of E.coli 
Plasmids generated by mutagenesis (see 3.1.1) or RF-cloning (section 3.1.2) were in-
troduced into competent E.coli Top10 cells (3.1.4) for replication. Therefore competent 
cells were thawed on ice and 5 µl of plasmid was added to the cells, mixed gently, and 
incubated for 30 minutes on ice. Followed by a heat-shock for 30 seconds in a 42°C 
water bath, cells were chilled on ice for 5 minutes. Afterwards, 200 µl SOC medium was 
added to the cells, followed by incubation for 1h at 37°C at 200 rpm. Finally, cells were 
plated on LB-agar plates containing the appropriate antibiotic (75 µg/ml final concentra-
tion) and the plates were incubated upside down at 37°C overnight.  
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3.1.6 Colony PCR 
For verification of cloning or mutagenesis, target DNA was amplified using FIREPol 
DNA polymerase. Therefore, clones were picked with a pipette tip and placed into 10 µl 
of water. After assembly of the PCR reaction mix, 1 µl of the bacterial solution was add-
ed to the PCR mix. After successful amplification of desired sequence, 200 µl of LB me-
dium including antibiotic was added and stored at 4°C until evaluation of sequencing. 
The primers used for amplification were located up- and downstream of multiple cloning 
site to assure amplification of insert and vector boundaries. The composition of the PCR 
mix for amplification of target sequence was as follows.  
 Volume in µl 
10x Buffer  2.5 
dNTP Mix (10 mM each) 0.5 
MgCl2 (25 mM) 2 
Forward primer (20 µM) 0.5 
Reverse primer (20 µM) 0.5 
Formamid 0.5 
Colony  1 
DNA polymerase (5 U/µl) 0.2 
dH2O 13 
Total  25 
 
The PCR protocol for the amplification was as follows: 
Step 1 95°C 5 min   
Step 2 95°C 30s  
Repeat 35x Step 3 55-65°C 30s 
Step 4 72°C 1 min/kb 
Step 5 72°C 7 min 
PCR products were analyzed on agarose gel (3.1.7) and the product size was verified 
by comparison with DNA ladder. Products of expected size were selected for sequenc-
ing. 
3.1.7 Agarose gel electrophoresis 
1% (w/v) Agarose gels were prepared in 1x TAE buffer by heating the mixture in a mi-
crowave oven. After cooling to ~60°C Midori Green Advance (1:20,000) was added to 
visualize the DNA. Samples were mixed with 5x loading dye and loaded on the gel. A 
molecular weight size marker (1 kb or 100 bp ladder) was used depending on the size of 
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the products. Samples were separated in 1x TAE at 5-10 mA/cm (usually 150 V for 25 
min) and were visualized and documented under UV light on a ChemiDoc system.  
3.1.8 Gel extraction 
PCR products (like megaprimers for RF-cloning) were gel purified using the QIAquick 
Gel Extraction Kit. Briefly, the products were resolved on agarose gels as described 
above and the fragments were excised. Gel slices were dissolved in a buffer containing 
a pH indicator and incubated for 10 minutes at 55°C. The mixture was then applied to 
the QIAquick spin column, and after several wash steps, the products were eluted in 30 
µl water.  
3.1.9 Sequencing  
Sequencing was performed based on the chain termination method using BigDye termi-
nators, which contains a set of dye terminators labeled with high-sensitivity dyes [82]. 
Each dye is fluorescent at a different wavelength. Sequencing is based on a mix of 
these fluorescence-labeled dideoxynucleotides. The excitation of dyes is done via a la-
ser beam followed by a detection of fluorescence by a CCD camera. PCR products 
(3.1.6) were diluted by the addition of 200 µl water and used in the following sequencing 
mix:  
 Volume in µl 
5x BigDye sequencing buffer 1.5 
Sequencing primer (5 µM) 0.5 
BigDye Terminator sequencing mix 0.5 
Diluted PCR product 2 
dH2O 6.5 
Total  11 
 
The PCR protocol for sequencing was as follows: 
Step 1 96°C 1 min   
Step 2 96°C 10 s  
Repeat 35x Step 3 50°C 5 s 
Step 4 60°C 4 min 
 
The products were subsequently purified by EtOH/NaAc precipitation (10 µl of the se-
quencing reaction product, 50 µl 96 % EtOH, 10 µl dH2O and 2 µl of 3M NaAc pH 4.6) 
followed by centrifugation by 4°C at 4000 rpm for 45 minutes. The pellet was washed 
once with 70% EtOH for 10 minutes at the same centrifugation conditions and air dried. 
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Samples were stored at -20° C until they were resuspended in 15 µl water and loaded 
on the capillary sequencer. 
3.1.10 Isolation and purification of bacterial plasmid DNA 
After validation of the clones by sequencing, clones were grown overnight in 2-5 ml LB-
medium with the appropriate antibiotic. For long term storage stocks were prepared from 
each colony by pelleting an overnight culture (4000xg, 10 min, 4°C). The pellet was re-
suspended in 730 µl LB medium and 130 µl glycerol, mixed well and stored at -80°C for 
later use. 
Dependent on the application plasmid isolation was done on “mini” or “midi” level, 
whereby the yield on plasmid DNA differed. QIAGEN Plasmid Mini Kit was used for 
small scale DNA purification with a yield of maximum 20 µg. For higher yields PureLink® 
HiPure Plasmid Filter Midiprep Kit (Invitrogen) was used. Purification was performed 
according to manufacturer’s protocol.  
In general, plasmid preparation procedure uses the modified alkaline lysis method. 
Therefore, cells are harvested by centrifugation and lysed under alkaline conditions, and 
the lysate is subsequently neutralized and adjusted to high-salt binding conditions in one 
step. After lysate clearing, the sample is ready for purification on the silica membrane. 
After a wash step plasmid DNA is eluted in high-salt buffer and the DNA is concentrated 
and desalted by isopropanol precipitation and collected by centrifugation. Afterwards, 
DNA was washed with 70% ethanol and centrifuged again. Finally, the supernatant was 
carefully discarded and the pellet was resuspended in appropriate volume of water. DNA 
concentration was assessed and plasmids were stored at -20°C until use. 
3.1.11 Measurements of DNA and RNA concentrations 
Nucleic acid concentration and quality was determined by photometry on a Nanodrop 
instrument (1 OD260nm = 50 µg double stranded DNA/ml or 1 OD260nm = 40 µg single 
stranded RNA/ml).  
3.1.12 Protein analysis 
During electrophoresis proteins are separated on polyacrylamide gels according to their 
size. The monomer acrylamide is cross-linked with N,N-methylenebis-acrylamide by 
polymerization initiators APS and TEMED. The separation of molecules is determined 
by the relative size of the pores formed within the gel. Non-covalent protein interactions 
are disrupted by a detergent (usually SDS) and disulfide bonds are degraded by DTT or 
β-mercaptoethanol, leading to size-dependent migration of the proteins in the gel.  
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For separation of proteins the Mini-PROTEAN Tetra system (Bio-Rad Laboratories) was 
used with handcast tricine based gels.  
Assembly of tricine gels 
The gels were prepared and stored up to one week at 4°C in cathode buffer. Volumes 
given below are sufficient for casting 4 mini gels. 
Sealing gel 10% separation gel Stacking gel 
700 µl TrisCl-SDS buffer 
1 ml 30% 
Acryl/bisacrylamide 
10 µl 10% w/v APS 
10 µl TEMED 
3.2 ml water  
6.6 ml 30% 
Acryl/bisacrylamide 
6.6 ml TrisCl-SDS buffer 
4 ml 50% v/v glycerol 
200 µl 10% w/v APS 
8 µl TEMED 
4.2 ml water 
1.2 ml 30% 
Acryl/bisacrylamide 
1.8 ml TrisCl-SDS buffer 
72 µl 10% w/v APS 
7.2 µl TEMED 
Samples were diluted in a 1:1 ratio with tricine sample buffer, incubated at room tem-
perature for 10 min or at 95°C for 5 min, depending on the application. Electrode as-
sembly was filled with cathode buffer, and the tank was filled with 1x anode buffer. The 
gels were run at 180 V for 30 to 45 min. 
Western blot 
By western blot proteins can be identified from a complex mixture of proteins by means 
of specific antibodies. 
Proteins were blotted onto polyvinylidene fluoride (PDVF) membrane by tank blot sys-
tem at 300 mA for 70 min. To block free antibody binding sites the membrane was incu-
bated for 1 h at room temperature or overnight at 4°C in blocking solution. Washing of 
membrane was performed in TBS-Tween. Incubation with anti-c-myc antibody (1:2000, 
diluted in TBS-Tween) or anti-ERGIC53 (1:500 in TBS-Tween) was done for 1 h at room 
temperature or overnight at 4°C. Membrane was washed at least three times for 10 min 
with TBS-Tween. Secondary antibody (goat anti-mouse HRP conjugated, 1:5000) was 
incubated for 1 h at room temperature. Membrane was washed as described earlier. For 
detection HRP substrate was added according to manufacturer’s instructions and visual-
ized using ChemiDoc. 
For incubation with another antibody the membrane was „stripped“ to release bound 
antibodies. Therefore, membrane was incubated twice with “Stripping” buffer for 10 min 
and washed afterwards (with PBS twice for 10 min, with TBS-Tween twice for 5 min). 
Subsequently the membrane was ready to use (starting with blocking solution).  
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3.1.13 Cultivation of mammalian cells 
HEK 293T cells originate from human embryonic kidney cells that were generated in 
1973 by transformation of cultures of normal with sheared adenovirus 5 [83].  
The adherent growing cells were cultivated in complete DMEM. For maintenance, cells 
were cultivated on 10 cm dishes and splited once a week in a 1:10 to 1:20 ratio. There-
fore, medium was aspirated and 2 ml of trypsin was added to detach the cells. After 2-3 
min, 8 ml of complete medium was added to stop trypsinization and the cells were re-
suspended carefully. For 1:10 ratio, one ml of the cell solution was spread to the desired 
number of plates and 9 ml of complete medium was added and mixed gently. After 2-3 
days medium was changed. 
For long-term storage cells were stored in liquid nitrogen. Therefore, cells of a confluent 
10 cm dish were trypsinized and pelleted by centrifugation (500xg, 2 min, room tempera-
ture). Subsequently, the pellet was resuspended in 3.8 ml freezing medium and divided 
to two cyro vials and put into a cooling container (Mr. Frosty), which was placed at -80°C 
overnight. The use of the container provides a –1°C/minute cooling rate required for 
successful cell cryo preservation and recovery. Afterwards, the vials are stored for long 
term in liquid nitrogen. 
For re-cultivation of frozen cells, vials were thawed at 37°C and directly mixed with 8 ml 
of complete medium. After 8 to 16 hours the medium was changed to eliminate DMSO 
contained in freezing medium. Usually, cells were cultivated for one to two weeks prior 
experimental use. 
3.1.14 Cell counting 
For cell counting, cells were trypsinized and resuspended in complete DMEM. After-
wards, 10 µl of cell suspension was mixed with 90 µl trypan blue, a diazo dye which is 
taken up only by dead cells, whereby these cells are stained blue. An aliquot of the mix 
was loaded on the Neubauer chamber and viable cells (“white” cells) were counted in 
bright field microscope as depicted in Figure 11.  
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Figure 11: Neubauer-
improved chamber counting 
grid detail.  
Cells located in the outer 
big 4 squares are counted. 
 
For calculation of cell number, the mean of counted cells per big square was multiplied 
by the dilution factor (which is 10, if diluted as described above) and the chamber factor 
(1*104) and gives the number of cells per ml.  
3.1.15 Transfection of HEK 293T cells 
For transfection of HEK 293T cells, Lipofectamine 2000 was used. This reagent is based 
on the lipofection, whereby genetic material is injected into a cell by means of lipo-
somes, which are vesicles that can easily merge with the cell membrane since they are 
made of a phospholipid bilayer. The positive surface charge of the liposomes mediates 
the interaction of the nucleic acid and the cell membrane, allowing for fusion of the lipo-
some/nucleic acid transfection complex with the negatively charged cell membrane.  
One day prior to transfection cells were seeded on 6-well plates to reach a confluency of 
80 to 90% on the next day. Per 6-well, 2 µg plasmid DNA was diluted in 150 µl of Opti-
MEM and mixed. In a second reaction vial 10 µl of Lipofectamine 2000 was diluted in 
150 µl of OptiMEM. The plasmid-OptiMEM mix was added to the diluted Lipofectamine 
and mixed by inverting. The plasmid-Lipofectamine-OptiMEM mix was incubated for 5 
min at room temperature. In the meantime, medium was aspired and 1 ml of OptiMEM 
was added to the cells. The plasmid-lipid complex was added carefully to the cells and 
mixed gently. Four hours later the medium was discarded and the cells were incubated 
with appropriate medium. 
3.1.16 CRISPR/Cas9 based gene editing technique 
Bacteria and archaea have evolved RNA-mediated adaptive defense systems that pro-
tect organisms from invading viruses and plasmids [84, 85]. The clustered regularly in-
terspaced short palindromic repeats (CRISPR) system has currently been adapted to 
genome editing research with a wide spectrum of organisms. Naturally, the system re-
lies on CRISPR RNAs (crRNAs) in complex with CRISPR-associated (Cas) proteins to 
direct degradation of complementary sequences present within invading viral and plas-
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mid DNA. Three types of CRISPR mechanisms have been identified, of which type II 
from Streptococcus pyogenes is the most studied, because single Cas9 along with crR-
NA and tracrRNA (trans-activating CRIPSR RNA) seems to be sufficient for cleaving the 
target DNA [86].  
Based on the type II CRISPR system an optimized two-component system using single 
guide RNA (sgRNA) and Cas9 was established [84] (Figure 12). Thereby, sgRNA con-
sists of a fusion between trRNA and crRNA which can be used to produce sequence-
specific double strand breaks (DSBs). The target sequence for introduction of DSB con-
sists of a 20-bp DNA sequence complementary to the sgRNA, followed by protospacer 
adjacent motif (PAM, 5'-NGG-3'). The Cas9 nuclease digests both strands of the ge-
nomic DNA three to four nucleotides 5' of the PAM sequence. By introducing different 
guide RNA sequences, the Cas9 can be programmed to introduce site-specific DNA 
double-strand breaks virtually anywhere in the genome where a PAM sequence is locat-
ed. The double-stranded break at the target site induces DNA repair mechanisms, such 
as non-homologous end joining (NHEJ) that create insertions and deletions leading to a 
premature stop codon, and homology-directed recombination (HR) for introducing new 
sequences. 
 
Figure 12: CRISPR Cas9 gene editing tool to modify genomic DNA.  
The nuclease Cas9 introduces double stranded breaks, which is repaired non-homologous end 
joining (NHEJ) or homologous recombination (HR). By NHEJ random insertions or deletions (in-
dels) at the target site are created. By means of recise changes based on template DNA can be 
introduced. Taken and modified from http://www.transomic.com/Products/transEdit.aspx, visited 
on 04-Dec-2017.  
 
The CRISPR/Cas9 gene editing tool was used to generate VKORC1 and VKORC1L1 
knockout HEK 293T cell lines. In addition, the same technique was used to accomplish 
VKORC1L1 knockout mice.  
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3.2 Characterization of VKORC1 and VKORC1L1 in vitro 
3.2.1 Generation of HEK 293T KO lines  
HEK 293T cells were used to knockout VKORC1, VKORC1L1 or both, since those en-
zymes are able to recycle vitamin K epoxide. The generation of KO cell lines was done 
by the CRISPR/Cas9 system which allows a highly specific site directed mutagenesis at 
the target site. CRISPR vector containing the target crRNA was used for transfection of 
HEK 293T cells. The sequence introduced into the vector was GCTCTACGCGCTG-
CACGTGAAGG for VKORC1 and CCTACCACGTGGAGCGGGAGAAG for VKORC1L1. 
Two days after transfection, cells were seeded on 96-well plates to yield single cell 
clones. Therefore, cells were trypsinized and complete DMEM was added. After visual 
inspection, cells were diluted to yield about one single cell per well in a 96 well plate. 
The suspension was distributed to three to four 96-well plates and once a week medium 
was changed. Two to three weeks later, cells were grown to confluence and splitted for 
maintenance and genotyping. Therefore, cells were resuspended in about 50 µl old me-
dium and 5 µl of cell suspension was transferred to two new 96-well plates. The remain-
ing cells were prepared for long-term storage. Therefore, cells were resuspended in 
freezing medium (composed of 90% FBS, 10% DMSO) and the plates were stored over 
night at -20°C. Afterwards, the plates were transferred to -80°C for long-term storage. 
For genotyping, cells were harvested by aspiration of medium and addition of 100 µl 
MiSeq lysis buffer. Cells were resuspended and transferred to 96-well PCR plate and 
lysed by incubation at 65°C for 10 min followed by 15 min at 95°C. Plates were stored at 
-20°C until use. An aliquot was used for target gene amplification by PCR. The genetic 
profile was analysed using MiSeq sequencer (Illumina Inc., San Diego, CA, USA) and 
clones with deleterious VKOR were chosen for further analysis.  
3.2.2 FIX cell-based assay 
For assessment of inhibitory potential of OACs and related compounds the recently pub-
lished cell-based FIX activity assay was used [30]. The in vitro assay is based on the 
indirect measurement of VKOR activity by means of FIX, which is γ-carboxylated in the 
cell if VKOR supplies GGCX with KH2. Subsequently, FIX is measured by clotting assay, 
which is a modified aPTT assay. The basic principle of the cell-based assay is shown in 
Figure 13. Thereby, KO HEK 293T cells are transfected with cDNA of F9 (see section 
3.1.15) and the cells were grown for 3 days in 3 ml expression medium supplemented 
with K1 and the respective drug dilution. The supernatant was transferred to VivaSpin 
columns and centrifuged at 4000 rpm for 20 min at room temperature. The complete 
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supernatant was transferred to a vial and the column was rinsed with 300 µl of Dade 
Owren’s Veronal buffer. Samples were stored at -40°C until measurement. If double 
knockout (DKO) cells were used, the bicistronic vector pIRES containing cDNA of F9 
and VKOR variant was transfected. Further steps were performed as described above. 
 
Figure 13: Overview of FIX cell-based assay.  
HEK 293T single or double KO cells were transfected with F9 or with F9 concomitant with VKOR 
cDNA. Afterwards, cells were grown in expression medium containing K1 or K1>O and a respec-
tive dilution of 4-hydroxycoumarine or 1,3-indandione. After three days of incubation the cells 
were harvested by concentration of the cell culture supernatant on VivaSpin columns and FIX 
activity was assessed using a modified aPTT assay.  
 
The activated partial thromboplastin time (aPTT) is a global screening procedure which 
is used for the diagnosis of coagulant disorders and therapeutic monitoring of both hem-
orrhagic and thrombotic disease. To evaluate FIX levels of cell culture samples a modi-
fied aPTT was used. Therefore, 50 µl of FIX-deficient plasma was mixed with 20 µl of 
the sample and 75 µl of Actin FSL, which contains purified soy and rabbit brain phos-
phatides with plasma activator. The addition of calcium ions triggers the coagulation 
process, and the clotting time is measured on a coagulation analyzer BCS XP. By 
means of a calibration curve of standard pool plasma, values are given in percent FIX 
activity. 
3.2.3 Measurement of cell viability 
The influence of oxidative stress on different cell lines was assessed using the CellTiter 
96® AQueous One Solution Cell Proliferation Assay, which is a colorimetric method to 
determine the number of viable cells. Thereby, a tetrazolium compound (MTS) is con-
verted exclusively by viable cells into formazan, which can be measured at 490 nm. WT, 
VKORC1 KO and VKORC1L1 KO and DKO HEK 293T cells were seeded on 96 well 
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plates (5*105 cell/ml). Four hours later, different concentrations of H2O2 (0 to 100 µM) or 
50 µM H2O2 combined w/o K1 (12 µM) and w/o warfarin (500 nM) were added. After 18 
h, 15 µl of MTS reagent was added and incubated for 2 h in a humidified, 5% CO2 at-
mosphere. Finally, the absorbance at 490 nm was measured with a 96-well plate reader. 
For calculations, mean values were made and blank values subtracted. To normalize, 
control (i.e. cells without treatment) was set to 100%. 
3.2.4 Molecular modeling of VKORC1 and VKORC1L1 
Two different approaches were adopted to model the human VKORC1 and VKORC1L1 
proteins. A homology model of VKORC1 was previously constructed based on the X-ray 
crystal structure of the bacterial homologue (Synechococcus sp.) of VKORC1 (PDB ID: 
3KP9) (http://www.pdb.org/pdb/home/; accessed on 12-Dec-2012) and 3.6 Å resolution 
using YASARA (version12.9.27) homology modeling program [19, 21, 78]. The model of 
human VKORC1L1 (hVKORC1L1) was generated in an automated manner on the I-
TASSER modeling server (http://zhanglab.ccmb.med. umich.edu/I-TASSER/; accessed 
on 21-Oct-2015) [19, 87]. Although mostly default parameters were applied for modeling 
on this server, the 3.6 Å resolution X-ray crystallographic structure of 3KP9 was as-
signed as a guiding template for modeling on this server. Of five generated models, the 
best one was chosen based on the calculated C-score of -0.46 (models with C-score >-
1.5 are considered to be topologically correct with respect to protein fold). Comparison 
of backbone Cα alignment between the model and template structures was assessed 
using Mustang function embedded in YASARA. Stereochemical parameter quality of 
both models and their template structure 3KP9 was assessed and compared using the 
MOLPROBITY server (http://molprobity.biochem.duke.edu/; accessed on 25-Dec-2015). 
The models were refined using a short 500 ps simulation (AMBER03 force field) in a 
solvated environment. The model with the lowest energy was chosen as the final model. 
Since VKORC1 and VKORC1L1 are transmembrane proteins, further simulations were 
performed by first identifying hydrophobic amino acid and subsequently embedding the 
protein (in a simulation cell) in a 70% phosphatidylcholine and 30% phophatidylethano-
lamine membrane using YASARA. The simulation cell was then solvated with water, 
avoiding water from entering between the lipid molecules. An equilibration simulation 
lasting 250 ps was done to further artificially stabilize the membrane in order to adapt to 
the protein and appropriate density without being damaged. Post equilibration, a 100 ns 
simulation was run with AMBER03 force field parameters and from the resulting trajecto-
ry the structure with the lowest energy was chosen as the final models for hVKORC1 
and hVKORC1L1 for further docking analysis. 
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We used the automated AutoDock module (© 1989-2013 by The Scripps Research Insti-
tute) with default settings for small molecule docking embedded in YASARA to search 
for possible warfarin interaction sites on hVKORC1 and hVKORC1L1 models [78, 88]. 
Structure data format files (.sdf) for the ligands acenocoumarol (CID 54676537), bro-
madiolone (CID 547539), brodifacoum (CID 54680676), coumachlor (CID 54682651), 
coumatetralyl (CID 54678504), dicoumarol (CID 54676038), fluindione (CID 68942), 
phenindione (CID 4760), phenprocoumon (CID 54680692), S-warfarin (CID 54688261) 
were downloaded from the Pubchem database 
(https://pubchem.ncbi.nlm.nih.gov/search/; accessed on 25-Sep-2015) and converted to 
PDB format (.pdb) on YASARA using the AUTOSMILES function. All ligands were flexi-
bly docked onto the model of hVKORC1L1 and hVKORC1. Docking poses on 
hVKORC1L1 were selected on the basis of pseudo-energy scoring function as well as 
the relative orientation of positively charged stabilizing arginine residues in the ER lu-
menal loop towards the negatively charged aromatic rings of warfarin. Docking on 
hVKORC1 for all ligands except warfarin were chosen on the basis of their similarity to a 
favorable docking position identified for warfarin on hVKORC1 [21]. All selected docks 
were subjected to 100 ns of membrane embedded simulation. The docked complexes 
with the lowest energy in the simulation trajectory were picked as the final docked struc-
tures and analyzed for identifying the putative binding residues. 
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3.3 Generation of VKORC1L1 KO mice  
3.3.1 Strategy for integration of loxP sites into Vkorc1l1 locus 
To study the biological impact of VKORC1L1, we generated Vkorc1l1 transgenic mice. 
By means of the CRISPR/Cas9 gene editing system, loxP sites will be integrated flank-
ing exon 2 (Figure 14). Therefore, sgRNAs were designed to bind up- and downstream 
exon 2. Oligo donor DNAs contain the loxP site and 60 bp overhangs on each side ad-
joining DSBs introduced by Cas9. In case of DNA repair without integration of donor 
DNAs exon 2 (and adjacent regions) will be deleted.  
 
Figure 14: Design of the CRISPR/Cas9 targeting muriune Vkorc1l1 locus  
sgRNAs complementary to the target sequence are located up- and downstream of exon 2. Oligo 
donor DNAs comprised of loxP sites, complementary sequences of the target and a site for re-
striction enyzmes are used for integration of loxP sites. 
 
The experimental design and preparation of the samples for microinjection was done in 
collaboration with Dr. Noelia Fradejas Villar at the Institute of Biochemistry and Molecu-
lar Biology, University Bonn. For cloning the vector px330 containing a human codon-
optimized SpCas9 (Streptococcus pyogenes) and chimeric guide RNA expression was 
used (Figure 15) [89].  
 
 
Figure 15: pX330-U6-Chimeric_BB-CBh-hSpCas9 vector design. Taken from 
https://www.addgene.org/42230/ visited on 13-Jan-2018. 
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After amplification of the Cas9 and sgRNAs, the products were in vitro transcribed and 
purified. Prior to use, the components were mixed in order to avoid clotting of the needle 
during microinjection.  
 Volume in µl 
Cas9 mRNA (100 ng/µl)  1 
sgRNAs (50 ng/µl) Each 0.5  
Oligo donor ssDNA (100 ng/µl) Each 0.5 
Nuclease-free water 2 
 
Microinjection was performed in collaboration with the animal facility at the University 
Hospital Bonn. Therefore, components of CRISPR/Cas9 were injected in BL6 oocytes 
(pronucleus). Approximately three weeks later pups were born and weaned another 
three weeks later. At the age of 8 to 10 weeks heterozygous mice were mated with BL6 
mice in order to verify germline mutation. Subsequently, mice were mated with BL6 for 
backcrossing to “dilute” possible off-target effects.  
3.3.2 Genotyping of transgenic mice 
Mice were kept under standard housing conditions in a 12 hour light-dark cycle with food 
and water ad libitum in accordance with local and state regulations concerning animal 
research. Mouse tail biopsies were used for genotyping. Therefore, about 2 mm of tail 
were cut and transferred into a 1.5 ml vial. For lysis of the tissue, 200 μl mouse tail lysis 
buffer containing 200 μg/ml proteinase K was added and incubated over night at 55°C 
followed by heat inactivation at 80°C for 30 min. For genotyping, the lysed tails were 
diluted 1:6 with water. The samples were used directly or stored at -20°C.  
Genotyping was performed using two different sets of primers. The scheme of for geno-
typing is depicted in Figure 16. RFLP-F and RFLP-R primers were used to amplify a 
2350 bp product for the WT allele and an 1140 bp for the KO allele. The second set am-
plifies products which are smaller in size. In the WT allele, all three primers can bind to 
the DNA, however, the cycling conditions restrict to amplify only the smaller product. 
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Figure 16: Overview of primers designed to genotype VKORC1L1 KO mice. 
The genotyping were performed with two different sets of primers. RFLP primers (in blue) were 
used to amplify products of 2.4 kb and 1.1 kb, respectively. L1_KO primers (in claret) were de-
signed to amplify smaller products to shorten PCR running time. Not drawn to scale. 
 
The reaction mix for both PCRs was set as follows: 
 Volume in µl 
1x DreamTaq buffer  23 
Diluted sample (1:6) 2 
Primer (each 20 µM) 0.5 
Solution S 2 
DreamTaq polymerase (5 U/µl) 0.25 
 
The program at the thermocycler for RFLP primers was as follows: 
Step 1 95°C 3 min   
Step 2 95°C 30 s  
Repeat 10x Step 3 68°C 30 s 
Step 4 72°C 2 min 30 s 
Step 5 95°C 30 s  
Repeat 10x Step 6 66°C 30 s 
Step 7 72°C 2 min 30 s 
Step 8 95°C 30 s  
Repeat 15x Step 9 64°C 30 s 
Step 10 72°C 2 min 30 s 
Step 11 72°C 7 min 
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The program at the thermocycler for L1_KO primers was as follows: 
Step 1 95°C 3 min   
Step 2 95°C 30 s  
Repeat 35x Step 3 68°C 30 s 
Step 4 72°C 30 s 
Step 5 72°C 7 min 
 
For analysis, the products were mixed with 5 µl of loading dye and 10 µl of the mix was 
loaded on a 1% agarose gel (3.1.7). 
3.3.3 Total RNA isolation 
For quantitative PCR, total RNA was isolated from tail cut (~5 mm). Therefore, the piece 
of tail was directly placed in 1 ml Trizol. After homogenization with pistil, 200 µl of chloro-
form was added and mixed vigorously. By centrifugation (15000 rpm, 4°C, 15 min), the 
aqueous phase (which contains the RNA) was separated from the organic phase. The 
upper phase was pipetted into a new cup and mixed with the same volume of 100% 
ethanol. The next steps were carried out according to manufacturer’s instructions using 
the RNeasy Mini Kit. For digestion of genomic DNA, incubation with RNase-Free DNase 
was included. Finally, the RNA was eluted in 50 µl RNase-free water and concentration 
of the sample was determined spectrophotometrically (3.1.11). The samples were stored 
at -80°C until use. 
3.3.4 cDNA synthesis 
RNA was reverse transcribed into cDNA using the qScript cDNA Synthesis Kit. The re-
action mix contains an optimized blend of random and oligo(dT) primers which allows 
unbiased first-strand synthesis. 
 Volume in µl 
5x qScript Reaction Mix  4 
RNA (up to 1 µg) Variable 
qScript RT 0.5 
dH2O Variable 
Total  20 
 
The mix was incubated at 22°C for 5 min followed by 42°C for 30 min. Subsequent incu-
bation at 85°C for 5 min lead to the inactivation of the enzyme. The samples were stored 
at -20°C until use.  
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3.3.5 Quantitative PCR using TaqMan assay 
For quantitative PCR (qPCR), the TaqMan assay was used to monitor the increase of 
PCR products by means of fluorescence in real-time. Thus, the probe contains a fluo-
rescent dye at the 5’ end (FAM, Fluorescein amidite) and a quencher (BHQ1, Black Hole 
Quencher 1) at its 3’ end. During PCR the primers and the probe hybridize complemen-
tary to the template and the DNA polymerase refills the strand. When the probe is 
reached, the polymerase cleaves off the probe by its 5’-3’ exonuclease activity. During 
degradation of the probe the fluorescent dye is no longer quenched and a fluorescence 
signal is detected which is proportional to the number of amplicons. 
The primer/probe mix for Vkorc1l1 contained 10 µM of each primer and 5 µM of the 
probe. The final concentration in the mix was then 500 nM for primers and 100 nM for 
the probe, respectively. As an internal control, Hprt1 (hypoxanthine phosphoribosyltrans-
ferase 1, Mm00446968_m1) was used as a housekeeping gene.  
AgPath-ID™ One-Step RT-PCR was used to analyze RNA directly. Thereby, the re-
verse transcription (by ArrayScript™ Reverse Transcriptase) is included in the reaction 
mix of real-time PCR (by AmpliTaq Gold® DNA Polymerase). Hence, the reverse pri-
mers for the respective gene (Vkorc1l1 or Hprt1) were used for cDNA synthesis. The 
reaction mix was set as follows. 
 Volume in µl 
2x RT-PCR Buffer  12.5 
RNA 1 
25x RT-PCR Enzyme Mix 1 
Primer/probe mix 1.25 
dH2O 9.25 
Total  25 
 
The program was as follows: 
Step 1 45°C 15 min cDNA synthesis 
Step 2 95°C 10 min RT inactivation and initial denaturation 
Step 3 95°C 15 s Amplification of target 
Step 4 60°C 1 min 
Repeat step 3 to 4 40 times  
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Secondly, the samples were analyzed in a two-step quantitative real-time PCR. Taq-
Man® Gene Expression Master Mix contains beside AmpliTaq Gold® DNA polymerase 
a uracil-DNA glycosylase (UDG). This enzyme destroys carry-over PCR products by 
removing any uracil in a single or double stranded amplicon. The reaction mix was set-
up as described below. 
 Volume in µl 
2x TaqMan® Gene Expression Master Mix 12.5 
cDNA 2 
Primer/probe mix 1.25 
dH2O 10.5 
Total  25 
 
The program was as follows: 
Step 1 50°C 2 min UDG incubation 
Step 2 95°C 10 min 
UDG inactivation, polymerase activation 
and initial denaturation 
Step 3 95°C 15 s Amplification of target 
Step 4 60°C 1 min 
Repeat step 3 to 4 40 times  
 
For evaluation of qPCR, the threshold cycle (CT) value was determined. Thereby, the CT 
value is equal to the cycle number at which the fluorescence crosses the threshold. 
Therefore, the CT value represents the detectable amount of amplicon product that has 
been generated during the early exponential phase of the PCR. The threshold cycle is 
indirectly proportional to the original relative expression level of the gene of interest. 
Samples were analyzed in duplicates and mean values were determined. The ratio of 
Vkorc1l1 expression of WT (+/+) to heterozygous KO (+/d) or homozygous KO (d/d) was 
calculated. Thus, the ratio for WT/WT was set as 1.  
ΔCT = CTVkorc1l1 - CTHprt1 
ΔΔCT = ΔCT+/d - ΔCT+/+ 
Ratio = 2-ΔΔCT 
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3.3.6 Phenotypic screen Vkorc1l1-/- mice 
Vkorc1l1-/- mice were characterized using a standardized, comprehensive phenotyping 
as established in German Mouse Clinic (GMC) with open access to the scientific com-
munity.In the GMC, experts from various fields of mouse physiology and pathology in 
close cooperation with clinicians work side by side at one location. The examinations 
comprise the following areas: allergy, behavior, clinical chemistry, dysmorphology, ener-
gy metabolism, eye development and vision, host-pathogen interactions, immunology, 
lung function, molecular phenotyping, neurology, nociception, and pathology. A stand-
ardized screen was conducted as depicted in Figure 17. 
 
 
Figure 17: Workflow for primary mouse screening in the German Mouse Clinic.  
The picture was taken from the website of the German Mouse Clinic 
https://www.mouseclinic.de/screens/overview/index.html visited on 25-Sep-2017. 
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4 Results 
4.1 Characterization of VKORC1 and VKORC1L1 in vitro 
4.1.1 Generation of HEK 293T knockout cell lines 
To study VKORC1 and VKORC1L1 independently, knockout (KO) cells of either enzyme 
were generated by means of CRISPR/Cas9 gene editing system (3.2.1). In addition, a 
double knockout (DKO) cell line was established to analyze different variants of 
VKORC1 or VKORC1L1 without sophisticated endogenous VKOR activity.  
HEK 293T cells harbor a triploid set of chromosomes 7 and 16, i.e. three copies of 
VKORC1 and VKORC1L1 in HEK 293T cells are present [90]. In Figure 18 the genetic 
profile of the single and double knockout cell lines is shown. In the VKORC1 KO cell line 
(clone 2D1), the gene locus of VKORC1 showed a 19 bp deletion concomitant with a 
base substitution resulting in a shortened protein of 88 amino acids (aa). VKORC1L1 
KO (clone 2H2) showed a deletion and an insertion in the VKORC1L1 gene, which led 
to a frameshift and resulted in longer proteins (214 and 215 aa, respectively). In DKO 
cells (clone 1F11), genetic manipulation generated insertion and deletion on VKORC1 
locus, whereby protein was reduced in length (123 aa, 130 aa, and 159 aa, respective-
ly). The VKORC1L1 locus showed an insertion of one nucleotide (prolonged: 215 aa) 
and a four nucleotide deletion (shortened: 55 aa).  
 
 
Figure 18: CRISPR/Cas9-mediated gene editing of VKORC1 (NM_024006.4) and VKORC1L1 
(NM_173517.4) loci in HEK 293T cells.  
The wild-type sequence for both genes (c.70-116 of VKORC1 and c.88-131 of VKORC1L1) is 
shown on the top, deletions are indicated by dashes, insertion and substitution is shown in red. 
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4.1.2 Characterization of HEK 293T knockout cell lines  
In order to verify the ability of VKORC1 KO and VKORC1L1 KO cells to activate FIX, 
hF9 cDNA was transiently expressed using the previously described cell-based assay 
[30]. After transfection, cells were supplemented with expression medium containing 12 
µM vitamin K1, supernatant was collected as described in section 3.2.2. For comparison, 
WT HEK 293T cells were used as a control, because these cells express endogenously 
VKORC1 and VKORC1L1. When analyzing the enzymes separately by means of 
VKORC1L1 KO and VKORC1 KO cells, both enzymes were able to provide substrate 
(KH2) for activation of FIX (Figure 19), as shown by FIX activity of 58% for VKORC1L1 
KO and 41% VKORC1 KO compared to 51% for WT HEK 293T cells. To completely 
inactivate vitamin K recycling a DKO HEK 293T cell line was generated, in which 
VKORC1 and VKORC1L1 were silenced. The assessment of FIX yielded no activity (i.e. 
below detection limit of 0.25% with SEM of zero) in the presence of 12 µM vitamin K1 
(Figure 19). 
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Figure 19: Measurement of FIX activity.  
WT, VKORC1L1 KO and VKORC1 KO and DKO HEK 293T cells were transfected with hF9 
cDNA and expression medium was supplemented with 12 µM K1. Three days post transfection 
cell culture supernatant was harvested and FIX activity was assessed. Measurements were per-
formed in triplicates, error bars represent +/- SEM. FIX activity in DKO cells was below detection 
limit of 0.25% in all replicates. 
 
HEK 293T cells were analyzed with regard to their expression level of VKORC1 and 
VKORC1L1. For this purpose cDNAs of both genes were cloned into one vector and a 
serial dilution was used to yield a standard curve during qPCR. Endogenously, VKORC1 
mRNA exceeded VKORC1L1 mRNA by approximately 10-fold (Table 1). In VKORC1 
KO cells VKORC1 mRNA could not be detected. In VKORC1L1 KO cells mRNA tran-
scripts of VKORC1L1 were detected, but with lower copy number compared to WT HEK 
293T cells. The same was observed in DKO cells, qPCR showed clear amplification 
curves with a lower copy number for both analytes compared to WT cells. When 
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VKORC1 or VKORC1L1 were overexpressed in DKO cells, equal copy numbers were 
detected. In contrast, analysis of protein expression level is difficult due to absent anti-
bodies which can discriminate between both VKOR enzymes. 
 
Table 1: Quantification of VKORC1 and VKORC1L1 transcripts in various cell lines. 
Endogenous mRNA expression level was determined in HEK 293T, VKORC1 KO, VKORC1L1 
KO and DKO cells. In addition, DKO cells after transfection of VKORC1/VKORC1L1 and F9 were 
used for analysis. 
Cell line 
Target 
amplification 
Copies/µl 
HEK 293T VKORC1 3.3*10
6
 
HEK 293T VKORC1L1 4.1*10
5
 
VKORC1 KO (2D1) VKORC1 Not detected 
VKORC1L1 KO (2H2) VKORC1L1 1.4*10
3
 
DKO (1F11) VKORC1 5.4*10
2
 
DKO (1F11) VKORC1L1 8.4*10
3
 
DKO (1F11), transfected with 
VKORC1+F9 
VKORC1 6.0*10
8
 
DKO (1F11), transfected with 
VKORC1L1+F9 
VKORC1L1 5.1*10
8
 
 
4.1.3 Susceptibility of HEK 293T cell lines to oxidative stress 
Hydrogen peroxide is present in HEK cells as a metabolite in low concentrations and is 
spontaneously converted to highly reactive hydroxyl radicals (HO•). To measure the 
potential to resist oxidative stress, cells were incubated with increasing concentrations of 
H2O2. By adding MTS, the dye is converted only by viable cells into formazan, which can 
be measured photometrically at 490 nm. Thus, lower extinction values represent for 
lower number of viable cells.  
VKORC1L1 KO cells were compared to VKORC1 KO and DKO HEK 293T cells, HEK 
293T WT cells served as control (Figure 20). The cell lines showed different susceptibili-
ties to H2O2 treatment. Incubation with 25 µM H2O2 did not result in great variance in 
comparison to the control, whereby the highest concentration (100 µM) showed marked-
ly reduction of viable cells in all cell lines. A considerable effect of H2O2 treatment was 
seen using concentration higher than 50 µM.  
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Taken together, VKORC1L1 KO and DKO cells were most affected by H2O2 treatment 
for concentrations ranging between 50 and 100 µM.  
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Figure 20: Cell viability in dependence of different H2O2 concentrations.  
Cells were incubated with different concentrations of H2O2. After 18 h, MTS was added to the 
cells and incubated for two hours, the absorbance was recorded at 490 nm with a 96-well plate 
reader. Measurements were performed three times in triplicates, values are shown as mean +/- 
SEM.  
 
In order to test the ability of vitamin K1 to reverse oxidative stress, cells were treated with 
50 µM H2O2 in combination with warfarin (500 nM) and K1 (12 µM). The results are 
shown in Figure 21. The negative control (black bars) displays cells without any treat-
ment and these values were set as a reference (100%). Treatment with 50 µM H2O2 is 
designated as positive control (white bars). The grey bars (in different nuances) show 
treatment with 50 µM H2O2 plus vitamin K1 alone, vitamin K1 in combination with warfarin 
or warfarin alone. In comparison to the negative control, H2O2 treatment resulted in re-
duced viability of the cells, as already shown in Figure 20. Supplementation of K1 led to 
partial reversal of H2O2 treatment since the cells showed higher values compared to 
positive control. Inhibition of VKOR by 500 nM warfarin did not reduce cell viability, but 
quite contrary reverse H2O2 treatment in all cell lines but not DKO cells. Combination of 
K1 and warfarin treatment appeared to reverse H2O2 treatment only little in DKO and WT 
HEK 293T cells. In VKORC1 and VKORC1L1 KO cells K1 and warfarin showed higher 
values compared to K1 supplementation alone.  
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Figure 21: Impact of vitamin K1 and warfarin on cell viability.  
Negative control: without H2O2, positive control: 50 µM H2O2. The other bars represent cells 
incubated with 50 µM of H2O2 +/- vitamin K1 (12 µM) and +/- warfarin (500 nM). Measurements 
were performed three times in triplicates, values are shown as mean +/- SEM. 
 
4.1.4 Inhibition profile of various oral anticoagulants in VKORC1 and 
VKORC1L1 KO cells 
To test the susceptibility of either VKORC1 or VKORC1L1 to OACs the VKORC1L1 KO 
and VKORC1 KO cells were exposed to different drugs. The experiments were per-
formed as described in 3.2.2 with K1 as substrate. The FIX activity assessed in cells 
incubated without drug was set to 100% and measurements from different drug concen-
trations were related to the control. The inhibition curves and calculations were made 
with GraphPad Prism 5.  
Coumarin (Figure 22, left graph) showed no ability to reduce FIX activity as normalized 
FIX activity did not fall below 80%, whereby concentrations up to 1 mM of coumarin 
were tested. In contrast, 4-hydroxycoumarin (Figure 22, right graph) was capable to in-
hibit VKORC1 (measured in VKORC1L1 KO cells) and VKORC1L1 (measured in 
VKORC1 KO cells), although a diverse inhibition pattern was observed. VKORC1 
showed higher susceptibility to 4-hydroxycoumarin compared to VKORC1L1. However, 
both enzymes were completely inhibited by 1 mM 4-hydroxycoumarin, i.e. no FIX activity 
was measured. 
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Figure 22: Inhibition curves of coumarin and 4-hydroxycoumarin tested in VKORC1 KO (blue 
curves) and VKORC1L1 KO (red curves) HEK 293T cells.  
Measurements were performed in triplicates, values are shown as mean and error bars are rep-
resented as SEM. 
 
Next, therapeutically used coumarins were investigated (Figure 23), namely dicoumarol, 
warfarin, phenprocoumon, and acenocoumarol.  
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Figure 23: Inhibition curves of OACs with 4-hydroxycoumarin backbone tested in VKORC1 KO 
(blue curves) and VKORC1L1 KO (red curves) HEK 293T cells.  
Measurements were performed in triplicates, values are shown as mean and error bars are rep-
resented as SEM. 
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This group of coumarins showed the same inhibition pattern as obtained for 4-
hydroxycoumarin, with VKORC1 being more sensitive than VKORC1L1. However, the 
difference in sensitivity for dicoumarol and warfarin was greater than for phenprocoumon 
and acenocoumarol since the curves showed higher divergence for VKORC1 and its 
paralog. A remark concerns the inhibition pattern of dicoumarol. It was not possible to fit 
the 4-parameter logistic curve for dicoumarol data, because it appeared to be biphasic. 
Therefore, direct measurements were used to estimate the half maximal inhibitory con-
centration (VKORC1 49.1% at 5 nM, VKORC1L1 48.2% at 100 nM of mean normalized 
activities with respect to control). 
The other group of OACs, the synthetic indandione derivatives, was investigated as well. 
Phenindione and fluindione (Figure 24) both showed high enzyme specificity since 
VKORC1 was inhibited at markedly lower concentrations than VKORC1L1. 
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Figure 24: Inhibition curves of OACs with 1,3-indandione backbone (phenindione and fluindione) 
tested in VKORC1 KO (blue curves) and VKORC1L1 KO (red curves) HEK 293T cells.  
Measurements were performed in triplicates, values are shown as mean and error bars are rep-
resented as SEM. 
 
Synthetic coumarins were originally intended for rodent control. Coumatetralyl and cou-
machlor belong to the group of rodenticides of the first generation, whereby bromadio-
lone and brodifacoum were developed later and are referred to second generation of 
rodenticides. Dose-response curves of the before mentioned rodenticides are shown in 
Figure 25.  
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Figure 25: Inhibition curves of rodenticides belonging to the first (coumatetralyl and coumachlor) 
and the second generation (bromadiolone and brodifacoum).  
Compounds were tested in VKORC1 KO (blue curves) and VKORC1L1 KO (red curves) HEK 
293T cells. Measurements were performed in triplicates, values are shown as mean and error 
bars are represented as SEM. 
 
Coumatetralyl and coumachlor showed less enzyme specificity compared to OACs since 
inhibition curves do not differ markedly. Indeed, those two rodenticides are slightly more 
effective to inhibit VKORC1. In contrast, bromadiolone and brodifacoum had a higher 
impact on VKORC1L1 compared to VKORC1, although the effect is not as prominent as 
seen for other anticoagulants (e.g. warfarin or fluindione). 
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Ferulenol, a natural occurring 4-hydroxycoumarin, was tested in VKORC1 KO and 
VKORC1L1 KO cells (Figure 26). The inhibition pattern of VKORC1 and VKORC1L1 
differed as VKORC1 showed a higher susceptibility to ferulenol treatment than 
VKORC1L1.  
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Figure 26: Inhibition curves of 
ferulenol tested in VKORC1 KO 
(blue curves) and VKORC1L1 
KO (red curves) HEK 293T 
cells.  
Measurements were performed 
in triplicates, values are shown 
as mean and error bars are 
represented as SEM. 
 
Half-maximum inhibitory concentration (IC50) was calculated as described by Fregin et 
al. by solving the 4-parameter logistic equation representing dose-response curve fits for 
the independent variable (drug concentration), as a function of the dependent variable 
(normalized activity), and substituting a dependent variable value of 50 since FIX mean 
activities were normalized to a maximum value of 100% in the absence of a drug (e.g. 
warfarin) [30]. Calculations were performed using GraphPad Prism 5 and the results are 
summarized in Table 2.  
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Table 2: Overview of OACs and rodenticides with K1 supplementation. 
The compound class as well as half maximum inhibitory concentrations (IC50) assessed in 
VKORC1L1 KO and VKORC1 KO HEK 293T cells are shown. Measurements were performed in 
triplicates. Enzyme activities assessed up to 1 mM coumarin;**Biphasic dose-response not fit-
table with logistic curve; values from n=3 direct measurements (VKORC1 49.1%, VKORC1L1 
48.2% mean normalized activities with respect to 0 nM dicoumarol); NA - not applicable, 4HC – 
4-hydroxycoumarin, C1 – VKORC1, L1 – VKORC1L1.  
Compound Compound class 
VKORC1 
IC50 (nM) 
VKORC1L1 
IC50 (nM) 
Ratio 
L1/C1 
Coumarin  Inactive backbone 
Not 
inhibitory* 
Not 
inhibitory* 
NA 
4-Hydroxycoumarin Active 4HC backbone 1978 25110 12.7 
Dicoumarol  
Naturally occurring and 
therapeutic 4HC  
5.0** 100.0** 20.0 
Warfarin 
Human therapeutic 
4HC and rodenticide 
1.9 25.2 13.4 
Acenocoumarol 
Human therapeutic 
4HC 
1.5 5.8 3.9 
Phenprocoumon 
Human therapeutic 
4HC 
3.6 10.5 2.9 
Phenindione 
Human therapeutic  
indandione 
2.9 258.0 89.0 
Fluindione 
Human therapeutic  
indandione  
4.8 268.5 55.9 
Coumatetralyl 
1st generation  
rodenticide 
1.9 2.8 1.5 
Coumachlor 
1st generation  
rodenticide 
0.7 1.0 1.4 
Bromadiolone 
2nd generation  
rodenticide 
1.6 0.8 0.5 
Brodifacoum 
2nd generation  
rodenticide 
0.5 0.4 0.8 
Ferulenol 
Naturally occurring 
4HC 
0.8 3.0 3.8 
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In addition, VKOR activity was assessed in VKORC1L1 and VKORC1 KO cells. In Fig-
ure 27 the inhibition curves are shown for warfarin, fluindione and coumachlor repre-
senting the three most important categories of OACs tested. In comparison to K1, the 
inhibition curves do not differ markedly when K1>O was used. One exception was ob-
served when VKORC1L1 KO cells were tested with fluindione as represented with high-
er dose requirements for inhibition. 
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Figure 27: Inhibition curves of warfarin, fluindi-
one and coumachlor tested in VKORC1 KO 
(blue curves) and VKORC1L1 KO (red curves) 
HEK 293T cells.  
In contrast to previous experiments, K1>O (12 
µM) was used. Measurements were performed 
in triplicates, values are shown as mean and 
error bars are represented as SEM. 
 
IC50 values where calculated for above mentioned compounds using K1>O as a sub-
strate and are summarized in Table 3.  
 
Table 3: Overview of compounds tested with supplementation of K1>O. 
Half maximum inhibitory concentrations (IC50) were assessed in VKORC1L1 KO and VKORC1 
KO HEK 293T cells. C1 – VKORC1, L1 – VKORC1L1 
Compound 
VKORC1 
IC50 (nM) 
VKORC1L1 
IC50 (nM) 
Ratio L1/C1 
Warfarin 2.4 27.0 11.3 
Fluindione 203.8 419.6 2.1 
Coumachlor 0.7 1.5 2.1 
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4.1.5 Investigation of antibiotics suspected to interfere with coagulation  
The group of β-lactam antibiotics, to which penicillins and cephalosporins belong to, has 
become widely used antimicrobials because of their broad antibacterial spectrum and 
excellent safety profile. Cephalosporins containing a methyltetrazole-thiol (MTT) group 
(Figure 28, lower panel) can cause hypoprothrombinemia, a bleeding disorder whereby 
prothrombin deficiency leads to impaired blood clotting [91]. 
 
General structure of cephalosporins1 Cephalosporin C2 
 
 
Moxalactam2 Cefamandole2 
 
 
  
Figure 28: Chemical structures of cephalosporins.  
Moxalactam and cefamandole are antibiotics containing a methyltetrazole-thiol (MTT) side chain 
(blue box). 
 
The results for three antibiotics of cephalosporin family are shown in Figure 29. Cepha-
losporin C was able to inhibit VKORC1 and VKORC1L1 only at high concentration (125 
µM). In contrast to the coumarins, VKORC1L1 showed higher susceptibility compared to 
VKORC1. Moxalactam did not have properties to inhibit VKOR, since normalized FIX 
activities did not fall below 80% irrespective of the enzyme investigated. Cefamandole 
showed similar inhibition profile like cephalosporin C, however the highest concentration 
(125 µM) was toxic to the cells (cells detached after incubation time).  
                                               
1
 http://whitesscience.com/product/qsar-modeling-of-beta-lactam-antibiotic-cephalosporin-
against-transpeptidase-using-mlr-method/, visited on 19-May-2018 
2
 https://en.wikipedia.org/wiki/, visited on 19-May-2018 
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Cefamandole 
Figure 29: Inhibition curves of selected antibi-
otics suspected to interfere with anticoagula-
tion therapy.  
Cephalosporin C, moxalactam and cefaman-
dole were tested in VKORC1 KO (blue curves) 
and VKORC1L1 KO (red curves) HEK 293T 
cells. Measurements were performed in tripli-
cates, values are shown as mean and error 
bars are represented as SEM. 
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To investigate the cumulative effect of warfarin and antibiotics, VKORC1 KO and 
VKORC1L1 KO HEK 293T cells were incubated with warfarin concentration specific for 
each cell line to reach half-maximal inhibition. VKORC1 KO cells were incubated with 25 
nM warfarin and different concentrations of cephalosporins, whereby VKORC1L1 KO 
cells were treated with 2.5 nM warfarin. The values were normalized to the control rep-
resenting cells incubated without any drug. The results are shown in Figure 30. Treat-
ment of warfarin yielded about 40% normalized FIX activity related to control. The addi-
tion of moxalactam, cefamandole or cephalosporin C did not result in further reduction of 
FIX activity. Only cefamandole at the lowest concentration (125 nM) resulted in reduced 
values, however increasing concentrations of that antibiotic gave results comparable to 
that of warfarin treatment alone. 
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Figure 30: Effect of warfarin and antibiotic combination on FIX carboxylation.  
VKORC1 KO shown in blue columns, whereas VKORC1L1 KO is shown in red. Control repre-
sents incubation without warfarin, whereby the second column shows warfarin incubation to yield 
half-maximal inhibition of endogenous VKOR (VKORC1 KO: 25 nM, VKORC1L1 KO: 2.5 nM 
warfarin). Subsequent columns show treatment of the cells with different antibiotic (moxalactam, 
Mox; cefamandole, Cef; cephalosporin C, CeC) and warfarin. Measurements were performed in 
triplicates, values are shown as mean and error bars are represented as SEM. 
 
4.1.6 Characterization of inhibitor binding sites on VKOR enzymes in 
double knockout cells 
DKO cells were generated to abolish endogenous VKOR activity and were proven to be 
unable to activate FIX at a given vitamin K concentration (4.1.1). To study the effect of 
mutant VKORC1 or VKORC1L1, the bicistronic vector pIRES was used which allows the 
simultaneous expression of two proteins separately but from the same mRNA transcript. 
The cDNA of F9 was cloned into multiple cloning site A (MCS A), whereby MCS B har-
bors cDNA of VKORC1 or VKORC1L1 and the respective variants. Cloning was per-
formed as described in sections 3.1.1 and 3.1.2. 
For warfarin and fluindione, OACs representing the two groups of investigated com-
pounds, dose-response curves were generated for overexpression of VKORC1 and 
VKORC1L1. In addition, loop swap variants were made. The alignment of loop regions 
of both enzymes showed 48 % identity (as indicated by asterisk in Figure 31) and 62 % 
similarity (as indicated by bold letters). The VKORC1 loop swap comprised amino acids 
Lys30 to Ser79 changed to Glu37 to Pro86 of VKORC1L1 and vice versa (Figure 31).  
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Figure 31: Alignment of loop region of VKORC1 and VKORC1L1.  
Human VKORC1 (NP_076869.1) protein sequence was aligned with sequence of VKORC1L1 
(NP_775788.2) using NCBI blast tool. Amino acids 30 to 79 of VKORC1 aligned to amino acids 
37 to 86 of VKORC1L1. Stars indicate identical amino acids, bold letters (grey background) rep-
resent amino acids with similar chemical properties. 
 
Endogenous VKORC1 showed higher susceptibility to warfarin and fluindione compared 
to VKORC1L1. In DKO HEK 293T cells, overexpression of VKORC1 presented highest 
susceptibility to warfarin and fluindione and VKORC1L1 required higher concentration 
for half-maximal inhibition (Figure 32). Calculations of IC50 values are given in Table 4. 
Thus, VKORC1 was about 27-fold more sensitive to warfarin treatment compared to 
VKORC1L1. Fluindione showed 6-fold higher potency to inhibit VKORC1. VKORC1 loop 
swap gave similar curves like those of VKORC1L1 WT for both compounds investigated 
which is also represented by similar IC50 values (e.g. VKORC1L1 WT: 474 nM and 
VKORC1 loop swap: 215 nM for warfarin). When VKORC1 loop was swapped into 
VKORC1L1 similar results were obtained, i.e. VKORC1L1 loop swap acted like 
VKORC1 WT with respect to warfarin and fluindione.  
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Figure 32: Inhibition curves for warfarin and fluindione assessed in DKO cells.  
Activity of VKORC1 (red) and VKORC1 loop swap (black), VKORC1L1 (blue) and VKORC1 loop 
swap (green) determined in DKO cells by overexpression of different constructs. Measurements 
were performed in triplicates, values are shown as mean and error bars are represented as 
SEM. 
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Table 4: IC50 values of warfarin and fluindione. 
DKO HEK 293T cells transfected with VKORC1 and VKORC1L1 and its respective loop swaps 
were supplemented with 12 µM K1 and warfarin to assess IC50 values by means of FIX cell-based 
assay. 
VKOR variant 
IC50 (nM) 
Warfarin Fluindione 
VKORC1 WT 16.8 121 
VKORC1 loop swap  251 572 
VKORC1L1 WT 589 738 
VKORC1L1 loop swap  16.8 309 
 
The previous experiment showed that the loop is important at least in warfarin and flu-
indione binding. To further limit the drug binding site, different modifications in VKORC1 
and VKORC1L1 were tested. First, it was proven that Phe55 in VKORC1 is essential in 
warfarin binding [21]. Therefore, phenylalanine 55 was substituted by alanine 
(Phe55Ala). As presented in Figure 33, this variant was resistant to warfarin treatment 
as concentrations up to 5 µM resulted only in ~40% reduction of normalized FIX activity.  
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Figure 33: Dose-response for warfarin of VKORC1 Phe55Ala (red curve) assessed in DKO cells.  
For comparison, VKORC1 WT is included (black curve). Measurements were performed in tripli-
cates, values are shown as mean and error bars are represented as SEM. 
 
By sequence alignment the corresponding amino acid of VKORC1 Phe55 in VKORC1L1 
was identified (Figure 34). To test the hypothesis that by introducing the “same” amino 
acid responsible for warfarin binding in VKORC1 would lead to a more sensitive en-
zyme, a mutant of VKORC1L1 at Leu62 was generated (Leu62Phe). Furthermore, the 
amino acids 60 to 62 of VKORC1L1 were changed to corresponding amino acids 53 to 
55 of VKORC1 (Ala60Arg, Ala61Val, Leu62Phe, see Figure 34), which represent the 
putative contact surface II of VKORC1 identified by previously published in silico analy-
sis [21]. 
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Figure 34: Alignment of loop region of VKORC1 with VKORC1L1. 
Amino acids 37 to 78 of VKORC1 aligned to amino acids 44 to 85 of VKORC1L1. Star indicates 
identical amino acids, bold letters represent amino acids with similar chemical properties. Red 
box shows contact surface II in VKORC1 identified by in silico analysis as published by 21. 
VKORC1 Phe55 is highlighted in yellow. 
 
The inhibition curves for VKORC1L1 Leu62Phe and the triple mutant comprising amino 
acids 60 to 62 are shown in Figure 35. Single and/or triple variant of VKORC1L1 was 
anticipated to move IC50 towards VKORC1, since more sensitive enzyme inhibition was 
expected. On the contrary, both constructs showed shift of dose-response curves to 
higher warfarin concentration. VKORC1L1 Leu62Phe required 3-fold higher warfarin for 
half-maximal inhibition compared to VKORC1L1 WT (Table 5). Moreover, the 
VKORC1L1 triple variant needed almost 4 times higher warfarin concentration for inhibi-
tion compared to VKORC1L1 WT. 
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Figure 35: Inhibition curves for warfarin of VKORC1L1 variants assessed in DKO cells.  
Normalized FIX activity is shown for VKORC1L1 Leu62Phe (blue) and 
Ala60Arg+Ala61Val+Leu62Phe (red). For comparison, VKORC1L1 WT is included (black curve) 
Measurements were performed in triplicates and values are shown as mean +/- SEM. 
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Table 5: IC50 values of warfarin for different VKORC1L1 variants. 
DKO HEK 293T cells transfected with VKORC1L1 variants were supplemented with 12 µM K1 
and warfarin to assess IC50 values by means of FIX cell-based assay. 
 
VKORC1L1 variants IC50 (nM) 
WT 474 
Leu62Phe 1543 
Ala60Arg+Ala61Val+Leu62Phe 1789 
 
The analysis of different OACs revealed different susceptibilities of the two enzymes 
investigated. By alignment of protein sequence and further in vitro analysis it was obvi-
ous that to some extent the loop plays an important role in drug binding. Furthermore, 
these results suggest that warfarin binding site of VKORC1L1 is different from VKORC1. 
On this occasion in silico analysis was performed to identify regions or single amino ac-
ids being responsible for different drug binding. Details of in silico analysis and subse-
quent in vitro experiments are described in the next section.  
4.1.7 In silico modeling of hVKORC1 and hVKORC1L1 
4.1.7.1 hVKORC1 in silico model 
In accordance with the template structure, the homology-based hVKORC1 model com-
prises similar secondary structural elements and overall protein fold i.e. four transmem-
brane domains and a long flexible/disordered ER luminal loop (Figure 36). An obvious 
similarity with the bacterial homologue is the presence of a highly conserved serine rich 
loose helix like region (Ser52-Ser57) in hVKORC1. The Trp59 (in bacteria Trp64) which 
has been suggested to be the anchor for this helix is in a similar position in our model. 
The TYA-motif (threonine, tyrosine, alanine) implicated in warfarin binding in previous 
studies was observed to be part of the fourth transmembrane helix and deep seated 
within the inner membrane (lipid part of the membrane). The critical cysteine disulfides 
(Cys43-Cys51 and Cys132-Cys135) are present in the ER lumenal loop and the fourth 
transmembrane domain.  
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Figure 36: In silico model of hVKORC1. 
Three dimensional structure shows four transmembrane domains and the ER luminal loop. The 
cysteines at amino acid positions 43, 51, 132 and 135 are depicted in blue, the TYA motif is 
shown in purple stick format. 
 
4.1.7.2 hVKORC1L1 in silico model 
The highest scored model from ITASSER for hVKORC1L1 showed a four transmem-
brane structure similar to that observed for the homology model of hVKORC1 (Figure 
36). Furthermore, the stereochemical parameters agree favorably when compared with 
the crystal structure represented by 3KP9. Structural alignment with 3KP9 showed a 
strong similarity of RMSD <1Å (i.e. 0.86 Å) over 110 aligned residues. Similarly align-
ment of the hVKORC1 and hVKORC1L1 model also showed strong structural similarity 
i.e. 0.96 Å over 146 aligned residues. Therefore the two models were more similar to 
each other across their entire length in comparison to the template 3KP9 especially in 
the region of the ER luminal loop. The ER luminal loops of both appear similar in struc-
ture but differed in the thioredoxin-like domain on 3KP9.  
The TYV-motif (threonine, tyrosine, valine), similar to TYA-motif in VKORC1, was ob-
served to be part of the fourth transmembrane helix. The critical cysteine disulfides 
(Cys50-Cys58 and Cys139-Cys142) are present in the ER lumenal loop and the fourth 
transmembrane domain.  
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Figure 37: In silico model of hVKORC1L1. 
Three dimensional structure shows four transmembrane domains and the ER luminal loop. The 
cysteines at amino acid positions 50, 58, 139 and 142 are depicted in blue, the TYV motif is 
shown in purple stick format. 
 
4.1.7.3 Docking of OACs on hVKORC1 
An initial coarse-grained rolling ball docking search using the deprotonated, open side-
chain form of S-warfarin yielded 14 interaction pair geometries. Visual inspection of the 
docked structures revealed one particular dock which was energetically most favorable 
(i.e. showed highest in silico binding energy) and was proximal to the loop cysteines and 
the CXXC motif. Docking of warfarin on VKORC1 model showed the concentration of a 
large number of high scoring docking poses within a hydrophobic pocket which is proxi-
mal to both disulfide bonds (Cys43-Cys51 and Cys132-Cys135). Simulation of one of 
these warfarin docked poses suggests that apart from strong hydrophobic interactions 
mediating this binding with several residues within this pocket, there are other types of 
interactions that come into play: A) cation-pi interaction of the warfarin rings with Phe55, 
B) charge stabilization of the anionic warfarin rings with proximal positively charged ar-
ginine residues (Arg33, Arg40 and Arg53), and C) a strong backbone hydrogen bond 
formed between an oxygen atom of warfarin and nitrogen backbone of Val134. When 
docking was performed on VKORC1 for the other OACs, they also showed favorable 
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docking poses (with high binding affinity) that were similar to the warfarin docking pose 
mentioned above indicating that this is the most likely binding site for OACs on VKORC1 
(Figure 38). 
 
 
 
Figure 38: Docking of several anticoagulants on hVKORC1. 
The backbone is depicted in green ribbon format while all docked coumarins are depicted in stick 
forms with different colors (warfarin: element; phenprocoumon: red; phenindione: green; fluindi-
one: yellow; dicoumarol: magenta; coumatetralyl: blue; coumachlor: cyan; brodifacoum: orange; 
bromadiolone: light blue, acenocoumarol: purple). The principle interacting residues in this bind-
ing pocket are depicted in blue stick format. 
 
4.1.7.4 Docking of OACs on hVKORC1L1 
The docking of warfarin as well as other OACs to hVKORC1L1 turned up a different site 
than the hydrophobic binding pocket observed on hVKORC1. This particular site on 
hVKORC1L1 also resides on the ER luminal loop, but actually lies diametrically opposite 
to it. The structural alignment of the hVKORC1L1 and hVKORC1 ER luminal loops 
shows that while they are very much similar in structure, they differ greatly in the amino 
acid composition, especially the distribution of charge stabilizing arginine residues.  
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Figure 39: Docking of several anticoagulants on hVKORC1L1. 
The backbone is depicted in grey ribbon format while all docked coumarins are depicted in stick 
forms with different colors (warfarin: element; phenprocoumon: red; phenindione: green; fluindi-
one: yellow; dicoumarol: magenta; coumatetralyl: blue; coumachlor: cyan; brodifacoum: orange; 
bromadiolone: light blue, acenocoumarol: purple). The principle interacting arginine residues in 
this binding pocket are depicted in blue stick format. 
 
4.1.8 Confirmation of in silico data by in vitro experiments 
Molecular modeling of warfarin to hVKORC1 revealed three putative arginines at posi-
tions 33, 40 and 53. To proof in silico data, the arginine residues were changed to glu-
tamic acid, which leads to reversal of polarity (from positively charged arginine to nega-
tively charged glutamic acid). The results are summarized in Figure 40 and the calculat-
ed IC50 values are given in Table 6. Compared to VKORC1 WT, all variants showed 
lower susceptibility to warfarin, the order of single mutants was 
Arg53Glu<Arg40Glu<Arg33Glu. Double mutants showed higher IC50 values, whereas 
Arg33Glu+Arg53Glu required about 80-fold more warfarin for half-maximal inhibition 
compared to VKORC1 WT. 
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Figure 40: Inhibition curves for warfarin of arginine variants of VKORC1 assessed in DKO cells.  
Arginine residues at amino acid positions 33, 40 and 53 were substituted by glutamic acid resi-
dues. Single as well as double mutants were tested with regard to their warfarin inhibition profile. 
For comparison, VKORC1 WT is included to the graph. Measurements were performed in tripli-
cates and values are shown as mean +/- SEM. 
 
Table 6: IC50 values of warfarin for different VKORC1 arginine variants. 
DKO HEK 293T cells transfected with VKORC1 variants were supplemented with 12 µM K1 and 
warfarin to assess IC50 values by means of FIX cell-based assay. 
 
VKORC1 variants IC50 (nM) 
WT 17.3 
Arg33Glu 129 
Arg40Glu 96 
Arg53Glu 39 
Arg33Glu+Arg40Glu 497 
Arg33Glu+Arg53Glu 1326 
 
In silico modeling of VKORC1L1 revealed putative binding sites with positively charged 
arginines stabilizing warfarin binding at positions Arg38, Arg42 and Arg68, which were 
mutated to glutamate (Figure 41 and Table 7). Single arginine mutants Arg38Glu and 
Arg42Glu showed almost indistinguishable inhibition pattern when compared to 
VKORC1L1 WT. The combination of Arg38Glu+Arg42Glu revealed an eight-fold higher 
requirement of warfarin compared to VKORC1L1 WT. The variants comprising Arg68 or 
a combination of all three residues were resistant to warfarin treatment, because con-
centration up to 5 µM showed maximum 20% reduction of normalized FIX activity 
(Arg68Glu) or even no effect (Arg38Glu+Arg42Glu+Arg68Glu).  
4 Results  76 
10 -3 10 -2 10 -1 100 101
0
20
40
60
80
100
IC50
VKORC1L1 WT
Arg38Glu
Arg42Glu
Arg68Glu
Arg38Glu+Arg42Glu
Arg38Glu+Arg42Glu+Arg68Glu
Warfarin concentration in µM
N
o
rm
a
liz
e
d
 F
IX
 a
c
tiv
ity
 (
%
)
 
Figure 41: Inhibition curves for warfarin of arginine variants of VKORC1L1 assessed in DKO 
cells.  
Arginine residues at amino acid positions 38, 42 and 68 were substituted by glutamic acid resi-
dues. Single, double and triple mutants were tested with regard to their warfarin inhibition profile. 
For comparison, VKORC1L1 WT is included to the graph. Measurements were performed in trip-
licates and values are shown as mean +/- SEM. 
 
 
Table 7: IC50 values of warfarin for different VKORC1L1 arginine variants. 
DKO HEK 293T cells transfected with VKORC1L1 variants were supplemented with 12 µM K1 
and warfarin to assess IC50 values by means of FIX cell-based assay. 
 
VKORC1L1 variants IC50 (nM) 
WT 474 
Arg38Glu 548 
Arg42Glu 602 
Arg68Glu Resistant* 
Arg38Glu+Arg42Glu 1624 
Arg38Glu+Arg42Glu+Arg68Glu Resistant* 
 
Of note, triple mutant showed reduced activity values, yielding about 15% FIX activity 
compared to 25% of double mutant and 44% of VKORC1L1 WT.  
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For quantification of overexpressed VKOR variants HEK 293T cells were transfected 
with myc-tagged VKOR variants. 48 hours post-transfection, cells were harvested. Ex-
pression was detected by Western Blot using an anti-c-myc- antibody including a load-
ing control (ERGIC-53). In Figure 42 VKORC1, VKORC1L1 and its loop swap variants 
were tested for their protein expression level. VKORC1L1 and its arginine variants were 
blotted as depicted in Figure 43. 
 
Figure 42: Western blot of VKOR variants analyzed for protein expression level with anti-c-myc-
HRP antibody. 
As loading control blot was stripped and tested for anti-ERGIC-53 expression. Mock – untrans-
fected cells 
 
 
Figure 43: Western blot of VKORC1L1 variants analyzed for protein expression level with anti-c-
myc-HRP antibody. 
As loading control blot was stripped and tested for anti-ERGIC-53 expression. Mock – untrans-
fected cells 
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4.2 Generation of VKORC1L1 KO mice 
In order to verify the biological function of VKORC1L1 in vivo a mouse model was used. 
Therefore, genetically modified mice were generated by means of CRISPR/Cas9 gene 
editing technique. SgRNAs were designed to introduce loxP sites flanking exon 2. 
Therefore, ssDNA oligonucleotides comprised of loxP sites and a restriction site were 
designed. 
4.2.1 Results from microinjection 
The results from multiple rounds of microinjections are shown in Table 8. Out of ten 
runs, 83 pups were born with equal sex distribution. In total six mice showed a deletion, 
whereby in four of them exon 2 was deleted. In addition, two mice showed an insertion, 
but sequencing revealed that nucleotides other than loxP sites were integrated. 
 
Table 8: Summary of pups resulted from microinjection of components of CRISPR/Cas9.  
The last row presents the mouse numbers which showed a deletion band in genotyping 
VKORC1L1. ° male * female 
Nr Microinjection Birth date Total Female Male 
Deletion 
of exon 2 
1 F518.1, F518.2xFragment1 14.04.2015 12 6 6 
 
2 F518.3, F518.4xFragment2 14.04.2015 10 4 6 #17°, #22° 
3 542.3xMix25.8.15 13.09.2015 11 6 5 
 
4 542.1, 542.2xMix26.8.15 14.09.2015 8 4 4 #55* 
5 F561.2xMix17.11.15 08.12.2015 8 4 4 
 
6 F561.1xMix17.11.15 06.12.2015 9 5 4 
 
7 593.1,593.2xVKORC1/1 25.03.2016 11 5 6 #226° 
8 594.1,594.2xVKORC1/1 08.03.2016 4 2 2 
 
9 598xVKORC1/1 14.03.2016 8 4 4 
 
10 599xVKORC1/1 15.03.2016 2 1 1 
 
Total 83 41 42 4 
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To verify the deletion, PCR products amplified with RFLP primers were loaded on a gel 
and the lower band was excised and sequenced. A summary of the genotypes is shown 
in Table 9, the sequences of the breakpoints are shown in Figure 44.  
 
Figure 44: Sequence of Vkorc1l1 locus upstream and downstream of exon 2 for founder mice. 
Using RFLP primers for amplification, the lower band showing a deletion was excised and se-
quenced. Mouse #55 showed a deletion of 1210 bp, additionally an insertion of 52 bp was ob-
served. 
 
In case of mouse #55, 1210 bp were deleted (c.195-940 to c.304+162), this genomic 
region includes exon 2 of Vkorc1l1. In addition, sequencing revealed a 52 bp insertion at 
the breakpoints. When this sequence was blasted, no significant similarity was found 
when the mouse genome and transcriptome was used. 
 
Table 9: Detailed description of transgenic founder mice.  
All mice showed a deletion of exon 2 of the Vkorc1l1 locus (NC_000071.6). 
Nr Founder mouse Description of deletion 
Size of 
deleterious allele 
1 17 c.195-938 to c.304+162 1210 
2 22 c.195-938 to c.304+162 1210 
3 55 c.195-940 to c.304+162, ins52bp 1262 
4 226 c.195-938 to c.304+158 1206 
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4.2.2 Genotyping of transgenic mice 
For determination of the genotype, a piece of tail was lysed and analyzed by PCR. In 
Figure 45, an exemplary result of genotyping PCR is shown. In panel A, L1_KO primers 
were used, resulting in fragments of ~500 bp for the WT allele and ~400 bp for the KO 
allele. In addition, RFLP primers (panel B) were used giving fragments of 2.4 kb (for WT) 
and ~1 kb (for KO), respectively. Thus, mice 153 and 154 were WT, 148, 149, 151, and 
152 were heterozygous KO and 150 was homozygous KO.  
 
A 
 
Figure 45: Genotyping Vkorc1l1 locus 
of genomic DNA from mouse tails. 
A: L1_KO primers were used or 
genotyping. B: RFLP primers were 
used. For size comparison, the 100 
bp ladder was loaded. In this exam-
ple, mice 148 to 154 were analyzed 
with regard to their VKORC1L1 geno-
type. As controls, a non-template 
control (NTC), WT (+/+) and hetero-
zygous KO (+/d) samples were in-
cluded.  
B 
 
 
To check whether the introduced mutation is giving germ line, the founder mice were 
mated with C57BL/6 (BL6) WT mice. A brief summary of those matings is given in Table 
10. Founder mouse #17 and #55 transfer their deleterious allele to the offspring, where-
as mating of founder #22 gave siblings with WT genotype. 
 
Table 10: Summary of pups after mating different founder mice (#17, #22, #55, and #226) with 
BL6. 
+/+ WT, +/d heterozygous KO 
 
Founder mice which showed a deletion 
#17 #22 #55 #226 
Total 40 39 16 9 
Female  16 24 9 5 
Male 24 15 7 4 
Genotyping 
+/+ 14 39 9 4 
+/d 24 0 7 5 
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When mating heterozygous KO mice, according to Mendelian law, one would expect 
half of the mice to be heterozygous. The other half should be in equal parts WT and 
homozygous KO. When mice from founder #17 were mated, only two out of 16 siblings 
showed the homozygous deletion of exon 2 in the Vkorc1l1 gene (Figure 46 A). Howev-
er, the mice did not show any abnormality or different behavior compared to their litter-
mates. 
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Figure 46: Distribution of genotypes of founder mouse #17. 
A: Mating of heterozygous KO mice; B:Mating heterozygous with homozygous KO mice; 
+/+ WT, +/d heterozygous KO, d/d homozygous KO 
 
The next question which should be answered is does the homozygous KO has any im-
pact on fertility. Therefore, the homozygous KO was mated with heterozygous KO. In 
Figure 46 B the genotypes of the siblings are summarized. In this mating, no WT mice 
are expected. The ratio of homozygous to heterozygous mice was expected to be 1:1 
and was actually 2:3.  
4.2.3 Verification of Vkorc1l1 knockout on RNA level 
In order to verify the KO on mRNA level, total RNA was isolated from tail biopsy. The 
qPCR was conducted with either RNA or cDNA (Figure 47) to exclude assay-associated 
bias. For amplification of Vkorc1l1 mRNA the primers bind in exon 1 and 2, respectively. 
The probe was designed to cover the exon1-2 boundary in order to avoid amplification 
of PCR products from genomic DNA. The results for both assays were similar with re-
spect to expression level of Vkorc1l1 mRNA throughout the different genotypes. After 
normalization to the house keeping gene Hprt the ratio between WT and heterozy-
gous/homozygous KO was calculated. Surprisingly, the homozygous KO gave reliable 
melting curves with both assays. The presence of a “real” PCR product was proven by 
gel electrophoresis. However, homozygous KO showed markedly reduction of CT values 
and in relation to the WT only 5% remained. 
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Figure 47: Results of qPCR using TaqMan assay. 
RNA isolated from mouse tails were analyzed either directly (A) or after cDNA synthesis (B) by 
qPCR. The graphs show the ratio of VKORC1L1 expression in relation to WT after normalization 
to housekeeping gene Hprt. +/+ WT, +/d heterozygous KO, d/d homozygous KO 
 
By alignment using BLAST, a processed pseudogene was located at chromosome 15. 
To verify this finding, primers which bind at start and stop codon of Vkorc1l1 cDNA were 
used for amplification of genomic DNA. Those primers would give a product of 40.1 kb, 
which is unlikely to be amplified during PCR. Elongation time of one min preferably am-
plifies products of 1 kb or smaller. As shown in Figure 48 A, the samples 148 to 154 as 
well as the controls (WT and heterozygous KO) showed a clear band at approximately 
500 bp which corresponds to the size of the Vkorc1l1 cDNA (531 bp). Accordingly, when 
using the primer set for qPCR, the amplicons were about 100 bp in size, which corre-
sponds to an amplicon generated with cDNA (108 bp). 
 
A 
 
B 
 
Figure 48: PCR products after amplification of genomic DNA. 
A: Primers were used that bind at start and stop of Vkorc1l1 mRNA. B: Vkorc1l1 primers for 
qPCR were used.  
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Sequencing of before mentioned PCR products as shown in Figure 48 A revealed a nu-
cleotide exchange at c.468T>C (Figure 49). For validation, PCR products of cDNA using 
the same primers were sequenced and revealed the WT sequence (c.468T).  
 
Figure 49: Sequence of processed pseudogene. 
PCR products using primers binding at start and stop sequence, respectively, were generated 
using cDNA and genomic DNA (gDNA). The respective position c.468T is marked with a red box 
and shows T>C substitution. 
 
4.2.4 German Mouse Clinic - Phenotyping report 
In total 61 mice were selected for phenotyping, of which 30 were Vkorc1l1-/- (15 animals 
per sex) and 31 were Vkorc1l1+/+ (15 females and 16 males). A total of three animals 
died before end of screening, two were mutant and one was control mouse.  
At the age of seven weeks mice were transferred to Munich, two weeks later analysis 
was started in a highly ordered manner (Figure 17). About 500 parameters belonging to 
14 different disease areas were measured during the primary screening. By using this 
highthroughput screen new hypotheses for the impact of Vkorc1l1 can be generated. 
A p-value <0.05 has been used as level of significance; which might be a hint for a new 
phenotype. However, depending on the effect size also statistically not significant differ-
ences might be biologically relevant. 
Figures and tables in this section were taken from the “Phenotyping report: Mouse line 
Vkorc1l1” with permission of the GMC. 
Over a time course of 12 weeks the weight of all mice were monitored. Interestingly, 
weight of Vkorc1l1-/- differed significantly in both sexes (Figure 50 and Figure 51).  
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Figure 50: Weight comparison of female 
Vkorcl1l1
+/+
 and Vkorc1l1
-/-
 mice. 
Red line represents Vkorcl1l1
+/+
, yellow 
line shows Vkorc1l1
-/-
. Weight was as-
sessed from week seven to 19.  
 
 
Figure 51: Weight comparison of male 
Vkorcl1l1
+/+
 and Vkorc1l1
-/-
 mice. 
Blue line represents Vkorcl1l1
+/+
, green 
line shows Vkorc1l1
-/-
. Weight was as-
sessed from week seven to 19. 
 
The open field test provides the opportunity to systematically assess novel environment 
exploration, general locomotor activity, and provide an initial screen for anxiety-related 
behavior in rodents [92]. The chamber design is a large square chamber with a size of 
45.5 x 45.5 cm. Chamber wall is 39.5 cm high, walls and floor use transparent Plexiglas. 
The open fleld arena is divided into a grid of equally sized areas by infrared photocell 
beams and beam breaks are recorded as one unit of exploratory activity. Mice will typi-
cally spend a significantly greater amount of time exploring the periphery of the arena, 
usually in contact with the walls, than the unprotected center area. Mutant mice showed 
a higher horizontal locomotion, the total distance travelled in the open field was signifi-
cantly increased (p = 0.014) compared to wild type littermates (Figure 52A). Vertical 
locomotion, measured as rearing, was not different in mutant and wild type mice (Figure 
52B). Anxiety-related behavior was determined as time spent in center (unprotected 
area). Mutant mice spent significantly less time in center (p=0.03) than wild type mice 
(Figure 52C). Thus Vkorc1l1-/- showed increased locomotor activity and increased anxie-
ty-related behavior. 
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Figure 52: Results of open field test. 
A: distance travelled; B: rearing activity; C: time spent in center. Red: female Vkorcl1l1
+/+
, yel-
low: female Vkorcl1l1
-/-
, blue: male Vkorc1l1
+/+
, green: male Vkorc1l1
-/-
 
 
Measurement of acoustic startle responses can provide general information regarding 
sensorimotor processing. Prepulse inhibition (PPI) is a neurological phenomenon in 
which a weaker prestimulus (prepulse) inhibits the reaction of an organism to a subse-
quent strong startling stimulus (pulse) [93]. The extent of the adaptation affects numer-
ous systems, but muscular reactions are measured, which are normally diminished as a 
result of the nervous inhibition (Figure 53). Deficits of prepulse inhibition manifest in the 
inability to filter out the unnecessary information. Abnormalities of sensorimotor gating 
have been linked to schizophrenia and Alzheimer's disease. 
Vkorc1l1-/- mice showed decreased acoustic startle reactivity (p=0.016) and decreased 
prepulse inhibition (p<0.001) compared to their wild type littermates.  
 
 
Figure 53: Acoustic startle response and prepulse inhibition. 
For PPI the observable and measured response is based on the motor output (startle) following a 
loud acoustic stimulus. Inhibition of the response to this stimulus is observed if the stimulus is 
preceded very shortly by a prepulse stimulus to which the organism normally does not respond. 
PPI is defined as reduction of a response to a stimulus [93]. 
 
Thus Vkorc1l1-/- mice showed a clear sensorimotor gating deficit as well as altered spon-
taneous locomotor activity and anxiety-related behavior. 
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The measurement of grip strength of fore limbs and combined fore and hind limbs was 
used to assess the muscle function. Vkorc1l1-/- mice showed decreased grip strength for 
two and four paws (Figure 54). The decreased grip strength correlated well with the re-
duced body mass.  
 
 
Figure 54: Measurment of grip 
strength of fore limbs (left panel) 
and combined fore and hind limbs 
(right panel). 
Red: female Vkorcl1l1
+/+
, yellow: 
female Vkorcl1l1
-/-
, blue: male 
Vkorc1l1
+/+
, green: male Vkorc1l1
-/-
 
For the assessment of coordination and balance, the accelerating rotarod was used. 
The accelerating speed was 4-40 rpm in 300 s. The experiment was repeated three 
times with 15 minutes intertrial intervals. Vkorc1l1-/- mice showed no difference at 
rotarod latencies (Figure 55), however slightly more passive rotations of female mutants 
were observed. 
 
Figure 55: Results of accelerating rotarod 
measuring the latency to fall. 
Red: female Vkorcl1l1
+/+
, yellow: female 
Vkorcl1l1
-/-
, blue: male Vkorc1l1
+/+
, green: 
male Vkorc1l1
-/-
 
For the assessment of nociception, the hot plate test was used. In the test, the mouse is 
placed on the hot plate (52°C) and the latency to the first contact avoidance response 
was registered. Vkorc1l1-/- mice did not show any significant difference for types of reac-
tion (lifting or licking of the feet or jumping) as well as none for latencies compared to 
Vkorc1l1+/+ mice (Figure 56).  
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Figure 56: Hot plate test results measuring the 
first reponse time. 
Red: female Vkorcl1l1
+/+
, yellow: female 
Vkorcl1l1
-/-
, blue: male Vkorc1l1
+/+
, green: 
male Vkorc1l1
-/-
 
Auditory evoked potentials were measured to determine hearing sensitivity in a subset 
of animals (10 animals per sex and genotype). The sound pressure threshold for neural 
activity was determined to a broadband click tone. Additionally, five different pure tone 
frequencies (6, 12, 18, 24, and 30 kHz) were measured. No genotype effects on hearing 
sensitivity were observed (Figure 57). 
 
 
Figure 57: Measurement of auditory evoked 
potentials. 
Red: female Vkorcl1l1
+/+
, yellow: female 
Vkorcl1l1
-/-
, blue: male Vkorc1l1
+/+
, green: 
male Vkorc1l1
-/-
 
 
For the assessment of body composition parameters like bone mineral content and bone 
mineral density as well as fat and lean composition were determined using DEXA (Dual-
Energy X-Ray Absorptiometry) scan. The major read outs are summarized in Table 11. 
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Table 11: Dual-Energy X-Ray Absorptiometry (DEXA): major read outs. 
Mice were tested with an age of 17 weeks. Values are shown as mean ±SD. Bone mineral con-
tent (BMC), Bone mineral density (BMD) 
 
 Female 
Vkorc1l1
+/+
 
Female 
Vkorc1l1
-/-
 
Male 
Vkorc1l1
+/+
 
Male 
Vkorc1l1
-/-
 
Number of animals N=15 N=14 N=14 N=14 
Body weight in g 23.4 ± 2.6 17.6 ± 2.1 30.1 ± 1.8 24.3 ± 1.6 
Total weight (DEXA) in g 21.5 ± 2.4 16.2 ± 2.1 28.0 ± 1.8 22.7 ± 1.6 
Bone area in cm² 8.08 ± 0.42 6.77 ± 0.55 8.66 ± 0.32 7.70 ± 0.57 
BMC in mg 486 ± 41 368 ± 48 542 ± 43 456 ± 60 
BMD in mg/cm² 60.1 ± 3.1 54.3 ± 3.1 62.6 ± 3.8 59.0 ± 3.4 
Lean mass in g 13.8 ± 1.3 10.4 ± 1.3 17.7 ± 2.1 14.9 ± 1.2 
Fat mass in g 7.3 ± 1.5 5.4 ± 0.8 9.8 ± 1.7 7.3 ± 0.8 
 
Compared to control mice, mutant mice showed significantly (p<0.001) reduced weight, 
bone area, bone mineral content and density (Table 11). In addition, lean and fat content 
were significantly (p<0.001) decreased in mutant mice (Table 11). All these reductions 
were more pronounced in females when compared to males. 
In mice, both skeleton and body composition are affected by the Vkorc1I1 mutation. 
Blood samples were collected in week 19 by retroorbital puncture under isoflurane anae-
thesia. Heparin-plasma samples were used for clinical chemistry, allergology and immu-
nology screen. EDTA samples were used for determination of hematological parameters 
and FACS analysis. Results are summarized in Table 12 to Table 13. 
In addition, blood samples after 6h fasting were tested. Unfortunately only male mice 
could be tested since female Vkorc1l1-/- weighted less than 18 g (which is the weight 
limit for the experiment due to local animal experiments committees review). Parameters 
after fasting are summarized in Table 14. 
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Table 12: Clinical chemistry – ad libitum fed values. 
Values were measured in week 19 and are shown as mean ± SD. ALT – alanine aminotransfer-
ase, AST – aspartate aminotransferase, LDH – lactate dehydrogenase, ALP – alkaline phospha-
tase, UIBC – unsaturated iron binding capacity, TIBC – total iron binding capacity 
 
 Female 
Vkorc1l1
+/+
 
Female 
Vkorc1l1
-/-
 
Male 
Vkorc1l1
+/+
 
Male 
Vkorc1l1
-/-
 
Number of animals n=14 n=13 n=14 n=14 
Sodium in mM  147 ± 1 149 ± 2 150 ± 2 149 ± 3 
Potassium in mM 4.2 ± 0.2 4.5 ± 0.4 4.2 ± 0.3 4.2 ± 0.3 
Chloride in mM 111.3 ± 1.5 114.2 ± 2.6 111.2 ± 1.7 111.4 ± 2 
Total protein in g/l  50.5 ± 3.2 50.5 ± 2.2 51.8 ± 1.6 51.7 ± 1.4 
Albumin in g/l  26.1 ± 1.4 26.4 ± 0.8 25.7 ± 1.1 26.1 ± 1.3 
Creatinine in µM  10.73 ± 1.02 10.05 ± 1.16 9.6 ± 1.27 10.26 ± 1.46 
Urea in mM  11.46 ± 1.3 13.40 ± 2.24 11.81 ± 1.36 14.10 ± 2.06 
Cholesterol in mM  2.193 ± 0.506  1.504 ± 0.666  2.639 ± 0.521  1.791 ± 0.451  
Triglyceride in mM  1.838 ± 0.593  1.532 ± 0.627  2.337 ± 0.629  1.578 ± 0.508  
ALT in U/l  34 ± 19 43 ± 29 28 ± 7 40 ± 27 
AST in U/l  52 ± 12 85 ± 38 43 ± 12 59 ± 19 
α-Amylase in U/l  662 ± 111 674 ± 107 745 ± 119 757 ± 84 
Glucose in mM  14.33 ± 2.07 12.40 ± 2.35 13.75 ± 2.02 13.10 ± 2.10 
LDH in U/l  170 ± 41 219 ± 67 142 ± 20 178 ± 36 
Calcium in mM  2.31 ± 0.04 2.26 ± 0.03 2.29 ± 0.04 2.24 ± 0.03 
Phosphate in mM  1.94 ± 0.22 1.93 ± 0.34 1.75 ± 0.32 1.68 ± 0.23 
ALP in µM  101 ± 18 107 ± 22 70 ± 14 85 ± 17 
Iron in µM  24.84 ± 3.17 23.46 ± 2.68 22.62 ± 3.39 21.42 ± 2.51 
UIBC [μmol/l]  38.0 ± 6.1 39.8 ± 2.2 41.6 ± 4.8 43.0 ± 3.1 
TIBC [μmol/l]  62.8 ± 3.8 63.3 ± 2.4 64.2 ± 2.7 64.4 ± 2.5 
 
Plasma urea levels were increased in Vkorc1l1-/- mice (p<0.001), but creatinine levels 
did not reflect this observation. Interestingly, plasma levels of sodium, potassium and 
chloride were significantly increased in female Vkorc1l1-/- mice compared to female con-
trol mice (p=0.011, p=0.002 and p=0.002, respectively). Plasma lipids cholesterol and 
triglycerides were significantly decreased (p<0.001 and p=0.002, respectively), plasma 
glucose levels were lower in mutant animals (p=0.03). Liver parameters AST and LDH 
were increased in Vkorc1l1-/- mice (p<0.001 and p=0.001, respectively), but ALT did not 
differ significantly. Marked decrease in plasma calcium levels were observed in mutant 
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mice (p<0.001) whereas plasma protein levels were not affected. ALP activity was slight-
ly elevated only in males (p=0.031). 
 
Table 13: Hematological parameters assessed in week 19. 
Values are shown as mean ± SD. WBC - White blood cell count; RBC - Red blood cell count; 
HCT - Hematocrit; HGB - Hemoglobin; MCV - Mean corpuscular volume; MCH - Mean corpuscu-
lar hemoglobin; MCHC - Mean corpuscular hemoglobin concentration; RDW - Red blood cell 
distribution width; PLT - Platelet count; MPV - Mean platelet volume; PDW - platelet distribution 
width 
 Female 
Vkorc1l1
+/+
 
Female 
Vkorc1l1
-/-
 
Male 
Vkorc1l1
+/+
 
Male    
Vkorc1l1
-/-
 
Number of animals n=14 n=14 n=14 n=14 
RBC in million/mm³ 10.59 ± 0.38 9.92 ± 0.31 10.82 ± 0.73 10.6 ± 0.61 
WBC in 10³/mm³ 8.69 ± 2.33 5.78 ± 2.14 6.16 ± 1.87 5.9 ± 1.64 
PLT in 10³/mm³ 917.7 ± 140.7 945.0 ± 116.9 1314.1 ± 191.4 1250.5 ± 164.4 
HGB in g/dl  16.44 ± 0.92 15.73 ± 0.6 16.68 ± 1.06 16.6 ± 0.88 
HCT in %  50.89 ± 1.88 48.29 ± 1.71 51.7 ± 3.12 51.21 ± 2.62 
MCV in fl  48.21 ± 1.12 48.79 ± 1.25 47.86 ± 0.66 48.36 ± 0.74 
MCH in pg  15.52 ± 0.51 15.86 ± 0.43 15.41 ± 0.51 15.66 ± 0.28 
MCHC in g/dl 32.26 ± 0.86 32.57 ± 0.49 32.27 ± 0.81 32.41 ± 0.55 
RDW in % 13.79 ± 0.56 14.04 ± 0.58 15.21 ± 1.1 14.86 ± 0.62 
MPV in fl 6.59 ± 0.2 6.44 ± 0.26 6.46 ± 0.16 6.42 ± 0.21 
PDW in fl  6.02 ± 0.32 5.77 ± 0.34 5.85 ± 0.28 5.74 ± 0.28 
 
Genotype-related differences in peripheral blood cell counts were predominantly a de-
crease in red and white blood cell counts (p<0.001 and p=0.002, respectively) but not 
platelets in female Vkorc1l1-/- mice, while effects on erythrocyte indices were rather sub-
tle. In females KO mice decreased red and white cell count, hemoglobin and hematocrit 
was associated with subtle differences in red cell and platelet distribution width as well 
as MCV and MCH. 
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Table 14: Clinical chemistry – after 6h fasting. 
In week 11 food was removed for 6h and blood was collected afterwards. Only male mice were 
examined due to restricted weight of female mice. HDL-cholesterol – High density lipoprotein-
cholesterol; NEFA - Non-esterified Free Fatty Acid 
 
 
Male 
Vkorc1l1
+/+
 
Male  
Vkorc1l1
-/-
 
T-test 
Number of animals n=14 n=14  
Glucose in mM  8.28 10.22 p<0.01 
Cholesterol in mM 2.730 1.696 p<0.001 
HDL-cholesterol in mM 2.075 1.450 p<0.001 
Non-HDL-cholesterol in mM 0.655 0.246 p<0.001 
Triglyceride in mM  1.397 0.725 p<0.001 
Glycerol in mM  0.305 0.207 p<0.01 
NEFA in mM  1.229 0.653 p<0.001 
 
As already mentioned, mutants showed compared to controls decreased body mass. 
Weight loss during 6h-fasting was high especially in male mutants compared to controls. 
Vkorc1l1-/- mice showed increased fasting glucose and decreased fasting blood lipid 
values.  
For baseline immune status the integrity of immune cell composition in the peripheral 
blood of mutant mice was evaluated (Figure 58 and Figure 59). 
 
 
Figure 58: Flow cytometric 
analysis of peripheral blood 
of female mice. 
Red: female Vkorcl1l1
+/+
, 
yellow: female Vkorcl1l1
-/-
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Figure 59: Flow cytometric 
analysis of peripheral blood 
of male mice. 
Blue: male Vkorc1l1
+/+
, 
green: male Vkorc1l1
-/-
 
 
FACS analysis revealed lower production of B1 cells and slightly increased frequency of 
NK cells as well as monocyte in Vkorc1l1-/- mice compared to Vkorc1l1+/+ mice. Further-
more, these cells remain favorably in inactivated stage.  
Cardiovascular screening including ECG and echocardiography did not reveal significant 
differences. In echocardiography an increased heart rate, mainly in females, was de-
tected (p=0.016). No signs of tachycardia could be seen during echocardiography. Scat-
ter plot analysis showed a strong impact of the body weight on heart parameters, thus 
explaining more pronounced impact of heart rate in female mice. During ECG analysis 
mainly male mice showed increased heart rate. However, no pathological phenotype 
was observed thus relevance of the findings is unclear.  
During pathological screen mice were examined macroscopically and microscopically. 
For that purpose five mice with an age of 18-19 weeks of each sex and genotype were 
analysed. The results are summarized in Table 15. 
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Table 15: Body, heart, liver and spleen weights. 
Medians, first and third quartile are shown for five mice for each sex and genotype. 
 
 Female 
Vkorc1l1
+/+
 
Female 
Vkorc1l1
-/-
 
Male  
Vkorc1l1
+/+
 
Male    
Vkorc1l1
-/-
 
Age of mice in d  
129 
[126 , 129] 
129 
[129 , 131] 
127 
[127 , 127] 
130 
[125 , 130] 
Body weight in g  
24.2 
[22.1 , 24.7] 
17.7 
[16.9 , 19.8] 
31.7 
[30.4 , 32.7] 
26.6 
[25.3 , 27] 
Heart weight in mg 
129 
[128 , 132] 
87 
[87 , 107] 
159 
[145 , 167] 
140 
[135 , 143] 
Tibia length in mm 
17.97 
[17.44 , 18.01] 
16.16 
[16.08 , 16.21] 
18.02 
[17.59 , 18.17] 
17.35 
[17.3 , 17.77] 
Liver weight in g  
1.237 
[1.091 , 1.295] 
1.012 
[0.944 , 1.379] 
1.794 
[1.619 , 1.885] 
1.776 
[1.69 , 1.79] 
Spleen weight in g  
0.11 
[0.082 , 0.124] 
0.059 
[0.057 , 0.072] 
0.087 
[0.083 , 0.087] 
0.077 
[0.069 , 0.08] 
 
Weight of spleen for female mice differed significantly between genotypes (p=0.032). 
Other parameters determined did not show statistical significant differences. When cal-
culating the ratio between liver weight and body weight both male and female mice 
showed a significant difference (each p=0.016) when comparing wild type and mutant 
Vkorc1l1 mice. During histological analysis no genotype-related changes of mutant mice 
had been detected. Tissues investigated included skin, brain, kidney, liver, heart, lung, 
thymus, spleen, adrenals, organs of the gastrointestinal system and reproductive sys-
tem. 
In week 18/19 the body weight was assessed and confirmed earlier findings. Data is 
summarized in Figure 60. 
 
Figure 60: Body weight assessed in week 
18/19. 
Red: female Vkorcl1l1
+/+ 
(f.con), yellow: fe-
male Vkorcl1l1
-/-
 (f.mut), blue: male 
Vkorc1l1
+/+ 
(m.con), green: male Vkorc1l1
-/-
 
(m.mut) 
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5 Discussion 
Vitamin K hydroquinone is an indispensable co-factor in post-translational activation of 
VKD proteins. In vitro, both VKOR enzymes, VKORC1 and VKORC1L1, are able to 
supply GGCX with KH2. Warfarin and other 4-hydroxycoumarin derivatives exert their 
effect by inhibition of VKORC1 [17, 59]. However, only little is known about the inhibitory 
effect of coumarins on VKORC1L1. 
In the first part of this thesis VKOR enzymes were tested with regard to their susceptibil-
ity to various coumarins and indandiones. HEK 293T VKOR KO cell lines were generat-
ed to allow the discrimination of endogenously expressed enzymes. The results led over 
to in silico analysis, which revealed distinct warfarin binding sites in VKORC1 and 
VKORC1L1. By means of VKORC1 and VKORC1L1 double knockout cells in silico data 
were verified by in vitro experiments. Results of overexpressed VKORC1 and 
VKORC1L1 and its respective variants confirmed distinct warfarin binding pattern and 
conceivably explained different inhibition pattern of OACs. 
In the second part of the thesis the generation of Vkorc1l1 knockout mice is described. 
The transgenic mice were created by means of CRISPR/Cas9 gene editing technique. 
In a first analysis the mice showed no lethal phenotype in contrast to Vkorc1 knockout 
mice but several diverse phenotypes have been observed which can be linked to neuro-
logical diseases, diabetes and fat metabolism. Detailed information regarding the func-
tion of Vkorc1l1 will be collected and may answer the question if Vkorc1l1 plays a role in 
γ-carboxylation of VKD proteins in vivo.  
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5.1 Characterization of VKORC1 and VKORC1L1 in vitro 
VKORC1 and VKORC1L1 KO HEK 293T cell lines 
In vivo, VKORC1 was proven to be the essential enzyme to drive the vitamin K cycle 
since Vkorc1-/- mice die due to intracranial bleeding [31]. However, in vitro, VKORC1 
and VKORC1L1 supply GGCX with KH2, the essential co-factor for γ-carboxylation [9, 
33].  
GGCX, VKORC1 and VKORC1L1 are endogenously expressed in HEK 293T cells. 
These enzymes are required for driving the vitamin K cycle and post-translational modi-
fication of vitamin K dependent proteins [9]. To discriminate between VKOR isozymes 
HEK 293T cell lines were generated in which one or both enzymes were knocked out. 
The endogenous activity of VKORC1 or VKORC1L1 was assessed by means of the cell-
based FIX reporter assay [30]. The single VKORC1 and VKORC1L1 KO HEK 293T cells 
showed FIX activities (Figure 19) comparable to that of WT cells proving that both en-
zymes independently recycle vitamin K and thus provide GGCX with the co-factor KH2. 
In contrast, DKO cells (in which both VKORC1 and VKORC1L1 were knocked out) 
showed no FIX activity when supplemented with 12 µM K1.  
Further characterization of KO cell lines was difficult because elucidation of VKORC1 
and VKORC1L1 knockout on mRNA and protein level were not feasible due to different 
reasons. mRNA expression profile was not conclusive since primer and probe design for 
qPCR cannot omit small changes in target sequence. In case of VKORC1 KO cells NGS 
revealed a large deletion and subsequently mRNA was not detectable (Table 1). Other 
clones showed only small changes in genomic DNA (e.g. two nucleotides deletion/ one 
nucleotide insertion in VKORC1L1 KO cells, Figure 18) and thus mRNA expression was 
detected (Table 1). However, copy number was markedly lower as determined in WT 
HEK 293T cells. Since all genomic alterations led to shift of reading frame, manipulation 
in VKORC1 and VKORC1L1 genes were considered to result in absent protein expres-
sion. 
Furthermore, detection of endogenous protein expression of VKORC1 and VKORC1L1 
in HEK 293T cells proved impossible due to absent suitable antibodies. Different anti-
bodies (from various companies) were tested and none of them showed reliable results.  
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Susceptibility to oxidative stress of HEK 293T knockout cell lines 
The harmful effect of free ROS can be due to either an excessive production of ROS 
and/or a deficiency of antioxidants. ROS include superoxide radical (O2∙), hydroxyl radi-
cal (HO∙) and nonradical molecules like hydrogen peroxide (H2O2), generated as a by-
product of normal aerobic metabolism, but increases under stress. Human antioxidant 
system consist of low-molecular-weight antioxidants such as reduced glutathione (GSH) 
and vitamins C and E as well as noncatalytic antioxidant proteins and ROS-metabolizing 
enzymes [94]. In addition, KH2 was shown to be an effective antioxidant [95] but is rapid-
ly oxidized [96]. 
KO HEK 293T cells were characterized with respect to their antioxidative properties. In a 
previous in vitro study, Westhofen and colleagues postulated that VKORC1L1 plays an 
ubiquitous and fundamental role in intracellular antioxidation [10]. Indeed, VKORC1L1 
KO cells were greatest affected by H2O2 treatment (Figure 20) underlining the putative 
antioxidative role of VKORC1L1 in scavenging ROS. Moreover, VKORC1 KO also ex-
hibit a reduced ability to compensate H2O2-induced cell death compared to WT HEK 
293T cells.  
Li and colleagues investigated the role of vitamin K in terms of oxidative injury in oli-
godendrocyte precursor cells [97]. The induction of oxidative stress by H2O2 (800 µM) 
could not be prevented by K1 administration (100 µM). In contrast to this study, we could 
reverse the effect of H2O2 treatment (50 µM) with 12 µM K1 in WT, VKORC1 KO and 
VKORC1L1 KO HEK 293T cells (Figure 21). The controversial results may be due to 
highly divergent H2O2 concentrations. In addition, high concentrations of vitamin K 
(higher than 50 µM) can be assumed to be toxic. In our assay H2O2 concentration of 100 
µM led to markedly reduced cell survival although vitamin K was present (Figure 20). 
Furthermore, endogenous expression level of VKOR enzymes as well as other proteins 
which may have an impact on antioxidative properties of distinct cell types could explain 
the debated results. Interestingly, warfarin showed antioxidative properties when WT 
and single KO HEK 293T cells were treated with H2O2. Indeed, Monti and colleagues did 
not see a negative effect of warfarin (up to 10 µM) on cell proliferation in HEK 293 cells 
[63].  
Vervoort and colleagues investigated the antioxidant properties of vitamin K in rat liver 
microsomes by means of lipid peroxidation which is initiated by ROS [95]. Vitamin K 
(without a reducing equivalent) did not contribute to the antioxidant properties. The addi-
tion of vitamin K epoxide prevented lipid peroxidation (inversely correlated with the for-
mation of TBARS (thiobarbituric acid reactive substances)) whereas co-incubation with 
warfarin abolished inhibitory properties of K>O. Furthermore they concluded that KH2 is 
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the antioxidant species of vitamin K (Figure 61). At time of this publication the enzymes 
responsible for vitamin K reduction have not been identified. Furthermore, the function of 
VKORC1L1 could not be clearified since rat liver samples were used for analysis and in 
this tissue VKORC1 is about 50 times higher expressed than VKORC1L1 [12]. 
 
Figure 61: Proposed reaction routes for 
the antioxidant action of vitamin K.  
KH2, KH2*, KO, and K represent different 
redox states of vitamin K, R* is a radical 
species. [95] 
 
Beside the well-known feature of being the exclusive co-factor for γ-carboxylation, KH2 
was recognized to have antioxidant properties. Both VKOR enzymes may provide KH2 
for antioxidation, thus reduced levels of KH2 due to reduced vitamin K recycling in 
VKORC1 and VKORC1L1 KO cells may explain these results. 
 
Determination of enzymatic activity of VKOR enzymes 
Both VKOR enzymes can utilize K as well as K>O to drive the vitamin K cycle, and cata-
lytic features are designated as VKR (vitamin K reductase) and VKOR (vitamin K 2,3-
epoxide reductase) activity, respectively. Previous studies have used two distinct types 
of assays to examine the capability of VKORC1 and VKORC1L1 to reduce K or K>O in 
vitro.  
The DTT-driven VKOR assay (i.e. conversion of K>O to K) was established in the late 
1970s [98, 99]. More recently, a modification of the DTT-driven assay was described 
whereby the conversion of K to KH2 (i.e. VKR activity) can be monitored using a sealed 
vial assay [96]. In general, microsomes or cell lysates are incubated with buffer, DTT 
and CaCl2. A defined concentration of substrate (i.e. K>O to assess VKOR activity or K 
for VKR activity) is incubated for 60 min at 30°C to allow substrate conversion. The reac-
tion is stopped by isopropanol/hexan and an internal standard is added. The hydropho-
bic vitamin K derivatives accumulate in the hexan phase, which is vaporized. Finally, the 
products are dissolved in isopropanol and analyzed by HPLC. The amount of K/KH2 is 
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calculated by means of internal standard and peak area of K vitamers. With this assay 
enzymatic parameters like vMAX and kM can be determined giving a more precise look 
into the reaction characteristics. Furthermore, VKOR/VKR activity can be assessed from 
tissues or cells reflecting endogenous or overexpressed protein levels, but discrimina-
tion between VKORC1 and VKORC1L1 is the major disadvantage of this assay because 
both enzymes catalyze the reduction of K and K>O. Furthermore, the use of the non-
physiological reductant DTT together with substrate could drive carboxyation of VKD 
proteins by non-catalytic active VKOR variants in vitro leading to artificial results [17, 98, 
99]. Another issue relates to the purification of VKOR enzymes. This is difficult because 
solubilization renders the enzyme inactive. Thus, microsomes instead of pure enzyme 
are isolated using CHAPS as detergent leading to native VKOR enzyme [26, 59, 100]. In 
general, DTT-driven VKOR/VKR assay is very sensitive to small changes of assay com-
ponents. As shown by Bevans and colleagues minor changes in DTT and K1>O concen-
tration led to variability of IC50 of warfarin ranging from 2.9 µM to 23.7 µM. In addition, 
pH plays an important role for reproducability and comparability of different studies 
[101].  
The cell-based assay used for determination of VKOR activity was first described in 
2011 [102]. In principle, this assay relies on the expression (either stable or transient) of 
a reporter protein which requires γ-carboxylation for biological activity. Supplementation 
of K or K>O determines the enzyme activity to be measured, i.e. VKR or VKOR activity, 
respectively. In our group, FIX is used as a marker for VKOR/VKR enzyme activity, oth-
er groups utilize chimeric proteins, e.g. fusion protein of FIX and protein C; FIXgla-PC 
[9, 102]. In contrast to the DTT-driven VKOR/VKR assay, the reporter protein is activat-
ed under physiological conditions, i.e.no DTT is required which is thought to reduce 
VKOR enzymes and lead to artificial results [21, 103]. One disadvantage may be the 
disability to determine enzymatic parameters as described above.  
The cell-based assay used in this study makes use of WT hFIX, which comprises 12 
glutamic acid residues in its Gla domain. Like other VKD proteins, FIX is post-
translationally modified by a process described as comprehensive and processive car-
boxylation [104]. During this process VKD proteins are bound via its propeptide to 
GGCX and Gla domain undergoes intramolecular movement to reposition Glu’s for en-
zymological modification [104]. Plasma derived FIX is fully carboxylated whereas re-
combinant protein is not. However, recombinant FIX which is carboxylated at least at 10 
Glu residues can be assumed as biologically active as BeneFIX (recombinant FIX con-
centrate for treatment of hemophilia B) is also not fully carboxylated [105]. If KH2 availa-
bility is decreased VKD proteins dissociate from the carboxylase leading to release of 
under- or uncarboxylated proteins [106]. In case of FIX the protein is secreted inde-
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pendent of carboxylation status [107]. In contrast, protein C is degraded intracellularly if 
poorly carboxylated [108]. Hence, measurement of extracellular FIX protein based on its 
activity is more accurate than measurement based on protein itself (i.e. antigen level). 
Tie et al. uses chimeric FIXgla-PC reporter to measure antigen level of protein C as an 
outcome which should also be feasible due to intracellular degradation of undercarbox-
ylated protein [102].  
 
Specific inhibition of VKORC1 and VKORC1L1 by OACs  
The aim of this study was to determine the inhibition profile of VKORC1 and VKORC1L1 
with respect to various coumarins and indandiones. Thus, VKORC1 and VKORC1L1 KO 
cells were generated to assess the endogenous inhibitory potential of compounds with 
4-hydroxycoumarin and 1,3-indandione backbone in the previously published FIX cell-
based assay. Of note, drug inhibition is not influenced by metabolic activity since cyto-
chrome P450 monooxygenases known to be involved in metabolism of K and warfarin 
are not expressed in HEK 293 cells [109]. Therefore, compounds stay at their initial con-
centration and metabolic degradation does not have an impact on experimental data.  
The naturally occurring coumarin showed no anticoagulatory effect in vitro, as concen-
trations up to 1 mM did not result in reduced FIX activity for both VKOR enzymes (Table 
2). In vivo, coumarin itself does not show an effect on coagulation, too [65]. In contrast, 
VKORC1 and VKORC1L1 were inhibited by 4-hydroxycoumarin at micromolar concen-
trations, indicating that the hydroxyl group at C4-atom is essential for inhibition of both 
enzymes. Furthermore, dicoumarol, the causative agent in sweet clover disease [64] 
and the first OAC drug, inhibited VKORC1 and VKORC1L1 with about three orders of 
magnitude higher efficacy than 4-hydroxycoumarin. However, data of dicoumarol ap-
peared to be biphasic and might explain the poor controllability in therapy of thrombotic 
events [64].  
Warfarin, a synthetic 4-hydroxycoumarin, was more potent than compounds mentioned 
above and revealed values of 1.9 nM for VKORC1 and 25.4 nM for VKORC1L1, repre-
senting about 13-fold higher efficacy for VKORC1 inhibition compared to VKORC1L1. 
The same tendency was observed with regard to acenocoumarol and phenprocoumon. 
Interestingly, those OACs revealed greater potential on VKORC1L1 inhibition compared 
to warfarin. Hence, warfarin might be the better choise to inhibit VKOR actvity in terms 
of liver-specific VKORC1 enzyme activity. 
The increased size and hydrophobicity of the variable 3-position side chains of 4-
hydroxycoumarins correlated with decreased IC50 values, best seen for 4-
hydroxycoumarin (VKORC1 IC50 2000 nM) and acenocoumarol (VKORC1 IC50 1.6 nM). 
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All synthetic coumarins tested in this study were more potent than dicoumarol irrespec-
tive of enzyme investigated.  
IC50 values for indandiones (phenindione and fluindione) were higher than those for 
most of 4-hydroxycoumarin drugs investigated. Fluindione exhibited higher IC50 values 
than phenindione, which was apparently due to the fluorine atom attached to the phenyl 
ring of phenindione. Furthermore, VKORC1L1 inhibition needed much higher concentra-
tions compared to coumarin-based compounds. This effect may be explained by the 
different chemical structures of the compounds, but further investigation is required. 
 
VKOR enzyme comparison 
Although VKOR isozymes are more than 50% identical in their amino acid composition, 
VKORC1 was more sensitive to therapeutically used 4-hydroxycoumarin derivatives 
compared to VKORC1L1. Some million years ago, gene duplication occurred resulting in 
VKORC1 and VKORC1L1 paralogues [110, 111] and both genes were maintained 
throughout evolution of vertebrates. Thus it is likely that VKOR paralogues carry out 
different functions, implying tissue rather than substrate specificity.  
The majority of published studies were not suitable to discriminate enzyme activities of 
VKORC1 and VKORC1L1 [9, 10, 30, 33, 101, 102, 109, 112, 113]. In addition, most of 
the studies focused on warfarin, the most prominent OAC. To date, a systematic over-
view on clinically applied OACs is lacking. In Table 16 results on VKOR enzyme inhibi-
tion with special regard to warfarin are summarized.  
Published data on the inhibitory potential of warfarin varied (Table 16) presenting IC50 
values from 2.2 µM [112] to 25 nM [30]. Differences in IC50 or Ki (inhibitory constant) 
values arise from the type of assay used (DTT vs. cell-based), the substrate (K1 vs. 
K1>O) and its concentration, the amount (endogenous vs. overexpressed) and source of 
protein (kidney- vs. liver-derived) tested. All these studies have in common that they 
were not able to discriminate between endogenous VKORC1 and VKORC1L1. Conclu-
sions from previous studies can only be made with regard to distinct inhibition profile of 
warfarin for both VKOR enzymes. Westhofen and colleagues incubated cell lysates 
overexpressing VKORC1 or VKORC1L1 with 5 µM warfarin and measured VKOR activi-
ty by the DTT-driven assay [10]. At this particular warfarin concentration VKORC1 was 
inhibited by half, whereas VKORC1L1 retained 70% of activity. Hammed et al. used hu-
man and rat VKORC1 or VKORC1L1 expressed in yeast Pichia pastoris and determined 
enzyme kinetic parameters Vmax and Km in DTT-driven assay. Comparison of inhibitory 
constants revealed 30- to 50-fold higher susceptibility of VKORC1 compared to 
VKORC1L1 [33]. In the present study, endogenous VKOR activity revealed (only) 13-
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fold difference in warfarin sensitivity when comparing VKORC1 with VKORC1L1 (Table 
2). In contrast, data of overexpressed VKOR enzymes are in accordance to Hammed et 
al. since warfarin was about 30-fold more effective in VKORC1 inhibition compared to 
VKORC1L1 (Figure 32, Table 4). Hence the results imply that expression level account 
for different results of inhibition pattern. In WT HEK 293T cells, VKORC1 mRNA was 
present in about 10-fold excess compared to VKORC1L1 mRNA, whereas in cells using 
overexpression mRNA level can be considered as equal. Thus results from endogenous 
vs. overexpressed protein cannot be compared directly, but comparison of overex-
pressed VKORC1 and VKORC1L1 might reflect the protein’s characteristics in vitro, 
because same expression level can be assumed. In liver and in HEK 293T cells, 
VKORC1 mRNA expression is higher than VKORC1L1 and results from endogenous 
studies may reflect in vivo situation well, especially with regard to coagulation. 
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Table 16: Overview of published assays to determine VKORC1 and/or VKORC1L1 inhibition. 
NA- not applicable, K1>O - vitamin K1 epoxide, K1 – vitamin K1, Ki – inhibitory constant, C1 – VKORC1, L1 – VKORC1L1, KO – knockout, DKO – double knock-
out. 
 
Gebauer 
2007  
[112] 
Tie et al., 
2011  
[102] 
Westhofen 
et al., 2007 
[10] 
Tie et al., 
2013  
[9] 
Fregin et 
al., 2013 
[30] 
Hammed et 
al., 2013 
[33] 
Haque et 
al., 2014 
[109] 
Matagrin et 
al., 2016 
[113] 
This thesis This thesis This thesis 
Expression 
system/  
Cell line 
Rat liver 
microsomes 
HEK 293 HEK 293T 
HEK 293 WT 
and C1 KO 
HEK 293T 
Pichia 
pastoris HEK 293-C3 
Pichia 
pastoris 
C1 KO and 
L1 KO HEK 
293T 
C1 KO and 
L1 KO HEK 
293T 
DKO HEK 
293T 
VKOR  
expression 
Endogenous Endogenous 
VKOR over-
expression  
Endogenous 
VKOR over-
expression 
VKOR over-
expression 
Endogenous 
VKOR over-
expression 
Endogenous Endogenous 
VKOR over-
expression 
Type of meas-
urement 
Direct Indirect Direct Indirect Indirect Direct Indirect Direct Indirect Indirect Indirect 
Activity meas-
urement 
K>O  
conversion 
FIXgla-PC 
K>O  
conversion 
FIXgla-PC FIX 
K>O  
conversion 
F9CH 
K>O  
conversion 
FIX FIX FIX 
Reporter ex-
pression 
NA Stable NA Stable Transient NA 
Inducible, 
stable 
NA Transient Transient Transient 
Substrate 25 mM K1>O 5 µM K1>O 50 µM K1>O 5 µM K1>O 10 µM K1 
Up to 0.2 mM 
K1>O 
50 nM K1 
Up to 0.2 mM 
K1>O 
12 µM K1 12 µM K1>O 12 µM K1 
Type of assay DTT assay ELISA DTT assay ELISA 
Clotting 
assay 
DTT assay FACS DTT assay 
Clotting 
assay 
Clotting 
assay 
Clotting 
assay 
Discrimination 
between C1 
and L1 
No No 
Yes 
(but remain-
ing endoge-
nous activity) 
Yes 
(in KO cells) 
Yes 
(but remain-
ing endoge-
nous activity) 
Yes No Yes Yes Yes Yes 
Warfarin inhibi-
tion 
IC50  
2200 nM 
IC50  
100 nM 
At 5 µM: 
C1: 53% 
inhibition 
L1: 29 % 
inhibition 
IC50  
< 50 nM 
IC50 25 nM 
Ki values: 
hL1/hC1: 29x 
rL1/rC1: 54x 
IC50  
125 nM 
Ki values: 
hC1: 1.65 µM 
hL1: 52 µM 
IC50: 
C1: 2 nM 
L1: 25 nM 
IC50: 
C1: 2.4 nM 
L1: 27 nM 
IC50: 
C1: 17.3 nM 
L1: 474 nM 
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Comparative data for warfarin and other compounds are sparsely available [103, 112, 
113] and all published data were generated by means of DTT-driven VKOR assay 
(Table 17). Gebauer tested different 4-hydroxycoumarins, whereby acenocoumarol 
was the most potent drug [112]. Hodroge and colleagues used microsomal preparation 
of P. pastoris overexpressing VKORC1. The inhibitory constant for warfarin was equal 
to previously published values (1.65 µM), acenocoumarol and fluindione were more 
effective by a factor of 5 and 7, respectively [103]. Recently, the same group published 
results for various 4-hydroxycoumarins with respect to both VKOR enzymes [113]. 
VKORC1L1 was shown to be less affected by OAC treatment whereby warfarin and 
fluindione were the compounds with the most distinct inhibition pattern yielding 30- and 
80-fold difference on both VKOR enzymes. Although obtained with different types of 
assays the results showed the same overall tendency proving the quality of the data 
presented in this study. However, IC50 values of the present study are much lower indi-
cating that the cell-based assay used here represents a more sensitive method. 
 
Table 17: Overview of published data for warfarin and other OACs. 
ND- not determined, K1>O - vitamin K1 epoxide, K1 – vitamin K1, Ki – inhibitory constant 
 
Gebauer 2007  
[112] 
Hodroge et 
al., 2011  
[103] 
Matagrin et 
al., 2016  
[113] 
This thesis This thesis 
Expression 
system/ Cell line 
Rat liver  
microsomes 
Pichia pastoris Pichia pastoris 
VKORC1L1 
KO  
HEK 293T 
VKORC1L1 
KO  
HEK 293T 
VKOR  
expression 
Endogenous 
VKORC1  
overexpression 
VKORC1  
overexpression 
Endogenous Endogenous 
Type of  
measurement 
Direct Direct Direct Indirect Indirect 
Activity  
measurement 
K>O conver-
sion 
K>O conver-
sion 
K>O conver-
sion 
FIX FIX 
Reporter  
expression 
NA NA NA Transient Transient 
Substrate 25 mM K1>O 
Up to 0.2 µM 
K1>O 
Up to 0.2 µM 
K1>O 
12 µM K1 12 µM K1>O 
Type of assay DTT assay DTT assay DTT assay Clotting assay Clotting assay 
Warfarin IC50: 2.2 µM Ki: 1.65 µM Ki: 1.65 µM IC50: 1.9 nM IC50: 2.4 nM 
Acenocoumarol IC50: 0.8 µM Ki: 0.33 µM Ki: 0.33 µM IC50: 1.5 nM ND 
Phenprocoumon IC50: 1.8 µM ND Ki: 0.72 µM IC50: 3.6 nM ND 
Fluindione ND Ki: 0.25 µM Ki: 0.25 µM IC50: 4.8 nM IC50: 204 nM 
 
Inhibitory data rely mostly on VKR activity, but data presented here were generated 
using K1 as a substrate, i.e.VKOR activity was assessed. To complete the picture of 
VKOR enzyme inhibition, VKR activity was evaluated using warfarin and fluindinione 
(usage of K>O as substrate). In the cell-based assay, endogenous VKOR and VKR 
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activity of VKORC1 in VKORC1L1 KO cells was equally inhibited by warfarin. However, 
fluindione showed heterogeneous results. Firstly, controversial to published data, flu-
indione was less potent on VKORC1 inhibition, regardless of K vitamer supplementa-
tion [103]. Secondly, IC50 values for VKR and VKOR activity differed by a factor of 40. 
On this issue only speculations can be made. It could be that the interaction between 
K>O and fluindione may lead to distinct inhibition profile. Or fluindione has different 
binding characteristics in the presence of K>O. Another possibility is that K>O accumu-
lates in the ER membrane. However, no data is available to strengthen one of the 
aforementioned aspects. These data potentially explain the difficulty in stable treatment 
of patients with fluindione compared to coumarin-based drugs. 
 
Clinical impact of VKOR enzyme inhibition 
Oral anticoagulants are used to treat and prevent thromboembolic events. Anticoagula-
tion status is measured by INR (international normalized ratio) which reflects the time 
required for clot formation based on prothrombin time. Patients are adjusted to an INR 
between 2 and 3, which mirrors about 20% residual activity of all VKD clotting factors 
that could be reflected by IC80 (Table 18). Calculations of this modified inhibitory con-
stant revealed essentially similar ratio of VKORC1L1 to VKORC1 compared to IC50 
values discussed before. Again, warfarin showed the highest discrepancy regarding 4-
hydroxycoumarin derivatives. Indandiones are by far more effective in VKORC1 inhibi-
tion compared to VKORC1L1 as already seen in calculation of IC50 values.  
 
Table 18: IC80 values reflecting patient’s INR of 2-3. 
Calculations based on inhibition curves generated for assessment of IC50 values. 
Compound 
IC80 (nM) for 
VKORC1 
IC80 (nM) for 
VKORC1L1 
Ratio VKORC1L1/ 
VKORC1 
Warfarin 7.8 79 10 
Acenocoumarol 3.9 21.7 6 
Phenprocoumon 11 97 9 
Phenindione 12 1187 99 
Fluindione 19 1445 76 
 
OACs have been used for more than six decades for long-term anticoagulation. One 
advantage is the experience of those drugs and its reversibility by vitamin K administra-
tion. The major disadvantage is the narrow therapeutic window leading to safety and 
efficacy issues. In addition, pharmacokinetic and pharmacogenetic factors influence the 
success of the therapy. Allelic variants of VKORC1 have an impact on dosing of OACs, 
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but no drug-specific variations have been reported [21, 67, 114]. Cytochrome P450 
(CYP) is a group of hepatic microsomal enzymes which incorporates a hydroxyl group 
into substrate, to which drugs like OACs belong to. Thereby, lipophilic compounds are 
transformed to more hydrophilic metabolites being ready for elimination and renal ex-
cretion. CYP2C9 is the principal metabolzing enzyme of OACs. About 30 variants are 
known of which CYP2C9*2 and *3 are the most frequent allelic variants in the Cauca-
sian population. Metabolism of warfarin and acenocoumarol by CYP2C9 depends on 
the enantiomer, drugs are admistered as racemic mixtures constisting of 50% of each 
enantiomer [69]. In general, S-enantiomers are more potent but are metabolized faster. 
Elimination of warfarin and acenocoumarol occurs almost completely by metabolism 
thus allelic variants of CYP450 have a higher effect. CYP2C9 does not play a major 
role in clearance of phenprocoumon because CYP3A4 is the key catalyst for metabo-
lism and about 40% of this drug is excreted as parent compound [69]. In contrast to 
VKORC1 and CYP2C9 allelic variants of GGCX are not known to have an impact on 
coumarin anticoagulant dose finding [67]. 
Recently, many efforts have been made with regard to variability in VKORC1 gene 
leading to distinct warfarin resistance types [21]. Dosing algorithms can predict the cor-
rect dose of OAC to omit under- or over-anticoagulation [115]. Of the OACs investigat-
ed acenocoumarol displays the shortest half-life of less than 10 hours [67]. Thus anti-
coagulation states below and above desired INR are frequently present with increased 
risk of bleeding and thrombosis during therapy. Data on IC50 values for VKORC1 re-
vealed potency of acenocoumarol being as effective as warfarin. Warfarin and fluindi-
one have medium-ranged half-lives of more than one day [67, 70]. The longest-acting 
clinically used agent is phenprocoumon with a half-life of more than 5 days. Those 
compounds showed IC50 for VKORC1 inhibition in low nanomolar range making them 
more favorable than acenocoumarol due to more predictable and stable anticoagula-
tion.  
 
Another enzyme of the vitamin K cycle 
In the past few years, it became apparent that a third - yet unknown - enzyme can pro-
vide GGCX with KH2 [102]. This enzyme catalyzes the reduction of K but not K>O (i.e. 
only VKR activity) which was shown independently by different groups [102, 116]. In 
the presence of 11 µM K1, Tie and colleagues detected their γ-carboxylated reporter 
protein (fusion protein of FIX and protein C; FIXgla-PC) even in the presence of very 
high warfarin concentrations (up to 15 µM). This is in contrast to our results, because at 
12 µM K1 we obtained no measurable FIX activity in DKO cells (Figure 19). Only at 
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higher K1 concentrations activity of the third enzyme was observed (e.g. 50 µM K1) 
[116]. The existence of another enzyme with VKR activity is in complete agreement 
throughout the literature [102, 116]. The divergent results concerning K concentration 
needed to bypass the vitamin K cycle may arise from the different cell lines. Although 
cell lines used by Tie and our group have the same origin (human embryonic kidney 
cells), HEK 293T cells express a SV-40 antigen - to yield higher expression levels - 
whereas HEK 293 do not [90]. Multiple independent passages could have an impact on 
the genome structure and thus may influence the expression level of the third enzyme. 
Moreover, Tie and colleagues’ measurement was based on γ-carboxylation meaning 
that even not fully carboxylated reporter protein was detected, too. In contrast, the as-
say used in this thesis the reporter protein (i.e. FIX) was measured only if the protein 
was fully carboxylated which might explain the different results, too. 
To proof the impact of the third enzyme warfarin and fluindione were tested in VKORC1 
and VKORC1L1 KO HEK 293T cells using K1>O instead of K1. Treatment with warfarin 
and 12 µM K1>O showed similar IC50 values when compared with 12 µM K1 supple-
mentation. Non-compliant data were generated for fluindione when VKOR activity was 
assessed. Especially VKORC1 characteristics resulted in 40-fold higher fluindione re-
quirement for inhibition, VKORC1L1’s increased by a factor of 2. A clear explanation for 
these results cannot be provided, interaction of K1>O and fluindione may be one.  
Overall, activity of third enzyme can be excluded in the assay setup used. When as-
sessing VKR activity (most of the data on endogenous VKOR activity were generated 
using K1) the third enzyme may impact results on IC50 values giving higher values due 
to its coumarin insensitivity. By determination of VKOR activity, activity of third enzyme 
is absent and inhibition characteristics can solely be attributed to VKORC1 or 
VKORC1L1. Thus, if IC50 values were affected by the third enzyme during K1 supple-
mentation, values should be lower when assessing VKOR activity which was not the 
case for both compounds tested. Therefore, data on endogenous VKORC1 and 
VKORC1L1 inhibition can be specifically attributed to the enzyme investigated because 
the third enzyme was proven not to be active in the experimental setting used. 
 
Impact of VKORC1L1 inhibition 
Results from mouse studies highlighted the importance of Vkorc1 in terms of blood 
coagulation. A constitutive knockout of Vkorc1 led to postpartal death due to predom-
inantely intrachranial hemorrhage and mice died two weeks after birth [31]. In addition, 
mice harboring one or two deleterious alleles showed significant reduction in the length 
of long bones [31]. Thus, Vkorc1 supplies Ggcx with co-factor in hepatic and extra-
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hepatic cells. For further examination of Vkorc1 function in extrahepatic cells a mouse 
model will be helpful which lacks Vkorc1 expression in all cells beside liver. This can be 
accomplished by knocking in Vkorc1 in liver cells (on top of constitutive Vkorc1 knock-
out) or by using a liver-specific promoter which allows expression of Vkorc1 in liver but 
no other cells. With this special approach mice should survive to adulthood and conse-
quences of gene deletion in extrahepatic tissues can be observed. Data from constitu-
tive Vkorc1 knockout already indicated an involvement in bone metabolism, which is 
plausible since osteocalcin and MGP are well known vitamin K dependent proteins with 
function in mineralization of bone.  
The impact of VKORC1L1 inhibition in vivo is not known yet since it is still unclear if 
VKORC1L1 supports KH2 generation for γ-carboxylation by GGCX in vivo. Results from 
mouse studies indicate that VKORC1L1 is not able to compensate lack of VKORC1 
activity since bleeding phenotype in constitutive Vkorc1-/- was not rescued [31]. In liver, 
were coagulation factors are synthesized, Vkorc1l1 expression is very low and not up-
regulated in Vkorc1-/- mice [12, 33]. Assessment of VKOR activity in Vkorc1-/- liver mi-
crosomes showed markedly reduced activity (by 97%) compared to control [33]. Fur-
thermore, Vkorc1l1-/- in osteoblasts revealed no difference in OCN levels compared to 
control mice [32]. Knockout of Vkorc1l1 in murine osteoblasts did not have an effect on 
γ-carboxylation of OCN suggesting a minor role of Vkorc1l1 in this special cell type. 
Further studies are needed to elucidate the effect of Vkorc1l1-/- in other cells than liver 
and osteoblasts. In the second part of this section this issue will be discussed in more 
detail.  
 
Inhibition of VKORC1 and VKORC1L1 by rodenticides and ferulenol 
In the US more than 13,000 exposures to rodenticides (warfarin and related com-
pounds) have been reported in 1996. The vast majority was unintended, however a 
small number (4%) was due to suicidal attempts.3 In cases of clinically relevant poison-
ing, high dose maintenance K1 therapy was needed to prevent fatal bleedings [71].  
Rodenticides are long lasting coumarin derivatives and the second generation of ro-
denticides emerged due to cross-resistance to warfarin and other compounds of the 
first generation. The substitution of methyl group by long, phenyl side-chains yielded 
tremendous increase in potency and duration of action [74]. Data on half-life of rodenti-
cides are sparsely available. It can be assumed that elimination is very slow (compared 
                                               
3
 https://edis.ifas.ufl.edu/pi113, visited on 10-Feb-2018 
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to therapeutically used OACs) and half-life ranges between several weeks up to sever-
al months [117]. 
In contrast to rodenticides, ferulenol is naturally occurring with a much higher potency 
than coumarin (also naturally occurring). Ferulenol is plant-derived and found in Medi-
terranean area. The prenylated 4-hydroxycoumarin was reported to cause hemorrhagic 
symptoms (ferulosis) in mammals [118]. Intoxication can occur in cattle, sheep, pig and 
horse, in men ferulosis have been reported only sporadically [119].  
Conclusive data on inhibitory potential of rodenticides with regard to VKOR enzymes 
are rare since most of the studies analyzed microsomes using the DTT-driven 
VKR/VKOR assay. Data presented here revealed that rodenticides appear to have high 
affinity for both VKORC1 and VKORC1L1, which is reflected by low discrepant meas-
urement of both enzymes. In contrast, ferulenol showed enzyme specificity comparable 
to coumarin-based OACs, with VKORC1L1 being less sensitive to ferulenol treatment 
than VKORC1.  
In previous studies different parameters (i.e. inhibitory constant ki, half maximal inhibi-
tory constant IC50) were assessed (Table 19) [63, 112, 118, 120].  
 
Table 19: Overview of published studies on VKOR inhibition of rodenticides and ferulenol. 
ND - not determined, ki - inhibitory constant 
 
Monti et al., 
2007 
[63] 
Gebauer 
2007 
[112] 
Hodroge et al., 2011 
[120] 
Louvet et 
al., 2015 
[118] 
Expression sys-
tem 
BHK cells with 
stable FX 
expression 
Rat liver 
microsomes 
Rat liver 
microsomes 
VKORC1 in 
Pichia pastoris 
Rat liver 
microsomes 
Warfarin 5 µM: 59 % IC50: 2.2 µM ki: 0.72 µM ki: 0.50 µM ki: 0.50 µM 
Bromadiolone ND ND ki: 0.13 µM  ki: 0.07 µM ND 
Brodifacoum ND IC50: 0.15 µM ki: 0.04 µM ki: 0.03 µM ND 
Ferulenol 10 nM: 67 % IC50: 0.098 µM ND ND ki: 0.03 µM 
 
The inhibitory constant Ki reflects the binding affinity, whereby half maximal inhibition 
constant IC50 mirrors the functional strength of the inhibitory drug. In the cell-based 
assay VKR/VKOR activity is measured indirectly which makes enzyme kinetic studies 
not suitable. In contrast, the DTT-driven VKOR assay allows determination of those 
parameters. Therefore, direct comparison is not applicable due to type of assay and 
biological material used. But values from warfarin can be related to other compounds 
and thus provide a basis for comparison of published results and data presented here.  
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Gebauer investigated brodifacoum and ferulenol, as well as warfarin in rat liver micro-
somes. In comparison to warfarin, brodifacoum was about 15-fold more potent [112]. 
Hodroge and colleagues tested warfarin, bromadiolone and brodifacoum in micro-
somes prepared from rat liver and P. pastoris after overexpresssion of VKORC1 [120]. 
Thereby, brodifacoum and bromadiolone were found to be more potent than warfarin 
when comparing the Ki values (~18 times vs. ~6 times, respectively). Data generated 
by Gebauer and Hodroge were similar with respect to brodifacoum yielding almost the 
same ratio to warfarin. In rat liver, VKORC1 is expected to be solely responsible for K 
recycling [33]. Therefore, inhibition values should be attributed to VKORC1, which 
would allow the comparison of the present data on VKORC1. In our assay, inhibition of 
endogenous VKORC1 revealed higher potential of brodifacoum (4-fold for VKORC1), 
but bromadiolone showed same inhibitory potential compared to warfarin (1.2-fold for 
VKORC1). With respect to VKORC1L1 inhibition, bromadiolone and brodifacoum had a 
30 to 60-fold higher potency, which is not reflected by previous studies. 
A French group described a 17- to 60-fold higher effect (depend on the species tested) 
on VKOR inhibition of ferulenol compared to warfarin [118]. Gebauer’s data revealed a 
22-higher potential of ferulenol to inhibit VKOR in the experimental setting. In the cell-
based assay, VKORC1 required 2.5-fold less ferulenol compared to warfarin for half 
maximal inhibition. In contrast, VKORC1L1 needed only one eighth of warfarin concen-
tration.  
Monti and colleagues compared warfarin and ferulenol treatment by means of FX sta-
ble expressing baby hamster kidney (BHK) cells. They state that ferulenol was much 
more effective compared to warfarin (three orders of magnitude) [63]. However, since 
BHK and HEK 293T cell originate from kidney, the results are doubtful. They have 
shown that by warfarin treatment (5 µM) resulted in only 40% less FX carboxylation. In 
contrast, in HEK 293T cells FIX levels were reduced by more than 90% when treated 
with 1 µM warfarin. Values can vary between cell lines and experiment, but the range 
should be consistent.  
 
Impact of antibiotics on coagulation 
Since many years, antibiotics are used to treat bacterial infections. Drug-drug interac-
tions influencing effectiveness are well known for oral contraceptives and alcohol and 
others. β-lactam antibiotics with MTT side chain are suspected to cause hypopro-
thrombinemia and platelet dysfunction [121]. Patients under antibiotic therapy showed 
prolongation of prothrombin time (PT) [122], however administration of cefamandole or 
moxalactam in healthy volunteers did not result in hypoprothrombinemia [123]. Antibiot-
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ics can destruct the intestinal flora which was supposed to lead to hypoprothrom-
binemia because a source of vitamin K disappeared. In animals like rats or mice antbi-
otic treatment can influence vitamin K status due to coprophagy and vitamin K2 pro-
duced by bacteria in gut may represent a dietary source. However, when rats were fed 
with vitamin K deficient diet they developed hypoprothrombinemia despite intact intes-
tinal flora when coprophagy was prevented [124]. Thus vitamin K2 produced by intesti-
nal flora is not sufficiently absorbed and does not contribute to vitamin K status without 
a second gut passage [125]. Data from animal studies cannot be transferred to human 
beings due to absent coprophagy, an important dietary source of vitamin K in animals 
[126]. Therefore, predisposition to antibiotic-associated hypoprothrombinemia can be 
assumed as malnutrition, malabsorption, total parenteral feeding and decreased renal 
function [123, 126].  
Therefore, a selection of antibiotics suspected to cause bleeding phenotype was tested 
in the cell-based FIX assay to determine the effect on VKOR enzymes by means of 
single KO cell lines. Cephalosporin C represents a β-lactam antibiotic without MTT side 
chain, whereby cefamandole and moxalactam belong to the same group of antibiotics 
containing MTT side chain. In the assay, antibiotic concentrations up to 125 µM were 
tested reflecting the maximum solubility of the compounds. Antibiotic containing MTT 
side chain was more effective on inhibition of γ-carboxylation of FIX when comparing 
cephalosporin C and cefamandole. But moxalactam (β-lactam antibiotic with MTT side 
chain) did not affect γ-carboxylation. Mitchell and colleagues studied rat liver micro-
somes and showed that neither moxalactam nor cefamandole inhibited carboxylation 
greater than 20%, whereby concentrations up to 2.5 mM were tested [127]. Thus, in 
vitro the bleeding phenotype of those antibiotics cannot be proven. It is assumed that 
MTT-containing cephalosporins are weak inhibitors of VKOR leading to the accumula-
tion of K>O in plasma which is also seen in patients under warfarin therapy [123]. In 
vivo, hypoprothrombinemia is favored by low vitamin K status caused by malnutrition or 
decreased renal function [126]. In contrast, data presented here were generated with 
saturated concentration of vitamin K. MTT-containing antibiotics are proposed to be 
weak inhibitors for VKOR enzymes and vitamin K status in vitro may superimpose with 
inhibitory effect of antibiotic [123]. MTT is released from parent compound and this 
moiety (or its metabolite) was found to inhibit γ-carboxylation of glutamic acid with an 
IC50 value of 1 mM, but MTT levels in human are considerably lower (0.03 mM) [128]. 
Thus, the different levels of K in vivo and in vitro might explain the contrary results. 
Moreover, systemic effects like vitamin K status cannot be mirrored in cell culture.  
In another experiment, the additive effect of β-lactam antibiotics and anticoagulation 
therapy was tested. Angaran and colleagues proved that cefamandole can have an 
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additive effect to warfarin leading to hypoprothrombinemia, whereby cefazolin’s (cepha-
losporin without MTT side chain) potential is intermediate, and vancomycin (glycopep-
tide antibiotic) does not influence the risk at all [129]. Contrary data were published in 
2005 when Holbrook et al. concluded that it is unlikely that cefamandole potentiate war-
farin therapy, whereby ciprofloxacin, a fluoroquinolone antibiotic, is highly probable to 
affect warfarin treatment [130]. A more recent study found out that different classes of 
antibiotics can significantly increase INR when administered concomitant with warfarin 
[131]. In vitro, co-incubation of warfarin and different concentrations of cephalosporin 
C, cefamandole and moxalactam did not result in an additive effect. However, metabo-
lism of warfarin and antibiotics is different in vivo since it is known that monooxygenas-
es relevant for metabolism of warfarin and vitamin K are not expressed in HEK 293 
cells [109]. MTT may be metabolized by Flavin-containing monooxygenase but expres-
sion level of this enzyme is not known in HEK cells [132]. In addition, the complexity of 
in vivo warfarin and antibiotic metabolism, their interaction among each other and po-
tential reuptake of the metabolites by the gastrointestinal system cannot be modeled in 
this in vitro study. Thus, conclusions from in vitro data presented here can only be 
drawn with regard to direct inhibition of VKOR enzymes. Antibiotics tested in this exper-
imental setting (with saturated K concentration) did not have any direct inhibitory effect 
on VKORC1 or VKORC1L1 since FIX activity was not reduced.  
 
Identification of warfarin binding sites in VKORC1 and VKORC1L1  
Investigation of different OACs in VKORC1 KO and VKORC1L1 KO HEK 293T cells 
revealed for most compounds different inhibition pattern whereby VKORC1 was more 
sensitive than VKORC1L1. To elucidate the molecular basis we had a closer look on 
the amino acid composition of both enzymes. For VKORC1 a 4TM structure is consid-
ered, however a 3TM structure is also under investigation (Figure 4) [21, 22, 133]. In 
contrast, the 4TM structure of VKORC1L1 is not subject of discussion (Figure 5) [10, 
22, 34]. Overall, VKORC1 and VKORC1L1 are identical to 44% and similar to 68% with 
respect to amino acid composition (Figure 62) and this alignment provided the basis for 
further experiments.  
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Figure 62: Human VKORC1 (NP_076869.1) protein sequence was aligned with sequence of 
human VKORC1L1 (NP_775788.2) using NCBI blast tool.  
The transmembrane domains (TM1 to TM4) and the loop region of VKORC1 are marked. Aster-
isks indicate identical amino acids, plus sign represents amino acids with similar chemical prop-
erties.  
 
In a first approach the loop of VKORC1L1 was swapped in VKORC1 cDNA and vice 
versa. For warfarin and fluindione loop swap showed almost similar inhibition curves as 
their WT counterparts. This suggests that the loop is  important (at least partially)and 
indicate that those amino acids are involved in drug binding. This is sustained by previ-
ously published in silico data on VKORC1, where three molecular surfaces for warfarin 
binding had been identified. Thereby, amino acids Ser52 to Phe55 located in the loop 
of VKORC1 belong to one of three contact surfaces with Phe55 forming hydrophobic 
interactions with warfarin (contact surface II) [21]. By sequence alignment, the amino 
acids Ser59 to Leu62 of VKORC1L1 correspond to the contact surface of VKORC1 
(Ser52 to Phe55). Neither single mutation (VKORC1L1 Leu62Phe) nor complete swap 
of the four amino acids (Ser59 to Phe62) of VKORC1 contact surface II showed lower 
susceptibility to warfarin, which indicates that warfarin binding sites of VKORC1 and 
VKORC1L1 are different. By swapping particular amino acids of VKORC1 identified to 
be involved in warfarin binding in VKORC1L1, we expected to approximate VKORC1L1 
variant to VKORC1 WT inhibition pattern, but the opposite was the case. 
In silico analysis of both enzymes revealed three distinct arginine residues to stabilize 
warfarin binding by their positive charge but do not necessarily align to the same amino 
acid of the counterpart (Figure 63). However, for none of the predicted arginine resi-
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dues in VKORC1 the corresponding amino in VKORC1L1 acid was predicted to be 
involved in warfarin binding. 
 
 
Figure 63: Alignment of VKORC1 (amino acids 30 to 79) with VKORC1L1 (amino acids 37 to 
86).  
Star indicates identical amino acids, bold letters represent amino acids with similar chemical 
properties. Red box indicate arginines in VKORC1 expected to be involved in warfarin binding; 
blue box represents arginines in VKORC1L1. 
 
Mutation of selected amino acids (Phe55, Arg33, Arg40 and Arg53) proved the in silico 
model of VKORC1. Whereby Phe55Ala showed a complete resistance, mutated argi-
nine residues shifted warfarin dose-responses to higher requirement for half-maximal 
inhibition.  
In silico analysis of VKORC1L1 revealed three putative arginines at amino acid posi-
tions 38, 42 and 68 to be involved in warfarin binding. Substitution of two arginines 
(VKORC1L1 R38E+R42E) yielded eight-fold higher IC50 value of warfarin compared to 
VKORC1L1 WT. The triple mutant VKORC1L1 R38E+R42E+R68E showed even com-
plete resistance to warfarin, whereby concentrations up to 5 µM were used. Therefore, 
in silico docking analysis was confirmed by inhibition data revealing resistance for the 
potential amino acids being involved in warfarin binding on VKORC1L1.  
Thus warfarin binding takes place in different regions of the loop in VKORC1 and 
VKORC1L1 and therefore might explain the different affinities of OACs on VKORC1 
and VKORC1L1 enzyme (Figure 64). Since almost all OACs bear a negative charge, 
this is of great consequence for their comparative binding. While in VKORC1 these 
arginines cluster around the hydrophobic pocket close to a short helix formed in the 
cytoplasmic loop (residues Arg33, Arg40 and Arg53 in VKORC1 as mentioned above), 
in the case of VKORC1L1 they occur around a region which is on the opposite site of 
this short helix (Arg38, Arg42 and Arg68). 
Moreover, in VKORC1L1 no amino acids were identified to form hydrogen bonds or 
phi-phi interactions to warfarin as shown for VKORC1 (Phe55) which might explain the 
reduced sensitivity of VKORC1L1 towards OACs compared to VKORC1. 
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Figure 64: Comparative binding poses for warfarin on VKORC1 and VKORC1L1. 
The structural alignment of the hVKORC1 and hVKORC1L1 models is shown. The backbone of 
hVKORC1 and hVKORC1L1 are depicted in green and blue colored ribbon format, respectively. 
The arginine residues clustered around the favored warfarin binding site of each model are de-
picted in stick format. 
 
Future perspectives of these results 
For many decades, warfarin has been the drug of choice for prevention and long-term 
treatment of arterial and venous thromboembolism [60]. OAC treatment is safe, cheap 
and effective when the patient is stable anticoagulized (i.e. a high time in therapeutic 
range is achieved). INR adjustment is challenging in the context of drug and food inter-
actions and liver disease, resulting in either undertreatment (with an increased risk of 
thromboembolism) or overtreatment (leading to bleeding). In the past few years, new 
drugs for oral anticoagulation - known as direct oral anticoagulants (DOACs) - had 
been approved for antithrombotic therapy. These DOACs (direct thrombin inhibitors 
(e.g. dabigatran) or direct factor Xa inhibitors (e.g. rivaroxaban)) produce a more pre-
dictable, less labile anticoagulant effect and have been shown to be at least as safe 
and effective as warfarin in stroke prevention in atrial fibrillation [134]. However, disad-
vantages for DOAC treatment are present especially in terms of reversing anticoagula-
tion therapy in emergency cases (antidot is available only for one drug) and special 
precaution should be taken for patients with renal impairment [134].  
OAC treatment reduces the risk of recurring arterial and venous thrombosis by affect-
ing carboxylation of VKD coagulation factors. A major side effect of long term OAC 
treatment is vascular calcification, a thightly regulated process in which vascular cells 
and VKD proteins are involved [135]. Vascular calcification is associated with an in-
creased risk of cardiovascular disease [136]. MGP is the most potent inhibitor of vascu-
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lar calcification which is highlighted by animal studies. MGP-/- mice died some 8 weeks 
after birth due to calcification and subsequent rupture of medium and large arterial ves-
sels [48]. OAC treatment thus leads to reduced γ-carboxylated (undercarboxylated) 
MGP levels. Another vitamin K dependent protein with regultatory properties is GRP 
which has, like MGP, calcium-binding properties and thus is assumed to be an inhibitor 
of vascular calcification [49]. However, knockout studies in mice revealed no pathologi-
cal effect suggesting a minor importance than MGP in terms of calcification [137]. 
Several studies showed an impact on vitamin K status and vascular calcification, 
whereby K2 is advantageous over K1. Tissue specific K1 accumulation in liver has been 
shown in rats which were fed with equal amounts of K1 and MK-4. In contrast, MK-4 
accumulated in non-hepatic tissues like arterial vessel wall [138]. To overcome side 
effects of OAC treatment in extra-hepatic tissues supplementation of K2 may be of im-
portance. Observational studies have shown an inverse relationship between high vit-
amin K (mainly menaquinones) intake and coronary calcification or risk of cardiovascu-
lar disease [5]. Furthermore, a systematic review and meta-analysis revealed that high 
pharmacological doses of MK-4 had beneficial effects on bone parameters [139]. How-
ever, health benefits of supplementation of vitamin K is still under debate and depend 
on the cohorts under investigation [140]. Of note, excess intake of vitamin K does not 
result in thrombosis even when taking supraphysiological doses [141]. Indeed, vitamin 
K supplementation interferes with OAC treatment, but data suggest that K2 supplemen-
tation should have minor effect on carboxylation of clotting factors with normal carboxy-
lation status of extra-hepatic VKD proteins like MGP or OCN. Furthermore, vitamin K 
supplementation in healthy people may have a positive effect on bone health and vas-
culature.  
Due to different inhibition pattern of warfarin, acenocumarol, phenprocoumon and flu-
indione one would expect different extent of treatment on extrahepatic VKD proteins. 
Based on the assumption – but data to support or withdraw this hypothesis is missing - 
that VKORC1L1 is capable of providing GGCX with KH2 in vivo, fluindione may be the 
drug of choice because of the distinct inhibition pattern. Theoretically, at a given dose 
VKORC1 is inhibited by 50% whereas VKORC1L1 is not affected at all meaning normal 
carboxylation of (extrahepatic?) VKD proteins. In liver, VKORC1 is the major enzyme 
responsible for vitamin K recycling, VKORC1L1 does not play a role in this particular 
tissue. This study also demonstrated that anticoagulation with fluindione might be diffi-
cult due to different inhibition pattern using different substrates (K vs. K>O). In this 
light, warfarin might be the “best” OAC to achieve stable anticoagulation irrespective of 
the substrate and comparably low VKORC1L1 inhibition. However, studies addressing 
the long term effect of different OACs on extra-hepatic tissues are lacking.  
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5.2 Generation of Vkorc1l1 KO mice 
Generation of transgenic mice is used intensively in research and allows studying of 
gene function in a model organism. In a constitutive KO, the gene function is absent in 
every cell. However, in 15% of KO mice, the severity of the phenotype (i.e. develop-
mental lethality) precludes the analysis of the gene’s impact [142]. Therefore, Cre/loxP 
technology was introduced to generate conditional KO [143, 144].  
Cyclization recombination of bacteriophage P1 (abbreviated as Cre) catalyzes the re-
combination between two loxP (locus of X over P1) sites independent of additional co-
factors (Figure 65). The loxP site is a 34 bp nucleotide sequence that can be genetical-
ly targeted around an essential exon in a gene [145].  
 
 
Figure 65: Cre/loxP system to generate constitutional or conditional KO mice. 
A: LoxP site is characterized by 13 bp palindromic sequences separated by a 8 bp spacer. B: 
The homologous recombination (hr) locus is characterized by the integration of two loxP sites 
flanking exon of the target gene. C: Cre binds to loxP sites and cuts at both loxP sites. During 
this process, gene fragment flanked by loxP sites is removed and recombination yields deletion 
of the respective exon. Dependent on the orientation of loxP sites, insertions and translocations 
can be generated (not shown).  
 
Conventionally, mice are generated by means of homologous recombination using em-
bryonic stem (ES) cells. Thereby, a vector harboring the desired modification including 
loxP sites is used to manipulate ES cells. Targeted ES cells are then injected into blas-
tocysts and subsequently transferred to the uterus of a recipient mouse which will act 
as a surrogate mother. Pups are called chimeras characterized by different coat colors 
(e.g. black and brown). The chimeric pubs are bred with WT mice to check if modified 
ES cells have contributed to the germline of the chimera. Overall, the procedure is time 
and lab consuming. Furthermore, additional time is needed due to extensive mating 
with WT mice for seven to ten generations in order to avoid strain specific bias. This is 
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due to the requirement of different strains of ES cells and blastocysts to identify chimer-
ic mice.  
In contrast, CRISPR/Cas9-mediated genome engineering provides a straight forward 
technique to generate transgenic mice. Extensive cloning and maintenance of ES cells 
can be slipped. The components of CRISPR/Cas9 were injected into oocytes at pronu-
cleus state and lab-intensive steps as described above can be omitted. In addition, 
extensive backcrossing as described above is not required. By means of this tech-
nique, constitutive as well as conditional KO can be generated [89, 146]. Our approach 
was to generate floxed mice in order to allow mouse study in case of lethal phenotype 
of constitutive KO. As shown in Table 9 a deletion of exon 2 and adjacent region was 
obtained, but integration of loxP sites failed. Other groups were more successful. Lo-
bocka and colleagues reported the integration of two loxP sites in one allele was suc-
cessful and 15% of pubs showed floxed target gene in heterozygous state [147]. The 
reason for failure of integration of loxP sites in Vkorc1l1 locus may be multi-faceted. 
One answer may lie in the gene itself. Vkorc1l1 is a small gene harboring only three 
exons which restricts selection and design of sgRNAs. Furthermore, the intronic se-
quence between exon 1 and 2 is large (36 kb) which may have an impact on the suc-
cess of process. Secondly, the reason may lie in the gRNA, which can be optimized in 
terms of length. A group from China generated KO mice by targeting exon 2 of FVII 
with gRNAs which differed in length. They yielded 23% and 54% mutation frequency 
for normal gRNA (20 nt) and truncated gRNA (17-18 nt), respectively. Even homozy-
gous KO was obtained. The variations they detected included substitutions, deletions 
(2-167 nt), and insertions (1-13 nt) [148]. However, constitutive Vkorc1l1 KO was not 
lethal and the necessity for generation of floxed gene does no longer exist. 
During any manipulation on genetic material non-desired, so-called off-target, effects 
can be generated. Thereby insertion, deletions or substitutions can occur at a site dif-
ferent from target. Fu and colleagues targeted eGFP in U2OS.EGFP cells (human 
bone osteosarcoma epithelial cell line expressing a fluorescent protein) at three differ-
ent positions and found out that for optimal effect different amounts of sgRNA‐/Cas9‐
expressing plasmids were required for the three target sites within the same gene. Fur-
thermore, they tested six sgRNAs in four different genes in U2OS.EGFP cells with re-
gard to their off-target effects. Whereas three target genes showed only one or even no 
off-target, gRNA for vascular endothelial growth factor A revealed multiple off-targets, 
most of them concerned protein-coding regions [149]. Such dramatic consequences of 
manipulation are not desired and the occurrence cannot be predicted. Nevertheless, in 
mice occurred off-targets can be washed out by certain cycles of breeding and back-
crossing.  
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Compared to the conventional approach, mice were generated in much shorter time. 
As shown in Table 8, generation of Vkorc1l1 KO mouse was successful in four mice, 
but one mouse (founder mouse #22) was not transmitting the deleterious allele to germ 
line. For establishment of Vkorc1l1 KO stock founder mouse #17 was selected. This 
mouse showed a deletion of 1.2 kb, expression of Vkorc1l1 should be completely omit-
ted in homozygous state. To proof this mRNA expression was quantified using real-
time PCR. Analysis revealed, irrespective if RNA or cDNA was used as a template, 
amplification of template even in homozygous Vkorc1l1 KO. The probe was designed 
to bind exon 1/2 boundary and should not give any amplification in homozygous 
Vkorc1l1 KO. By database search it became apparent that the reason for amplicons in 
qPCR in homozygous Vkorc1l1 KO samples may be due to a “processed pseudogene” 
[150]. Processed pseudogenes arise by integration of transcribed mRNA of the parent 
gene at a new locus in the genome.  
The alignment of the Vkorc1l1 mRNA (NM_027121.4, 4935 bp) with the murine ge-
nome resulted in a match with 99% identity over more than 1 kb including the cDNA 
sequence of Vkorc1l1 (i.e. from start to stop codon) (Figure 66). Only at three positions 
nucleotide exchange was observed, one substitution in the coding region (c.468T>C) 
and two substitutions in 3‘UTR (c.531+1T>C and c.531+11A>G, respectively). 
 
 
Figure 66: Screenshot of alignment of Vkorc1l1 mRNA to the murine genomic sequence by 
using BLAST.  
A part of the mRNA (1114 bp) was also found on chromosome 15 (NC_000081.6). Database 
search was assessed on 07-Jul-2018. 
 
In order to verify the hypothesis of processed pseudogene primers binding at start and 
stop of Vkorc1l1 cDNA were used for amplification of gDNA. A product of the expected 
size was generated, sequencing revealed single base substitution at c.468T>C (Figure 
47 and Figure 48). On the basis of these results we concluded that amplification in 
qPCR in KO samples was due to contamination of RNA sample with gDNA.  
Studies on protein level failed due to appropriate antibody against Vkorc1l1 which 
would represent the ultimate proof of the absence of Vkorc1l1 protein. Another possibil-
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ity to verify Vkorc1l1 KO could be done on RNA level by means of a Northern Blot. Af-
ter size separation RNA is blotted on a membrane and incubated with DNA probes 
which allow detection of RNA-DNA hybrids. However, based on RNA and DNA analy-
sis presented here Vkorc1l1 KO mice were considered to lack endogenous expression 
of Vkorc1l1 protein in mice constitutively.  
 
Phenotypic screen of Vkorc1l1 KO mice 
As described before, generation of the KO mice was sucessful and Vkorc1l1 KO mice 
did not show lethal phenotype as seen with Vkorc1 KO [31]. For phenotypic analysis 
the cohort of founder mouse #17 was expanded. In cooperation with German Mouse 
Clinic (GMC) Vkorc1l1 KO phenotype was examined [151]. GMC was founded in 2001 
being the first facility worldwide with open access for the scientific community and de-
veloped a large scale of comprehensive and standardized phenotypic check-up with 
more than 550 parameters. The screens are designated to the areas of behavior, bone 
and cartilage development, neurology, clinical chemistry, eye development, immunolo-
gy, allergy, steroid metabolism, energy metabolism, lung function, vision and pain per-
ception, molecular phenotyping, cardiovascular analyses and pathology4. In December 
2016, mating of Vkorc1l1+/- mice was started to obtain Vkorc1l1-/- mice and respective 
control animals (Vkorc1l1+/+ mice). At age of 7 weeks mice were sent to GMC facility, 
characterization started after two weeks of acclimatization period. An overview and 
time scale of the screen is depicted in Figure 17. 
The first and most impressive result of the screen was that mutant mice weighed less 
compared to their wild type littermates. This observation was consistent throughout the 
screen over more than 12 weeks.  
Secondly, Vkorc1l1 KO mice showed differences in behaviour when compared to their 
WT littermates. In the open field – a measure of spontaneous reactions to a novel envi-
ronment – Vkorc1l1-/- mice showed increased locomotor activity and speed along with 
decreased time spent in center. These results indicate that the knockout mice are 
slightly hyperactive when confronted with a mildy stressful situation. In addition, the 
results point to heightened anxiety. Results from PPI suggested deficits in sensorimotor 
gating, which is largely regulated by neuronal connections between different brain re-
gions. However, further examination is needed to resolve the impact of Vkorc1l1 in 
terms of behavioral changes observed during the phenotypic screen. A first hint can be 
provided when the Vkorc1l1 expression pattern in different brain regions is elucidated. 
                                               
4
 https://www.mouseclinic.de/about-gmc/general/index.html, visited on 29-Sep-2017 
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As mentioned already, antibodies binding specifically to Vkorc1 or Vkorc1l1 proteins 
are to date not available. However, this issue could be resolved using advanced ap-
proaches like in situ hybridization, Vkorc1l1-specific aptamers or transgenic mice har-
boring fluorescence protein N- or C-terminal fused to Vkorc1l1. Information for Vkorc1l1 
expression pattern, especially with regards to Vkorc1, could be meaningful in terms of 
specific enzyme function. 
The correlation between vitamin K and sphingolipids was initially demonstrated in bac-
teria, where it was found to be essential to cell membrane structure synthesis by induc-
tion of a specific enzyme (3-ketodihydrosphingosine (3-KDS) synthase) which is in-
volved in the initial step of sphingolipid biosynthesis [152]. Earlier findings were then 
confirmed in rodents, thus warfarin treatment was associated with decreased 3-KDS 
synthase activity and significant reductions in brain sulfatides, sphingomyelin and cere-
brosides. Warfarin-induced alterations in sphingolipid synthesis could be reversed by 
subsequent administration of vitamin K [153]. Vitamin K in the brain occurs predomi-
nantly as MK-4 (K2 derivative), anatomically distributed in all brain regions, although 
concentrations differed according to regions [154]. Sphingolipids are important for cel-
lular events such as proliferation, differentiation, senescence, cell–cell interaction, and 
transformation. Furthermore, they have been linked to alterations in aging processes 
and neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.  
Vkorc1l1 KO mice were different compared to WT mice, thus suggesting that Vkorc1l1 
does play a role in brain function. Indeed, in the neurological screen Vkorc1l1 KO mice 
showed increased locomotor activity. Increased body tone and hyperactivity could be 
an indicator of neuronal hyperexcitability. This could be due to either reduced inhibitory 
or increased excitatory signaling, which is also involved in epilepsy disorders.  
Knowledge of Vkorc1l1 expresion in vivo is currently restricted to mRNA expression 
profile assessed in different tissues [12]. It was shown that Vkorc1l1 is uniformely ex-
pressed with highest level in brain suggesting an important function in this organ. To 
date, special brain regions of Vkorc1l1 expression have not been identified and further 
experiments are needed to clearify the function of Vkorc1l1 (especially in the context of 
its paralog Vkorc1) in brain. Years ago it was shown that vitamin K intake have an im-
pact on sphingolipid biosynthesis (which is dependent on warfarin treatment) [153]. 
One explanation is that in brain or more precisely in distinct brain regions yet unknown 
VKD proteins are involved in sphingolipid metabolism which are dependent on γ-
carboxylation for proper function. Another possibility is that enzymes or enzyme com-
plexes are dependent on KH2 but do not need to be γ-carboxylated.  
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The analysis of clinical chemistry revealed some deviations compared to control mice. 
Marked effects on body weight as well as plasma lipid concentrations in both, fasting 
and the ad libitum fed state suggest that the Vkorc1l1 knockout affects energy metabo-
lism with a predominat effect on lipid metabolism. In addition, glucose metabolism ap-
peared slightly altered as well. Vkorc1l1-/- mice showed lowered glucose levels and a 
reduced body fat mass compared to their Vkorc1l1+/+ littermates, which might be an 
indicator of disturbed energy metabolism. In men insufficient supply with carbohydrates 
leads to low glucose plasma level [155]. Enhanced protein catabolism may also induce 
lowered body weight, and could also be due to insufficient supply of carbohydrates and 
thus may induce increased urea concentration in plasma [155, 156]. Morevover, in-
creased liver parameters (i.e. AST and LDH, but not ALT) were detected which could 
indicate muscle or erythrocyte damage. Elevated levels of sodium and chloride may be 
due to loss of body fluid balance. Increased concentration of potassium and urea may 
be an indicator of kidney dysfunction. Indeed, not all parameters were significantly in-
creased thus interpretation is difficult. Furthermore, the morphological screen did not 
yield any pathological findings during histological examination. Overall, a clear picture 
of liver dysfunction or renal impairment was not observed. Remarkable is the clear 
sexual dimorphism observed in many parameters during the phenotypic screen, hence 
in most cases females were more affected. 
 
Age-related phenotype of Vkorc1l1-/- mice 
Aging and antioxidative defense mechanisms are closely connected. Aging affects all 
cells and not one tissue is directly responsible for aging which makes research difficult. 
Several knockout mouse models have been generated to elucidate the function of a 
protein in terms of antioxidation and aging. Glutathione peroxidases (GPx) and super-
oxide dismutases (SOD) are enzymes which scavenge ROS. Manganese superoxide 
dismutase (MnSOD) is encoded by Sod-2 and located in the mitochondrial matrix, 
where it is the only scavenger. Homozygous Sod-2 KO showed a lethal phenotype and 
mice died shortly after birth [157]. In heterozygous state enzyme activity was sufficient 
under normal metabolism, but pathophysiological conditions caused elevated mito-
chondrial superoxide production [158]. Mice in which Sod-1, Sod-3, and GPx1 genes 
were deleted appeared to be viable. Cupper zinc superoxide dismutase (CuZnSOD), 
encoded by Sod-1, is located in the cytoplasm and mitochondrial intermembrane 
space. Homozygous Sod-1 KO mice showed accelerated age-dependent pathologies 
and a rapid, age-dependent decline in fertility in female [159]. Thus, knockout of a sin-
gle gene can have a tremendous effect on viability, life span and fertility in mouse 
model. Phenotypic screen of our Vkorc1l1-/- mice did not show any abnormalities in 
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terms of viability and fertility. Characterization of an age-related phenotype can provide 
a better understanding of function of Vkorc1l1 in vivo in terms of aging.  
 
Future perspectives based on these results 
Vkorc1l1 KO mice provide a fundamental basis for further research of Vkorc1l1 protein 
function in vivo. Knowing that Vkorc1l1 KO is not lethal constitutes a great step forward 
because it suggests that even if Vkorc1 and Vkorc1l1 are isozymes both enzymes have 
different tasks most probably due to their tissue distribution. On the basis of mRNA 
expression studies this suggestion is substantiated having highest Vkorc1 expression 
in liver and high mRNA levels of Vkorc1l1 in whole brain [12]. An important outcome of 
the phenotypic screen was that Vkorc1l1 KO mice were lighter than their WT litterma-
tes. In addition, Vkorc1l1 KO mice showed different behaviour and energy metabolism 
with a predominat effect on lipid metabolism. Further experiements are required to ex-
plore the effect of Vkorc1l1 KO in detail. 
In vitro data suggest that Vkorc1l1 is involved in aging processes because it is specu-
lated that the enzyme has a function in scavenging ROS. Indeed, it was shown that 
VKORC1L1 mRNA is upregulated when HEK 293T cells were treated with 75 µM H2O2 
(peak after 40 min), whereby VKORC1 mRNA stayed constant [10]. Hence, it would be 
meaningful to screen aged Vkorc1l1-/- mice to strengthen this hypothesis.  
However, one major issue remains: both VK OR enzymes can reduce K and K>O to 
provide KH2 as a potent antioxidant [96]. To investigate the impact of KH2 in antioxida-
tion and aging processes the source of KH2 needs to be eliminated thus both enzymes 
must be silenced (although Vkorc1l1 mRNA is highest in brain minor Vkorc1 mRNA 
expression was detected, too) [12]. But due to the lethal phenotype of Vkorc1-/- one 
would expect that Vkorc1/Vkorc1l1 double KO mice are lethal postpartum or even die 
in utero. By tissue- or cell-specific Vkorc1-/- using Cre/loxP system lethal effects of con-
stitutional Vkorc1-/- can be omitted. Another possibility is to knock-in Vkorc1 specifically 
in liver in a constitutional Vkorc1-/- mouse and generate Vkorc1/Vkorc1l1 double KO 
mice without a bleeding phenotype. This would allow to evaluate the effect of KH2 ab-
sence on antioxidation and aging processes in vivo. However, results of these mice 
studies may be confounded due to the third yet unknown enzyme which can reduce K 
to KH2 [102, 116]. Because the enzyme is still unknown one cannot guess for tissue 
distrubution and expression level especially in brain.  
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A.1 List of primers 
CRISPR/Cas9 to generate VKORC1L1 mice 
Oligo donor Up ATGTGGCTGGGTTTCTGGACATCATGACACACTACTAGCCATGA
CTAAACGTCCACTGATATAACTTCGTATAGCATACATTATACGAA
GTTATGATATCACCAAGGTCAACACATGATAAGCAGCAGTGACT
CACACTTCACTCTCGTGGTTCTCTATT 
Oligo donor Dw TTCTTTAAAAAAAAAAAAACCTGGGCTTTTTTTGGGGGGTGGGG
GGTCTCATTAACCTCAATAACTTCGTATAGCATACATTATACGAA
GTTATGATATCTGCGTGGAAATTGATTTCAGGGAGATAATTCAA
GGAAGGACAGGTACTATAAAGAAAATG 
sgRNA Up GTTAAAGCTGAAGTGTCGTG 
sgRNA Dw TGGTATCAGTGGACGTTTAG 
For genotyping of VKORC1L1 mice 
RFLPprimerUp_Fw GGGTGAGAGAATTCGTGCAT 
RFLPprimerDw_Rv AATGTGAATTGCAGCAAGCC 
L1_KO_1F ACTGTGAAGGGGTTGTCCTG  
L1_KO_2R CGAGGATTTGGTCTTTTGGGT 
L1_KO_3F TACTGGGTTCAATTCCAGCAC 
For amplification of murine VKORC1L1 cDNA 
mL1_Start_F ATGGCGGCGCCCGTCCTG 
mL1_Stop_R TCAGTCTTCCTTAGGCTGCAGCTG 
For quantitative PCR (TaqMan assay) 
L1_TM_F_neu CCTGGGTGAAGTGCTCCG 
mL1_TM_Sonde_neu 5‘-FAM CTCGACCCCATCTGGAGGCCA BHQ1-3‘ 
TM_VKORC1L1_R AGACACTGTTTGGCTGGTTTAATAC 
TM_HMBS_F AGTCATGTCCGGTAACGGC 
TM_HMBS_R CAGGGTACAAGGCTTTCAGC 
S_HMBS 5’-FAM ACCGCGGAAGAAAACGGCTC BHQ1-3‘ 
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Introduction of mutations in hVKORC1 
R33E-For CACGTGAAGGCGGCGGAGGCCCGGGACCGGGAT 
R33E-Rev ATCCCGGTCCCGGGCCTCCGCCGCCTTCACGTG 
R40E-For CGGGACCGGGATTACGAGGCGCTCTGCGACGT 
R40E-Rev ACGTCGCAGAGCGCCTCGTAATCCCGGTCCCG 
R53E-For GCCATCAGCTGTTCGGAGGTCTTCTCCTCCAGG 
R53E-Rev CCTGGAGGAGAAGACCTCCGAACAGCTGATGGC 
F55A-For GCTGTTCGCGCGTCGCCTCCTCCAGGTGGG 
F55A-Rev CCCACCTGGAGGAGGCGACGCGCGAACAGC 
Introduction of mutations in hVKORC1L1 
L62F-For AAGTGCTCCGCCGCCTTTGCCTCCAGATGGG 
L62F-Rev CCCATCTGGAGGCAAAGGCGGCGGAGCACTT 
60AAL-RVF-For CCCTGGGTGAAGTGCTCCCGCGTCTTTGCCTCCAGATGGGGT 
60AAL-RVF-Rev ACCCCATCTGGAGGCAAAGACGCGGGAGCACTTCACCCAGGG 
R68E-For GCCTCCAGATGGGGTGAAGGATTTGGTCTTTTG 
R68E-Rev CAAAAGACCAAATCCTTCACCCCATCTGGAGGC 
R38E_F GCCTACCACGTGGAGGAGGAGAAGGAGCGGG 
R38E_R CCCGCTCCTTCTCCTCCTCCACGTGGTAGGC 
R42E_F GAGCGGGAGAAGGAGGAGGACCCCGAGCACC 
R42E_R GGTGCTCGGGGTCCTCCTCCTTCTCCCGCTC 
R38+42E-For TACCACGTGGAGGAGGAGAAGGAGGAGGACCCCGAGCAC 
R38+42E-Rev GTGCTCGGGGTCCTCCTCCTTTCCTCCTCCACGTGGTA 
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A.2 Plasmids 
pX330-U6-Chimeric_BB-CBh-hSpCas9 (Plasmid #42230) 
A human codon-optimized SpCas9 and chimeric guide RNA expression plasmid [89] 
used for generation of knockout mice. Picture taken from 
https://www.addgene.org/42230/ visited on 19-Jan-2018. 
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Retro Double CMV 
Plasmid used for generation of HEK 293T knockout cell lines in collaboration with Klara 
Höning from the Institute of Molecular Medicine at the University Hospital Bonn. Picture 
generated with SnapGene Viewer. 
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pIRES 
Plasmid used for expression of F9 and VKORC1/VKORC1L1 and its variants in differ-
ent HEK 293T cell lines. Vector information taken from www.clontech.com visited on 
19-Jan-2018 (PR852529; published 20 May, 2008). 
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pCMV6 XL4 
Plasmid was used for expression of human F9 and was purchased from Origene. 
cDNA (2.9 kb) was cloned in at NotI restriction sites. Vector information taken from 
www.origene.com visited on 19-Jan-2018. 
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pcDNA 3.1 myc/His 
Plasmid was used for expression of myc-tagged VKOR enzymes to verify expression 
by western blot. Vector information taken from www.sigmaaldrich.com visited on 19-
Jan-2018. 
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